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ABSTRACT 
 
Vascular integrity is essential for proper vessel function, and for the maintenance of tissue and organ 
homeostasis. Endothelial cells (ECs) in the inner lining of the blood vessels form a barrier that 
dynamically regulates permeability across the vessel wall. Permeability via EC-EC junctions is 
transiently increased during inflammation, whereas abnormally or persistently elevated EC 
permeability promotes disease pathogenesis. For example, in sepsis, systemic capillary leakage 
compromises blood perfusion, and may lead to hypovolemic shock and multiorgan failure. Despite 
the significant amount of research on the mechanisms that control the EC barrier, no targeted 
therapies currently exist to seal the leaky vessels and maintain tissue perfusion. 
 
The aim of this study was to investigate how vascular permeability is controlled via an EC-derived 
growth factor angiopoietin-2 (ANGPT2), which is upregulated in various human diseases, including 
sepsis. ANGPT2 was found to signal via b1-integrin, and therefore the function of endothelial b1-
integrin in vascular permeability was investigated. The results identified a novel signaling pathway, 
where ANGPT2–b1-integrin signaling promotes EC permeability. b1-integrin was found to play a 
previously uncharacterized role in inflammation-induced vascular permeability, and an antibody 
against b1-integrin inhibited vascular leakage, improved EC junction integrity and protected from 
cardiac failure in LPS-induced murine endotoxemia. 
 
Earlier studies have shown that ANGPT2 destabilizes blood vessel integrity in a context-dependent 
manner via its classical receptor TEK receptor tyrosine kinase (TIE2) on ECs. These studies have 
raised interest on ANGPT2 as a potential target in various diseases, including cancer and ocular 
neovascular diseases. This study revealed that ANGPT2 can promote EC destabilization 
independently of TIE2, which is downregulated during inflammation. These results suggest that a 
better understanding of the signaling function of ANGPT2 is necessary, in order to optimally target 
ANGPT2 in disease. 
 
This study also highlights the crucial role of endothelial b1-integrin in controlling inflammation-
induced EC permeability. The results showed that various inflammatory agents induced EC 
monolayer destabilization via b1-integrin, manifested by the loss of junctional VE-cadherin, the 
formation of actin stress fibers, and altered EC-extracellular matrix (ECM) adhesions. The EC-ECM 
adhesions that formed in inflammation were elongated fibrillar adhesions that can be distinguished 
from focal adhesions by the presence of the adapter protein tensin-1. Furthermore, b1-integrin 
promoted inflammation-induced EC contractility and reduced the EC barrier function. Importantly, 
targeting b1-integrin using a monoclonal antibody, or via a heterozygous genetic deletion in the 
endothelium of gene-targeted mice decreased vascular leakage in LPS-induced murine endotoxemia. 
Notably, the b1-integrin antibody was effective both as a prophylactic and as an intervention therapy, 
administered after the onset of systemic inflammation and vascular leakage, and its mechanism of 
action was independent of attenuating systemic inflammation, and of the vascular stabilizing function 
of TIE receptors. 
 
In summary, this thesis provides new knowledge on the mechanisms that lead to vascular leakage via 
ANGPT2 and b1-integrin. b1-integrin was identified as a potentially universal regulator of EC 
permeability. A major finding was that targeting the EC b1-integrin in a preclinical model of sepsis 
decreased vascular leakage, thereby improving cardiac function. The results of this thesis call for 
further studies in evaluating the translational potential of b1-integrin mediated vascular permeability. 
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TIIVISTELMÄ 
 
Verisuoniston oikeanlainen toiminta on välttämätöntä kudosten ja elinten toiminnalle. Verisuonten 
sisäpinnan endoteelisolukerros muodostaa verisuonten sisäseinämän ylläpitäen kudosten tasapainoa 
ja immuunivastetta. Verisuonten endoteelisolukerroksen läpäisevyys lisääntyy tulehdusreaktiossa 
sekä monissa sairauksissa. Esimerkiksi sepsiksessä kapillaariverisuonten vuoto aiheuttaa nesteen 
kertymistä kudoksiin ja samalla heikentää veren virtausta ja kudosten hapen saantia, mikä voi johtaa 
septiseen sokkiin ja monielinvaurioon. Mittavasta tutkimustiedosta huolimatta kapillaarivuotoon ei 
toistaiseksi ole lääkettä, ja uusia keinoja verisuonivuodon estoon sairauksissa tarvitaan kipeästi. Tässä 
väitöskirjatutkimuksessa löydettiin uusi signaalinvälitysreitti, joka lisää verisuonten läpäisevyyttä 
tulehduksen yhteydessä. Prekliinisissä kokeissa verisuonten vuotoa pystyttiin estämään hiiren sepsis-
mallissa. 
 
Tutkimuksen tarkoituksena oli selvittää niitä solutason mekanismeja, jotka säätelevät 
endoteelisolujen läpäisevyyttä ja miten verisuonivuotoa voidaan estää prekliinisessä sepsis-mallissa. 
Tutkimus keskittyi erityisesti selvittämään endoteelisolujen angiopoietiini-2 (ANGPT2)-
kasvutekijän sekä soluadheesioproteiinien, integriinien, merkitystä endoteelisolujen liitosten 
purkautumisessa ja verisuonivuodossa tulehduksessa. 
 
Tutkimuksessa löysimme uuden signaalinvälitysreitin, joka lisää endoteelisolukerroksen 
läpäisevyyttä. Endoteelisolujen väliset liitokset heikentyivät sekä ANGPT2- että b1-integriini-
välitteisen viestinnän seurauksena. Havaitsimme, että tulehduksen välittäjäaineet aktivoivat b1-
integriinin toimintaa, mikä johti soluliitosten heikkenemiseen. Lisäksi osoitimme, että tulehduksen 
aiheuttama verisuonivuoto oli vähäisempää hiiren sepsismallissa, jos toinen b1-integriiniä koodaava 
alleeli oli poistettu hiiren endoteelisoluista tai jos b1-integriinin toimintaa estettiin vasta-aineella. 
 
ANGPT2-kasvutekijän ennestään tunnetut tehtävät välittyvät endoteeliperäisen TIE2-reseptorin 
kautta. ANGPT2:n määrä lisääntyy monissa sairauksissa, ja ANGPT2 on lääkekehityksen kohteena 
erityisesti silmän verisuonisairauksien hoitoon. Tämä tutkimus osoitti, että ANGPT2 lisää 
endoteelisoluviljelmän läpäisevyyttä myös ilman TIE2-reseptoria, jonka määrä laskee tyypillisesti 
tulehduksessa. 
 
Työssä kuvasimme miten endoteelin läpäisevyys nousee ANGPT2-välitteisesti muuttuneen b1-
integriinin toiminnan seurauksena. Huomasimme, että ANGPT2–b1-integriini-signaalinvälitys johti 
endoteelisoluliitosten heikkenemiseen, aktiinitukirangan muutokseen stressisäikeiseksi, sekä 
uudentyyppisten soluadheesioiden muodostumiseen lisäten endoteelisolukerroksen läpäisevyyttä 
tulehduksessa. Pre-kliinisessä sepsis mallissa b1-integriiniä estävä vasta-aine vähensi merkittävästi 
verisuonivuotoa sekä estohoitona että interventiohoitona, kun vasta-aine annosteltiin systeemisen 
tulehduksen ja verisuonivuodon jo alettua. Vasta-ainehoito myös kohensi endoteelisoluliitoksia ja 
ehkäisi sepsiksen aiheuttamaa sydämen vajaatoimintaa. Mekanistisesti, b1-integriini-vasta-aineen 
verisuonia parantavat vaikutukset eivät johtuneet yleisestä tulehduksen laskusta. 
 
Yhteenvetona voidaan todeta, että tässä väitöskirjassa esitetään uutta tietoa endoteelisolujen 
läpäisevyyteen ja verisuonivuotoon johtavista mekanismeista. Tässä työssä kuvataan b1-integriini 
endoteelisolujen läpäisevyyden säätelijäksi. ANGPT2 aktivoi b1-integriinin johtaen 
adheesiomuutoksiin ja endoteelin läpäisevyyden nousuun. Lyhytaikainen b1-integriini-vasta-
ainekäsittely sekä yhden b1-integriini-alleelin poisto vähensivät sepsiksen aiheuttamaa 
verisuonivuotoa ja suojasivat sepsiksen aiheuttamalta sydämen vajaatoiminnalta hiirimallissa. 
Väitöskirjatyön tutkimustuloksilla voi olla merkitystä kehitettäessä verisuonia vakauttavia hoitoja. 
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INTRODUCTION 
 
Blood and lymphatic vasculatures span throughout the body maintaining tissue oxygenation and fluid 
homeostasis. The blood vessels consist of endothelial cells (EC) that form the inner layer of the blood 
vessels, mural cells that cover the endothelium, and an extracellular matrix (ECM) surrounding the 
vessels. The ECs form a semi permeable barrier with vascular bed specific sieving activity (Monahan-
Earley et al., 2013). The EC barrier is regulated by the cellular actin cytoskeleton and adherens and 
tight junctions that connect ECs together, as well as EC adhesion to the underlying basement 
membrane (BM). Integrin cell adhesion receptors serve to transport signals from cells to the ECM 
and vice versa. They also anchor ECs to the BM and mediate connections of junctional proteins to 
the actin cytoskeleton (Cerutti and Ridley, 2017). 
 
Acute and chronic inflammation increase fluid leakage and inflammatory cell infiltration into the 
tissues through the EC barrier. When acute inflammation turns chronic, vessel undergo profound 
changes in their structure and function (Claesson-Welsh, 2015). In systemic inflammation such as 
sepsis, the overwhelming inflammatory response causes capillary leakage leading to decreased blood 
volume and shock. Tissue edema and hypoxia contribute to subsequent organ failure. Mortality of 
patients with sepsis remains high. 30 million patients are estimated to develop sepsis annually, with 
an estimate of 6 million deaths from septic shock (Gyawali et al., 2019). In case of microbial sepsis, 
rapid initiation of antibiotic use is crucial. However, when septic shock develops, current treatments 
can be ineffective, and as of now, no targeted therapies exist to correct the capillary leakage (Gyawali 
et al., 2019). 
 
Two major growth factor receptor signaling systems regulate vascular morphogenesis and EC 
functions: Vascular endothelial growth factor (VEGF)–VEGF receptor (VEGFR) and the 
angiopoietin (ANGPT)–TIE growth factor receptor systems. An important function of the ANGPT1–
TIE2 signaling system is the maintenance of vascular stability, whereas ANGPT2, which is produced 
by activated ECs in vascular diseases, functions as a context dependent agonist/antagonist for TIE2 
(Saharinen et al., 2017a). 
 
Circulating ANGPT2 levels are increased in various vascular diseases, including sepsis, where high 
ANGPT2 levels correlate with poor patient prognosis (Leligdowicz et al., 2018). In addition, 
preclinical results have demonstrated an essential role of ANGPT2–TIE2 signaling in vascular 
destabilization and leakage (Eklund et al., 2017). The current work aimed to discover molecular 
mechanisms that lead to EC destabilization. We sought to elucidate how ANGPT2 and integrins are 
involved in EC destabilization, and how this leads to vascular leakage. 
 
We found that ANGPT2 and b1-integrin decreased EC stability in inflammation and in ECs where 
TIE2 levels were decreased. In inflammation, ANGPT2 supported the formation of b1-integrin and 
tensin-1-positive fibrillar matrix adhesions and actin stress fibers, and decreased VE-cadherin in EC 
junctions. ANGPT2–b1-integrin signaling promoted stress fibers via intracellular ERK and RhoA-
ROCK signaling pathways. Moreover, b1-integrin mediated inflammation-induced EC contractility 
and permeability. Notably, both b1-integrin antibodies or a heterozygous EC-specific deletion of b1-
integrin decreased vascular leakage in a preclinical murine sepsis (endotoxemia) model. In addition, 
b1-integrin antibodies protected from endotoxemia-induced cardiac failure and improved EC junction 
integrity. Discoveries in this work shed light onto why elevated ANGPT2 levels are harmful in 
vascular leakage syndromes, and suggest that endothelial b1-integrin acts as a mediator of EC 
permeability. These findings may have translational impact for regulation of vascular stability and 
leakage. 
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REVIEW OF THE LITERATURE 
 
1. Blood and lymphatic vascular systems 
 
The vasculature comprises of blood vascular and lymphatic vascular systems, which carry blood and 
lymph throughout the body sustaining physiological functions, respectively. However, the blood and 
lymphatic vessels are also involved in disease (Monahan-Earley et al., 2013). 
 
1.1 Blood vascular system 
 
The cardiovascular system in vertebrates is a closed system where blood leaves and enters the 
circulation via the heart. The cardiovascular system is the first organ system to develop during 
embryogenesis, and its correct function ensures the functioning of the gas-exchange system of the 
lungs (Monahan-Earley et al., 2013). 
 
1.1.1 Structure and development of the blood vasculature 
 
The inner layer of the blood vessel wall consists of a single EC layer. The ECs are flat in shape, 
however, depending on the vessel size, EC thickness can vary 100-fold in the human body (Florey, 
1966). One example are the cubic ECs of the post-capillary high endothelial venules that aid 
lymphocyte circulation from the blood stream to lymph nodes (Miyasaka and Tanaka, 2004). 
 
The blood vasculature is a hierarchic network of vessels with different functions. Arteries and 
arterioles transport oxygen rich blood from the heart to tissues, and veins and venules return carbon 
dioxide rich blood to the heart, destined to small circulation of the lungs followed by gas-exchange 
in the alveolar capillaries. The capillaries also connect peripheral arterioles and venules in the tissues 
(Monahan-Earley et al., 2013). The endothelium of arteries and veins is covered by a smooth muscle 
cell layer. The endothelial and smooth muscle cells are embedded in the extracellular matrix (ECM). 
The ECM plays a major role in vessel development, growth and maturation. Approximately 300 genes 
code for ECM proteins, consisting of 200 different glycoproteins, over 30 proteoglycans and over 40 
collagens that assemble into various ECMs. The ECM provides important signaling cues during 
vascular development and supports functions of the mature vessels by interacting with EC surface 
receptors (Hynes and Naba, 2012). The inner EC layer of arteries and veins is called tunica intima, 
the smooth muscle cell layer is called tunica media, and the outermost ECM layer is called tunica 
adventitia. Tunica adventitia connects the vessels to the surrounding tissues and organs (Mazurek et 
al., 2017). Especially in arteries, the tunica media and tunica adventitia contain fibers that provide 
elasticity and support the vessel structure under high pressure. Veins have thinner wall structures than 
arteries and valves to prevent back flow of the blood (Udan et al., 2013). 
 
Capillaries serve to release oxygen, hormones and nutrients into tissues, and respond to angiogenic 
signals (Augustin and Koh, 2017). Only one single red blood cell can pass through the capillaries at 
a time. The capillaries are covered by pericytes in a vascular bed and tissue specific manner (Mazurek 
et al., 2017). The capillaries are embedded in a specialized ECM, the basement membrane (BM), 
which offers mechanical support to the vessels (Marchand et al., 2019). The BM mainly consists of 
collagen IV and laminin, forming a network supported by nidogen. The major proteoglycan in the 
vascular BM is perlecan (Thomsen et al., 2017). In angiogenic vessels, in disease and during injury, 
the BM composition is altered and a provisional matrix, which is rich in plasma fibronectin (FN), is 
formed. The early provisional matrix matures into late provisional matrix, enriched with FN produced 
by the ECs (Barker and Engler, 2017). 
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The luminal side of the endothelium is lined with a glycocalyx that consists of proteoglycans, 
glycoproteins, glycosaminoglycans, and plasma proteins. The thickness of the glycocalyx varies 
depending on the vascular bed, and is important for maintenance of the vascular barrier and other 
vascular functions (Uchimido et al., 2019). 
 
During embryogenesis, the vascular system initially forms via vasculogenesis. Angioblasts, or the 
precursors of ECs that originate from extraembryonic and embryonic mesoderm, migrate to the sites 
of blood islands to form the first vessels, a primary capillary plexus (Adams and Alitalo, 2007; Swift 
and Weinstein, 2009). According to mouse embryo studies, vasculogenesis takes place during 
embryonic days (E) 6.5–9.5 of the 21 days long murine pregnancy (Drake and Fleming, 2000). 
 
The vascular tree continues to grow mainly via angiogenesis and vasculogenesis. Angiogenesis, or 
the formation of new blood vessels from preexisting ones, is driven by growth factor gradients and 
signals from the surrounding matrix. The primary capillary plexus branches out into a complex 
network where capillary, venous and arterial vessel specification and vessel hierarchy are 
distinguished. Vessels can also expand by a progress called intussusception, where one vessel divides 
into two (Swift and Weinstein, 2009). Maturing ECs secrete growth factors to attract mural cells that 
cover the maturing vessels and further differentiate for organ specific functions (Jain, 2003; von Tell 
et al., 2006). Hypoxia guides vessel growth to meet the oxygen need in a growing embryo, but also 
during pathological vessel growth in various diseases (Koch et al., 2011). 
 
The endothelial cells and the vessels they form show remarkable tissue and vessel-type specific 
heterogeneity, reflecting their specialized functions (Monahan-Earley et al., 2013). Thus, even though 
ECs share many functions, there is no single protein known that would be entirely specific to ECs, or 
expressed to the same extent in all ECs (Aird, 2007b). Due to this heterogeneity, genetic mouse 
models that have been designed to target EC-specific genes via endothelial specific gene promoters 
seldom work with the same efficiency in all EC types or in all tissues (Minami and Aird, 2005). 
Recent advancements in e.g. single cell sequencing technologies will elucidate the knowledge of the 
molecular heterogeneity of the vasculature. 
 
1.1.2 Functions of the blood vascular system 
 
In addition to its function as a transport system, the blood vessels control blood flow and pressure, 
which are crucially regulated by vascular integrity (see 1.3), as well as mechanisms of vasodilation 
and vasosuppression. The blood vasculature also has essential functions during wound healing and in 
control of local tissue inflammation (Aird, 2007a; Schwartz et al., 2010). Moreover, tight control of 
the blood clotting cascade is crucial for homeostatic regulation of the vasculature. Upon injury, 
platelets are attracted to the site of injury by von Willebrand factor produced by ECs. Tissue injury 
triggers the clotting cascade via tissue factor, which becomes exposed due to retraction or apoptosis 
of ECs, leading to thrombin production that further enhances coagulation and fibrin clot formation to 
seal the vessel. Proteinase activated receptors on ECs sense the pro-coagulogenic factors and are 
involved in the initiation of clotting (Yau et al., 2015), whereas ECs also inhibit unnecessary clotting. 
The blood clot is eventually dissolved, via release of pro-fibrinolytic molecules and 
metalloproteinases by ECs (Yau et al., 2015). In certain diseases, such as sepsis, aggravated 
coagulation processes may occur, leading to disseminated intravascular coagulation, highlighted by 
shortage of coagulation factors and increased bleeding (Gando et al., 2016). 
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1.2 Lymphatic vascular system 
 
The lymphatic vascular system is important for the control of tissue fluid homeostasis, lipid 
adsorption in the gut, and for the function of the adaptive immune system. The lymphatic ECs share 
properties with blood vascular ECs but have evolved into a different purpose. The lymphatic 
capillaries lack mural cell coverage, whereas larger collecting lymphatic vessels are covered by 
smooth muscle cells. The lymphatic network is an open-ended system. Lymphatic capillaries collect 
the lymph from the interstitial space in the peripheral tissues. The lymphatic vessels gather at the 
thoracic duct, where the lymph is returned to the blood stream (Vaahtomeri et al., 2017). The lymph 
nodes are specialized structures in this system, and are essential for the adaptive immunity (Schwager 
and Detmar, 2019). A specialized hybrid vessel, termed the Schlemm’s canal, can be found in the 
eye. It shares features of both blood and lymphatic vessels, but its formation relies on the lymphatic 
growth factor receptor signaling (Aspelund et al., 2014). 
 
The first lymphatic structures, the jugular lymph sacs, arise in the developing embryo, after 
commitment of the lymphatic ECs at E9.5, via lymphatic EC migration from the cardinal vein 
(Vaahtomeri et al., 2017). Moreover, lymphatic progenitors from non-venous origin contribute to the 
development of the lymphatic vasculature in an organ-specific manner (Martinez-Corral et al., 2015). 
Lymphangiogenesis can be further induced in many pathological conditions, like inflammation, tissue 
repair and cancer (Vaahtomeri et al., 2017). 
 
1.3 Endothelial cells and the vascular barrier 
 
The integrity of the EC layer is pivotal for the proper function of the vascular barrier, which is 
maintained via EC-EC and EC-ECM adhesions and contributes to the permeability of the vessels in 
a vascular bed -specific manner.  
 
In general, arterial ECs form tighter EC-EC connections than ECs in the veins. In certain tissues such 
as in the skin, lungs and the heart, as well as in the central nervous system, capillary ECs form a 
continuous endothelium that allows the passage of only small molecules, like water, and prevents the 
passage of plasma proteins and circulating cells. The lowest permeability is in the blood-brain and 
the blood-retinal-barriers. Fenestrated endothelium can be found in the kidney glomeruli, intestine 
and endocrine glands. Fenestrated EC-EC junctions have pores, but the cell layer appears organized 
and continuous. Pores in the fenestrae permit the passage of small peptides, and also allow fast water 
and solute transport, which is important for the function of these vascular beds. Sinusoidal 
endothelium is discontinuous and unorganized and the most permeable, allowing passage of large 
plasma proteins. Sinusoids can be found for example in the liver and the bone marrow (Augustin and 
Koh, 2017). 
 
Two distinct routes have been reported to mediate permeability across the vascular endothelium. In 
the paracellular route protein and cell passage occurs via the EC junctions, whereas in the transcellular 
route transport occurs via transcytosis through ECs, especially in the sinusoidal vascular beds 
(Augustin and Koh, 2017). The vesiculo-vacuolar organelles (VVO) are vacuolar structures of ECs 
that have been shown to carry out extravasation of macromolecules. VVOs span the whole EC width 
from luminal to abluminal side, forming a structure through which plasma proteins can leak 
efficiently (Cheng and Nichols, 2016). In certain tissues the paracellular route has been found to be 
the major mechanism of inflammation induced permeability and leukocyte extravasation (Schulte et 
al., 2011). The regulation of paracellular permeability via EC junctions and the actin cytoskeleton is 
discussed below. 
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1.4 Endothelial cell junctions 
 
EC integrity and paracellular permeability are regulated via adherens and tight junctions that can be 
seen as an electron dense area in the transmission electron microscope and encompass most of the 
EC longitude (Wallez and Huber, 2008). ECs undergo adhesional changes as the junctions form. 
Initial focal contacts turn into focal adhesions, which are in contact with the adherens junctions, tight 
junctions and actin cytoskeleton in the matured endothelium (Kasa et al., 2015). Adherens and tight 
junctions are intertwined with each other and with the actin cytoskeleton. 
 
1.4.1 Adherens junctions 
 
Adherens junctions are dynamic structures that allow regulated passage of molecules and immune 
cells across the ECs. The composition of adherens junctions varies across the vasculature, but the 
most abundant proteins are vascular endothelial cadherin (VE-cadherin) and catenins, of which ECs 
express a-, b-, and g-catenins and p120-catenin (Campbell et al., 2017). Adherens junction proteins 
are linked to actin cytoskeleton, and changes in actin filaments affect adherens junctions, and vice 
versa. b- and g-catenin (or plakoglobin) link VE-cadherin to the actin cytoskeleton by binding to the 
cadherin tail via their arm region, and by forming a complex with a-catenin via their amino terminal 
region. a-catenin further links this cadherin-catenin complex to the actin cytoskeleton (Figure 1). 
VE-cadherin is also in contact with p120-catenin. In addition to forming a link between VE-cadherin 
and actin cytoskeleton, p120-catenin regulates VE-cadherin expression and trafficking (Campbell et 
al., 2017; Gavard, 2014). 
 
1.4.2 VE-cadherin 
 
VE-cadherin is a transmembrane glycoprotein present in adherens junctions in virtually all vascular 
beds. VE-cadherin is a member of the classical cadherin family that in blood vessels forms homotypic 
(zipper-like) interactions across the EC junctions in a calcium-dependent manner (Lampugnani et al., 
2018). 
 
VE-cadherin is needed for the proper formation of the vasculature. Murine derived embryonic bodies 
fail to develop vessels in vitro, if they are mutated to lack the Cdh5 gene coding for VE-cadherin. 
VE-cadherin inactivation, however, does not influence the proliferative capacity of stem cells (Vittet 
et al., 1997). VE-cadherin knock-out mice die at E9.5 during embryonic development, due to 
impaired ECs survival and angiogenesis (Carmeliet et al., 1999). 
 
VE-cadherin is considered as a key regulator of vascular stability, and its conditional deletion in adult 
mice or inhibition using blocking antibodies resulted in increased vascular permeability in the lungs 
and the heart (Corada et al., 1999; Frye et al., 2015). No alterations in tight junction protein claudin-
5 were found in mice lacking the Chd5 gene (Frye et al., 2015). However, in cultured ECs VE-
cadherin is known to regulate the composition of tight junctions (Taddei et al., 2008). 
 
VE-cadherin associates with the platelet and endothelial cell adhesion molecule 1 (PECAM1, termed 
CD31 from hereon) and the vascular endothelial growth factor receptor (VEGFR) 2 through its 
intracellular domain. These interactions, together with integrin cell adhesion receptors, also comprise 
the EC mechanosensory complex, which mediates the EC responses to fluid shear stress (Tzima et 
al., 2005). 
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The appearance of VE-cadherin in the lymphatic vasculature differs from that of the blood 
vasculature. VE-cadherin is organized into button-like structures in lymphatic capillaries, but adopts 
the zipper-like morphology in lymphatic capillaries undergoing lymphangiogenesis and in collecting 
lymphatic vessels. The button-like junctions contain gaps that are thought to facilitate fluid uptake 
from the interstitium. The zipper-like lymphatic capillary junctions of embryonic lymphatic vessels 
mature into button-like junctions after birth. Lymphatic VE-cadherin junctions retain plasticity and 
undergo remodeling from buttons to zippers during inflammation (Baluk et al., 2007; Yao et al., 
2012), and in lacteal lymphatic capillaries when neuropilin-1 and VEGFR1 are deleted, promoting 
VEGFR2 signaling and resisting chylomicron uptake (Zhang et al., 2018). 
 
The junctional assembly of VE-cadherin is under complex regulation of various protein kinases, 
phosphatases and small guanosine triphosphatases (GTPases), that determine VE-cadherin 
phosphorylation status and downstream signaling (Dejana and Lampugnani, 2018). Nine amino acid 
residues can be phosphorylated in the tail region of VE-cadherin by various kinases. Five different 
phosphorylation sites have been characterized to regulate permeability (Orsenigo et al., 2012; Potter 
et al., 2005; Turowski et al., 2008; Wallez et al., 2007). Physiological differences in basal VE-
cadherin phosphorylation have been found, including variation between arteries and veins. The 
phosphorylation of VE-cadherin is increased upon inflammatory or angiogenic stimuli, and can be 
mediated via the proto-oncogene tyrosine protein kinase (Src), and other kinases, like the p21-
activated kinase PAK (Gavard and Gutkind, 2006), stimulating VE-cadherin internalization. 
However, increased phosphorylation of VE-cadherin is insufficient to lead to its internalization, and 
additional stimulus is needed (Lambeng et al., 2005; Orsenigo et al., 2012). 
 
1.4.3 Tight junctions 
 
The abundance of tight junction proteins varies in different vascular beds due to differences in vessel 
structure. For example, in post-capillary venules, where leukocyte trafficking occurs, tight junctions 
are less prominent and receptors required for leukocyte adhesion abundant, especially during 
inflammation. On the contrary, the blood-brain-barrier, which is a specialized vascular bed to protect 
the brain, has a high content of tight junction proteins to fortify the endothelial structure and prevent 
leakiness. Large arteries, like the aorta, have also well-organized tight junctions that mediate 
resistance to high rates of pulsatile blood flow (Aird, 2007a). 
 
Claudins and occludins represent the most important tight junction components in ECs. They 
participate in permeability regulation and interact with adherens junctions. Claudin-5 has been shown 
to be important in maintaining blood-brain-barrier integrity, and its deletion in the mouse genome 
results in death after birth due to hemorrhaging (Tsukita et al., 2019). Another important component 
is the intracellular zonula occludens-1 (ZO-1) to which the claudins and occludins are linked (Figure 
1). ZO-1 also associates with proteins involved in cellular tension sensing, mediating interaction of 
tight junction proteins with VE-cadherin. ZO-1 has been shown to regulate angiogenesis and support 
EC integrity via both VE-cadherin and the actin cytoskeleton (Tornavaca et al., 2015). 
 
1.5 Endothelial actin cytoskeleton 
 
Most of the data concerning EC actin cytoskeleton is derived from in vitro studies. A cortical actin 
structure is essential for endothelial monolayer integrity. It is formed during EC adhesion to ECM, 
after the maturation of initial focal complexes into stable focal contacts (Figure 1). The cortical actin 
contains filamentous actin (F-actin) that is formed via polymerization of globular b- and g-actins (G-
actin) through nucleation and elongation steps. F-actin also forms the membrane skeleton that adjusts 
EC membranes accordingly, whereas the cortical actin rim is a separate structure that interacts with 
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membrane skeleton. Membrane skeleton is composed of short F-actin fibrils, whereas cortical actin 
is composed of longer fibrils, which are in continuous contact with several actin binding proteins that 
link them to other cellular structures (Prasain and Stevens, 2009). Filamin links actin to cell 
membrane proteins and links F-actin fibrils for the construction of cell-cell contacts and cell-matrix-
contacts where cortical actin is formed (Kumar et al., 2019).  
 
The third type of F-actin, actin stress fibers, are composed of short F-actin fibrils. Typically, when 
stress fibers form, the cortical actin rim is dismantled. Stress fibers may stretch through the cell 
cytoplasm, and generate centripetal tension by acquiring contractile forces via the actomyosin 
contractility machinery (Figure 1). Stress fiber contractility promotes retraction of EC membranes, 
pulling contacting ECs away from each other and leading to gap formation in the junctions of EC 
monolayers. On the contrary, cortical actin supports membrane stability (Prasain and Stevens, 2009). 
 
Contractility of F-actin is generated via binding of myosin motor proteins along with cross-linking 
proteins such as alpha-actinin to stress fibers (Figure 1). Phosphorylation of the myosin light chain 
(MLC) of myosin II regulates its activity. At least two distinct signaling pathways lead to contractile 
stress fiber formation. The Ca2+/Calmodulin pathway activates MLC kinase (MLCK) which 
phosphorylates MLC. Additionally, the Ras homolog gene family member A (RhoA) – Rho-
associated protein kinase (ROCK) signaling can induce MLC activity via direct phosphorylation, or 
indirectly, via phosphorylation-mediated inhibition of the MLC phosphatase (Huveneers et al., 2015; 
Kassianidou et al., 2017). Formation of the F-actin fibril is regulated by several actin binding proteins 
of the GTPase protein family. Whereas RhoA can promote stress fiber formation, Ras-related C3 
botulinum toxin substrate 1 (Rac1) and Ras-related protein 1 (Rap1) support cortical actin (Huveneers 
et al., 2015). In ECs, the FYVE, RhoGEF and PH domain containing 5 (FGD5), which is a Guanine 
nucleotide exchange factor (GEF), inhibits stress fiber formation via Rap1 and the cell division 
control protein 42 (Cdc42) mediated signaling promotes cortical actin (Braun et al., 2019). 
 
2. Growth factor regulation of endothelial cells 
 
Extracellular signals regulate multiple EC functions via two major endothelial growth factor receptor 
systems: the angiopoietin (ANGPT)–TIE and the vascular endothelial growth factor (VEGF)–
VEGFR system. Both systems are vital in the development of the blood and lymphatic vasculatures, 
and in homeostasis (Lohela et al., 2009; Saharinen et al., 2017a). 
 
2.1 VEGF–VEGFR system 
 
VEGF–VEGFR system comprises of five ligands: VEGF-A (termed VEGF from hereon), - B, -C and 
-D, the placental growth factor (PlGF), and three receptors: VEGFR1, VEGFR2 and VEGFR3. VEGF 
has four splice variants that differ in their matrix binding properties, with different signaling 
outcomes. VEGF is a ligand for VEGFR1 and VEGFR2, and can also bind neuropilins 1 and 2. 
VEGF-B and PlGF bind VEGFR1, and VEGF-C and VEGF-D bind VEGFR3, but also VEGFR2 in 
their fully processed forms (Jha et al., 2017). In adult mice, VEGFR3 is enriched in lymphatic ECs, 
although the receptor is also found in blood vessels. VEGF is produced by virtually all cells of the 
body, and its expression is highly upregulated in hypoxia (Apte et al., 2019). VEGFRs are major 
regulators of EC functions, such as EC proliferation, cell survival and migration, but the receptors 
are also found on other cell types (Greenwald et al., 2019; Licht and Keshet, 2013). 
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VEGF was originally described as the Vascular Permeability Factor, and it is a strong inducer of 
vascular permeability via VEGFR2 (Li et al., 2016; Senger et al., 1983). VEGF signaling is crucial 
during development, and heterozygous deletion of even a single allele of Vegf results in death of the 
mouse embryos at around E11 due to impaired vascular formation resulting in various developmental 
anomalies (Carmeliet et al., 1996; Ferrara et al., 1996), and homozygous deletion of Vegfr2 in mice 
result in a similar phenotype (Shalaby et al., 1995).  
 
In adult mice, autocrine VEGF plays a role in EC survival, and conditional EC specific deletion of 
VEGF leads to death of the mice over 25 weeks (Lee et al., 2007). In addition, inhibition of VEGF 
Figure 1. Endothelial cell-cell and cell-matrix adhesions. A) Adherens junctions (AJ) connect to actin cytoskeleton 
via catenins and B) tight junctions (TJ) connect to actin cytoskeleton via ZO1 binding to claudins and occludins. 
Focal AJs may further contain vinculin that enforces the actin coupling and mediates tension, whereas linear AJs 
associate with cortical actin in cells with less tension. C) Focal adhesions (FA) and D) fibrillar adhesions connect to 
actin cytoskeleton via integrin adaptors. FA signaling is complex, and only as subset of the signaling mediators are 
illustrated. Fibrillar adhesions were originally characterized in fibroblasts and are enriched with tensin1 instead of 
talin1. E) Actin stress fiber tension is elicited by myosin binding to actin fibers. Activation of the actomyosin 
contractility is under dynamic regulation. Information derived from multiple sources (Georgiadou and Ivaska, 2017; 
Huveneers et al., 2015; Lo, 2017).  
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for 2-3 weeks using a VEGF trap, induces the regression of capillaries e.g. in the thyroid and small 
intestine within, and loss of fenestrae in the capillaries of the kidney (Kamba et al., 2006). 
 
VEGF is induced by the hypoxia inducible factor (HIF) signaling in response to low oxygen pressure, 
resulting in neoangiogenesis (Majmundar et al., 2010). This mechanism is at play in solid tumors, 
where hypoxia drives VEGF expression and angiogenesis. Similarly, in neovascular eye diseases, 
VEGF is the main driver of pathological angiogenesis. Drugs that target VEGF have therefore been 
used in cancer and neovascular eye diseases, with higher efficacy in the latter (Ferrara and Adamis, 
2016). 
 
2.2 Angiopoietin (ANGPT)–TIE system 
 
The ANGPT–TIE system is composed of two major ligands, ANGPT1 and ANGPT2, and two 
receptors, the Tyrosine kinase with Ig and epidermal growth factor homology domains 1 (TIE1) and 
the TEK receptor tyrosine kinase (TIE2). ANGPT growth factors modulate the phosphorylation status 
of the TIE receptors in this system. ANGPT1 is an agonistic ligand for TIE2, whereas ANGPT2 is a 
context dependent agonist/antagonist. A third ligand, ANGPT4, has also been characterized, but not 
studied extensively (Eklund et al., 2017). 
 
2.2.1 TIE receptors 
 
TIE2 and TIE1 receptors are type I transmembrane protein receptor tyrosine kinases (Dumont et al., 
1994; Partanen et al., 1992). Both receptors are enriched in the ECs of both vascular and lymphatic 
vessels (Partanen et al., 1992), but there is some expression also in haematopoietic cells, and e.g. 
TIE2 is expressed in a subtype of macrophages (TIE2 expressing macrophages) and hematopoietic 
stem cells (Arai et al., 2004; Batard et al., 1996; De Palma et al., 2005). 
 
TIE2 and TIE1 are closely related. Their ectodomains consist of three fibronectin type III domains, 
three epidermal growth factor repeats and three Ig-like domains (Figure 2) (Barton et al., 2006). Both 
receptors have an intracellular, carboxyterminal kinase domain that mediates downstream signaling 
(Figure 2). TIE2 ligand binding domain resides in the second Ig repeat, whereas TIE1 does not 
directly bind ANGPTs (Barton et al., 2006; Davis et al., 2003), and therefore its signaling mechanisms 
are not completely understood. 
 
Figure 2. Schematic presentation of the 
ANGPT–TIE system. A) TIE 
extracellular domains consist of Ig-like 
domains, FN type III domains, and EGF-
like domains. Intracellular domains of 
TIEs and of VE-PTP consist of kinase and 
phosphatase domains, respectively. Blue 
arrows indicate receptor activation, red 
arrow indicates receptor inhibition. B) 
Structure of ANGPTs. SCD = 
superclustering domain, CCD = coiled-
coil domain, FLD = fibrinogen-like 
domain. Linker regions (blue arrows). 
Panel A) adapted from Thurston & Daly 
(Thurston & Daly, 2012) Panel B) 
adapted from study I.  
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TIE1 interacts with TIE2 in EC-EC junctions upon ANGPT stimulation of ECs, regulating TIE2 
activity and internalization (Korhonen et al., 2016). The interacting interfaces of the receptors were 
found to depend on charged regions within the receptor ectodomains (Seegar et al., 2010). TIE1 gene 
silencing in cultured ECs, or deletion in the mouse genome, also impaired ANGPT1 induced TIE2 
phosphorylation further indicating the importance of TIE1 in TIE2 biology (D'Amico et al., 2014; 
Korhonen et al., 2016; Savant et al., 2015). Moreover, TIE1 was needed for ANGPT2 agonistic 
activity, but the detailed mechanisms are yet to be clarified (D'Amico et al., 2014; Korhonen et al., 
2016). 
 
TIE2 phosphorylation is negatively regulated by the vascular endothelial protein tyrosine phosphatase 
(VE-PTP, official name PTPRB). VE-PTP is a membrane bound tyrosine phosphatase with 17 
fibronectin type III repeats in its extracellular domain, and an intracellular phosphatase domain 
(Figure 2) (Eklund et al., 2017). VE-PTP regulates ANGPT–TIE signaling by dephosphorylating 
TIE2 at the kinase domain thus inhibiting downstream signaling (Li et al., 2009). Antibodies targeting 
VE-PTP extracellular domain induce the formation of similar enlarged vessels as does the genetic 
inactivation of VE-PTP (Winderlich et al., 2009). 
 
2.2.2 Angiopoietin-1 
 
ANGPT1 is a secreted glycoprotein that consists of an N-terminal superclustering domain, a coiled-
coil domain and a C-terminal receptor binding domain (Figure 2) (Leppanen et al., 2017; Thurston 
and Daly, 2012). ANGPT1 can form dimers or trimers via the coiled-coil domain that further cluster 
into oligomers such as tetramers, pentamers and higher order multimers, via the superclustering 
domain (Kim et al., 2005; Saharinen et al., 2017b). ANGPT1 is produced in mesenchymal cells 
surrounding vessels (Davis et al., 1996). Using a fluorescent reporter mouse, ANGPT1 expression 
has been identified in the pericytes of choriocapillaries and in neuronal cells of the ganglion and inner 
nuclear layers of the retina (Park et al., 2017). In addition, pericytes in the lung express ANGPT1 
(Kato et al., 2018). ANGPT1 is also produced and stored in the granules of platelets, from where it 
can be rapidly released (Brindle et al., 2006; Li et al., 2001). 
 
ANGPT1 binding to TIE2 on cell membranes induces TIE2 translocation to EC junctions. Here, TIE2 
receptors interact in trans, from one cell to another, resulting in TIE2 phosphorylation and 
downstream activation of the phosphoinositide 3 kinase (PI3K)– protein kinase B (from hereon called 
Akt) pathway (Fukuhara et al., 2008; Saharinen et al., 2008). In general, ANGPT1 binding to TIE2 
induces downstream signaling leading to EC stabilization via the actin cytoskeleton, EC-EC junction 
enforcement and anti-inflammatory signaling, however, in certain vascular beds ANGPT1 can also 
induce non-leaky vascular remodeling. Akt phosphorylates the transcription factor forkhead box O1 
(FOXO1). This leads to FOXO1 cytoplasmic localization preventing its nuclear translocation and 
transcription of its target genes, including ANGPT2 (Figure 5) (Daly et al., 2006; Wilhelm et al., 
2016). Another result from PIK3 signaling is phosphorylation of the endothelial nitric oxide synthase 
(eNOS), which signals for endothelial stability (Fukuhara et al., 2008; Kim et al., 2000a; Saharinen 
et al., 2008). ANGPT1 can also promote the migration of sub-confluent ECs via extracellular signal-
regulated kinase (ERK) signaling and TIE2 localized in EC-ECM contact sites (Fukuhara et al., 2008; 
Saharinen et al., 2008). Although ANGPT1 does not bind to TIE1, it stimulates TIE1 receptor 
phosphorylation, likely via its interaction with TIE2 (Korhonen et al., 2016; Saharinen et al., 2005). 
 
2.2.3 Angiopoietin-2 
 
ANGPT2 is structurally homologous to ANGPT1 (Figure 2), but forms mostly dimers via the coiled-
coil domain, resulting in weak TIE2 agonist activity, despite of similar TIE2 binding affinity of the 
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ANGPT1 and ANGPT2 fibrinogen-like domains (FLDs) (Davis et al., 2003; Fiedler et al., 2003; 
Maisonpierre et al., 1997; Saharinen et al., 2017b). ANGPT2 has been found to activate TIE2 to some 
extent in the lymphatic ECs and in non-inflammatory conditions, whereas ANGPT2 acts an 
antagonist, inhibiting TIE2 phosphorylation and downstream signaling in inflammation (Figure 5) 
(Gale et al., 2002; Kim et al., 2016; Korhonen et al., 2016; Reiss et al., 2007; Souma et al., 2018). 
 
ANGPT2 expression is increased in numerous diseases, such as sepsis, cancer, neovascular eye 
diseases and many others (Saharinen et al., 2017a). ANGPT2 produced by activated ECs is stored 
and secreted via Weibel-Palade bodies, which are storage granules that harbor, in addition to 
ANGPT2, von Willebrand factor and P-selectin, released upon a regulatory stimulus. Although 
considered an EC-specific growth factor, ANGPT2 is also expressed by retinal horizontal cells in 
adult mice (Hackett et al., 2002). In vitro, ANGPT2 is released from Weibel-Palade bodies upon 
various stimuli, such as phorbol 12-myristate 13-acetate (PMA) and the inflammatory agents 
thrombin and histamine (Fiedler et al., 2004). The expression of ANGPT2 is controlled by the Akt–
FOXO1 pathway (Daly et al., 2004; Potente et al., 2005), and is elevated by tumor necrosis factor-a 
(TNFa), VEGF, hypoxia, hyperglycemia, and during angiogenesis (Hackett et al., 2002; Kim et al., 
2000b; Mandriota and Pepper, 1998; Rasul et al., 2011). 
 
ANGPT2 induces TIE2 translocation to the junctions of cultured ECs, where it is the only 
endogenously expressed ligand. In comparison to exogenous ANGPT1, ANGPT2 induces weak TIE2 
phosphorylation, which is increased if TIE2 is ectopically expressed (Saharinen et al., 2008). In 
stressed HUVEC cultures, where Akt signaling is low, ANGPT2 can act as a TIE2 agonist and, similar 
to ANGPT1, phosphorylate TIE2 and induce Akt activation (Daly et al., 2006). When added to ECs 
together with ANGPT1, ANGPT2 acts as an antagonist, and inhibits ANGPT1–TIE2 signaling dose-
dependently (Yuan et al., 2009). 
 
2.3 ANGPT–TIE system in vascular development 
 
ANGPT–TIE signaling is essential for proper vascular development. Genetic deletion of either Tie2 
or Angpt1 in mice results in embryonic death at E10.5–E12.5 because of defects in the cardiovascular 
development (Dumont et al., 1994; Jeansson et al., 2011; Sato et al., 1995; Suri et al., 1996). In these 
mice, the embryos have less ECs, and the developing vasculature fails to mature normally. Ectopic 
expression of Angpt2 during embryonic development results in vascular defects and a phenotype 
comparable to that of Tie2 or Angpt1 deleted mouse embryos, and lethality at around E10 
(Maisonpierre et al., 1997). Angpt1 can be deleted after E12.5 without causing major defects or 
lethality, indicating a specific timeframe where its activity is needed (Jeansson et al., 2011).  
 
Genetic mouse models have further revealed that ANGPT2 is not as crucially needed for embryonic 
blood vascular development as ANGPT1. Angpt2 deficient pups are born, but die within two weeks 
after birth due to generalized lymphatic dysfunction. Specifically, Angpt2 deletion leads to impaired 
zipper-to-button transformation of the junctions of initial lymphatic vessels, and to altered pericyte 
coverage of the maturing lymphatic vessels (Gale et al., 2002; Zheng et al., 2014). Interestingly, the 
lymphatic defects are corrected in an Angpt1 knock-in into the Angpt2 locus (Gale et al., 2002). 
 
Universal deletion of Tie2 leads to impaired vascular development and embryonic edema (Thomson 
et al., 2014). Not surprisingly, a similar phenotype was found in Angpt1 and Angpt2 double knock-
out mice. If universal deletion is induced at E12.5, the Angpt1-Angpt2 double knock-out mice survive, 
but develop embryonic edema and have defective lymphatic vascular development (Thomson et al., 
2014). Deletion of Angpt1 and Angpt2 at E16.5 allows the mice to develop postnatally. At the age of 
three weeks the mice develop glaucoma that arise due to defective function of the ocular lymphatics 
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and the Schlemm’s canal, similar to Tie2 deleted mice (Thomson et al., 2014). Interestingly, 
heterozygous mutations in Tie2 and Angpt1 have also been found in human patients with primary 
congenital glaucoma (Souma et al., 2018). The less studied ANGPT4 (originally ANGPT3 in the 
mouse) was recently found to be important for venous remodeling in the mouse retina as well as 
retinal fluid clearance and neuronal function (Elamaa et al., 2018). 
 
Embryonic Tie1 deletion is lethal at E13.5. TIE1 null mice have compromised capillary remodeling, 
and loss of ECs in the microvasculature (Puri et al., 1995). Tie1 can be deleted in adult mice without 
harmful effects under homeostasis. Interestingly, when syngeneic tumors are implanted in the 
knockout mice, tumor growth is decreased, but the mechanisms are not yet understood (D'Amico et 
al., 2014). TIE1 is also an important factor in lymphatic development and in the development of the 
postnatal retinal vasculature (D'Amico et al., 2014; Qu et al., 2010). Lymphatic capillaries and the 
collecting lymphatics fail to develop if only the TIE1 ectodomain is expressed, and the TIE1 
intracellular domain is required both during embryonic development and after birth (Shen et al., 
2014). As mentioned above, TIE1 has been found to be required for certain ANGPT-mediated 
vascular responses, however, the mechanism explaining the various biological phenotypes of Tie1 
gene targeted mice have remained somewhat elusive until now. Further highlighting the importance 
and complexity of TIE receptor signaling, the universal deletion of Ve-ptp leads to embryonic 
lethality, and causes severe defects in angiogenesis, but not vasculogenesis, and in heart function 
(Baumer et al., 2006; Dominguez et al., 2007).  
 
3. Integrins 
 
Integrins are cell adhesion receptors that mediate EC adhesion to the ECM, or to other cells. Integrins 
are found in all cell types and are essential for many cellular functions, including cell movement, cell 
division and sensing the environment. Integrins also serve as pathogen receptors for several bacteria 
and viruses (Bachmann et al., 2019; Stewart and Nemerow, 2007). Integrins form ab heterodimers 
that differ in their specificity for ECM components as their ligands. 18 alpha subunits and 8 beta 
subunits have been found in vertebrates, making up 24 different integrin heterodimers (Figure 3). By 
binding to the ECM, integrins connect the ECM to the intracellular actin cytoskeleton. Uniquely, 
integrin signaling within a single cell is bidirectional (Sun et al., 2016b). 
 
 3.1 Structure and function of integrins 
 
3.1.1 Integrin structure and activation 
 
The integrin subunits are 90-160 kD in size and are comprised of several subdomains that form the 
complex structure. In brief, integrins contain a large ectodomain, flexible linker region, a 
transmembrane helix spanning the cell membrane, and, in most cases, a short cytoplasmic domain 
Figure 3. Integrin heterodimers. Schematic 
presentation of integrin heterodimers and major 
ligands. Integrins reported to be expressed in the 
ECs are marked with red circles. Information for 
the schematic has been combined from several 
articles (Hodivala-Dilke et al., 2003; Humphries et 
al., 2006; Welser et al., 2017). 
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(Figure 4) (Bachmann et al., 2019). The extracellular portion of alpha subunits consist of the b-
propeller, a thigh domain, and two calf domains (Figure 3). Some alpha chains additionally have an 
alpha-I domain (also called alpha-A) inside the b-propeller. The b-propeller has several subdomains, 
including the N-terminal Ca2+ binding domains, which affect ligand binding. The extracellular 
domain of the beta subunit consists of a beta-I domain, a plexin-semaphorin-integrin domain, four 
EGF modules, and a beta-tail domain (Figure 4) (Bachmann et al., 2019). 
 
Integrins do not have any enzymatic activity, and are activated via a conformational change into an 
open-extended conformation (Figure 4). Integrins can be activated outside-in via ligand binding to 
integrin ectodomain, or inside-out via adaptor protein binding to integrin intracellular tail. Inside-out 
activation of the integrins leads to a conformational change as the intracellular and membrane 
spanning portions of alpha and beta subunits separate from each other allowing the extracellular head 
domain to open into an extended form from a bent closed conformation (Figure 4). This opening 
enhances ECM binding of integrins. Talin is one of the best characterized integrin adapter proteins 
that binds to integrin beta cytoplasmic tails mediating integrin inside-out activation (Kechagia et al., 
2019). Outside-in signaling is supported by ligand binding to the extracellular region, and similarly 
promotes the open extended conformation (Bachmann et al., 2019). As of recently, inside-in signaling 
of integrins has also been reported to take place, regulating anoikis (Alanko et al., 2015). 
 
Ligand binding of integrins is dependent on Ca2+, Mn2+, and Mg+ ions. Integrins bind to various ECM 
proteins, such as collagens, laminins and fibronectins, as well as cell adhesion molecules such as 
vascular cell adhesion molecule (VCAM) and intercellular cell adhesion molecule (ICAM). 
Typically, a given integrin can bind many ligands, which may, to some extent, be explained by shared 
consensus sequences recognized by the integrin ligand binding domain. Four major types of ligand-
integrin interactions have been reported: 1) binding of the RGD (arginine-glycine-aspartic acid) 
peptide motif, present e.g. in FN and vitronectin, 2) binding of the LDV (leucine-aspartate-valine) 
motif, found in eg. FN and in cell adhesion molecules, 3) binding of alpha-I domain containing 
integrins to laminin and to collagen via the GFOGER motif and 4) highly specialized laminin binding 
(Bachmann et al., 2019; Humphries et al., 2006). 
 
3.1.2 Integrin mediated cell adhesions 
 
The characterization of the integrin adhesome has led to the identification of approximately 200 
proteins that regulate integrin mediated cell adhesion (Horton et al., 2016; Winograd-Katz et al., 
2014). Collectively, integrin mediated adhesions are dynamic structures that transduce mechanical 
forces in stable and migratory cells and in homeostasis and disease (Sun et al., 2016b). Actin 
Figure 4. A schematic of the three integrin 
conformational states. From left to right: bent-
closed, extended closed, and extended open 
conformations. Ligand or adaptor binding induces 
conformational activation of integrins. Inhibitory 
adaptor protein binding confines integrins into 
bent-closed conformation. The characteristic 
protein domains of alpha- and beta- subunits are 
indicated for the open extended conformation. 
Schematic adapted from Su et al. (Su et al., 2016). 
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cytoskeleton rearrangements are orchestrated via integrin activation and clustering, facilitating 
adhesional changes and cell membrane movement. Various types of integrin-mediated adhesions 
have been observed that differ in their function, subcellular location and molecular composition. An 
important factor affecting the adhesion formation is the composition of the ECM, which stimulates 
integrin outside-in signaling. The adhesions include nascent adhesion, focal contacts, focal adhesions, 
fibrillar adhesions, podosomes and invadopodia (Geiger and Yamada, 2011). Nascent adhesions and 
focal contacts can transform rapidly into focal adhesions during cell migration and further mature 
into fibrillar adhesions. Fibrillar adhesions are elongated adhesions, which contain FN, a5b1-integrin 
and the adapter protein tensin promoting mechanotransduction and adhesive signaling (Figure 1) 
(Georgiadou and Ivaska, 2017; Pankov et al., 2000). 
 
Podosomes are specialized actin structures that mediate mechanosensing and matrix degradation, 
most importantly in immune cells like monocytes (Linder and Wiesner, 2016). Invadosomes, 
including podosomes, are called invadopodia. Leukocytes and cancer cells use invadopodia for matrix 
degradation during BM invasion (Seano and Primo, 2015). Integrins and integrin adaptors link to the 
actin cytoskeleton core of the invadopodia, along with several actin binding proteins, like cortactin 
(Seano and Primo, 2015). Interestingly, another podosome-like adhesion structure has been 
identified, which does not connect to the actin cytoskeleton, but rather to clathrin-containing 
structures via avb5-integrin mediating cell adhesion (Lock et al., 2019). 
 
An essential feature in integrin adhesions is integrin trafficking that facilitates the dynamic nature of 
cell adhesions. In in vitro cancer cell models active b1-integrin is trafficked frequently to intracellular 
vesicles, whereas inactive b1-integrin is endocytosed but rapidly returned to the cell membrane 
(Arjonen et al., 2012; Moreno-Layseca et al., 2019). The integrins are endocytosed in Ras-related 
protein (Rab5) positive early endosomes that mature into late endosomes, and can be targeted for 
degradation by lysosomes, or alternatively recycled back to the cell membrane in Rab11 positive 
recycling endosomes (Moreno-Layseca et al., 2019).  
 
 3.2 Integrin adaptor proteins 
 
Integrin adaptors are involved in both activation and inhibition of integrins. 88 adaptor proteins that 
directly bind integrins, have been reported so far, but only a small subset of these has been well 
characterized. Some adaptors bind many integrin tails and some have a more limited binding 
specificity. For example, b1-integrin has been reported to bind 32 adaptor proteins, of which five 
adaptors are unique to b1-integrin, and many of these have not been studied in detail (Bachmann et 
al., 2019). Adaptors regulate integrin signaling, of which the best characterized is the 
mechanosensory signaling, but additional functions affecting e.g. metabolism are emerging 
(Bachmann et al., 2019). Activating adaptors switch the integrin heterodimer from a low affinity 
ligand binding conformation to a high affinity one. The best characterized activating adaptors are 
talins (Figure 4) and kindlins, which are essential for integrin clustering at cell adhesions.  
 
Integrin inhibiting adaptors bind either the beta or the alpha subunit. Integrin cytoplasmic domain 
associated protein 1 (ICAP1), filamin and Docking protein 1 (Dok1) bind beta subunits, whereas 
SHANK associated RH domain interacting protein (SHARPIN), nischarin and the mammary-derived 
growth inhibitor bind alpha subunits (Morse et al., 2014). 
 
Some adaptor proteins link integrins to actin cytoskeleton. The most studied are talins, tensins (Figure 
4) and filamin, which bind universally to several integrin beta tails. Talin-1–integrin–actin complex 
is the first to assemble in the formation of focal contacts that mature to focal adhesions (Figure 1). 
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Talin-2, in contrast, is found in fibrillar adhesions, but its function is unclear (Gough and Goult, 
2018). Tensin-1 and tensin-3 promote fibrillar adhesions in fibroblasts, whereas tensin-2 can be found 
in focal adhesions. Tensin-1 and -3 promote the activated integrin conformation, in analogy to talin-
1. Tensin-1 can replace talin in the b1-integrin tail, and promote fibrillar adhesion formation in the 
cell center (Figure 1) (Georgiadou and Ivaska, 2017). 
 
Regulation of the integrin activation state is crucial for proper cellular function. Activating and 
inhibiting adaptors compete in binding to the beta tail determining the conformational state. For 
example, talin and kindlin mediated integrin activation is inhibited by filamin binding. Additionally, 
talin binding is inhibited by Dok1, and ICAP1 inhibits binding of kindlin. Inhibitors that bind to the 
integrin alpha tail, like SHARPIN, bind to the same conserved site, but can still inhibit binding of 
integrin activators to the beta tail (Morse et al., 2014). 
 
Some of the integrin binding proteins have catalytic activity, like kinases and phosphatases, and they 
mediate signaling at cell adhesion sites, including the Focal adhesion kinase (FAK) (Tanjore et al., 
2008). In addition, several signaling pathways are induced downstream of activated integrins 
including Src, ERK, and Akt-mediated signaling (Figure 1) (Georgiadou and Ivaska, 2017; 
Huveneers et al., 2015; Lo, 2017). Integrins can also be phosphorylated by several kinases, which 
may regulate the adaptor binding (Chatterjee et al., 2018; Gahmberg et al., 2019). In platelets, the 
role of phosphorylation has been better characterized. Tyrosine phosphorylation of the b3 integrin 
tail by Src regulates aIIbb3-integrin signaling, with effects for example in platelet aggregation 
(Durrant et al., 2017; Phillips et al., 2001). In summary, the integrin signaling is complex, and 
regulates in a context-dependent manner various cellular functions including cell adhesion, migration, 
cell division, organelle compartmentalization, chromosome segregation, proliferation and 
metabolism (Bachmann et al., 2019). 
 
3.3 Endothelial integrins 
 
ECs express a subset of integrins. The integrin expression pattern may vary depending on the vascular 
bed studied, and in quiescent and angiogenic ECs (Stupack and Cheresh, 2002). ECs have been 
mainly reported to express five different b1-integrin heterodimers, two different av-integrin 
containing heterodimers, and the a6b4-integrin (Figure 3) (Hodivala-Dilke et al., 2003; Welser et al., 
2017). Further, it seems that avb8-integrin is needed in a non-EC-specific manner for the 
development of the vasculatures in the brain, spinal cord and eye (Table 1). Endothelial RGD binding 
integrins can bind to several ligands containing the consensus sequence, but a5b1-integrin is 
considered as the major FN receptor, avb5-integrin is primarily a vitronectin receptor, and avb3-
integrin binds FN and vitronectin. All of them can bind other RGD containing ligands, e.g. 
osteopontin (Humphries et al., 2006). The other EC integrins have binding specificity towards 
collagens and laminins (Figure 2) (Hodivala-Dilke et al., 2003). Endothelial b1-integrin can 
heterodimerize with several alpha subunits to form integrins with varying specificity to ECM proteins 
(Figure 2) (Hodivala-Dilke et al., 2003). In addition, lymphatic ECs express a9b1-integrin (Bazigou 
et al., 2009). 
 
The functions of EC integrin heterodimers have been studies during vascular development (Table 1), 
whereas the roles of EC integrins in the mature vasculature are less well understood. In addition, 
various EC integrins have been studied during postnatal angiogenesis or in the tumor vasculature, 
however, less is known about the function of EC integrins in other types of diseases. Below, the most 
insightful studies have been referred to, and focus has been taken on the known roles of b1-integrin 
during development. 
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b1-integrin is a major integrin expressed by ECs, and known to be critical for embryonic 
development. Ubiquitous deletion of Itgb1 leads to retarded development and death of the embryos 
by E5.5 (Stephens et al., 1995). Embryos, where Itgb1 has been deleted from the endothelium, die 
between E9.5–10.5 (Table 1) (Lei et al., 2008; Tanjore et al., 2008). b1-integrin is dispensable for the 
formation of the vascular plexus via vasculogenesis, but is necessary during the angiogenic expansion 
of the vasculature (Table 1) (Lei et al., 2008; Tanjore et al., 2008). Deletion of endothelial b1-integrin 
at different developmental time points using various Cre lines has elucidated the function of b1-
integrin during vascular development. Deletion of b1-integrin using the Tie2-Cre driver mice is lethal 
by E10.5, whereas its deletion using the Tie1-Cre delays the death of the embryos by one day, until 
E11.5 (Table 1) (Carlson et al., 2008), and using the constitutive Cdh5-Cre until E13.5–E17.5 
(Yamamoto et al., 2015). Deletion using the constitutive Cdh5-Cre revealed that b1-integrin is 
essential in arterial lumen formation (Table 1) (Zovein et al., 2010). Deletion of b1-integrin 
postnatally using a tamoxifen-inducible Cdh5-iCre compromised the development of the retinal 
vasculature (Table 1) (Yamamoto et al., 2015). 
 
In contrast to b1-integrin, other endothelial integrins appear to play less critical functions during 
vascular development (summarized in Table 1), and even the endothelial deletion of Itga5 did not 
result in a major vascular phenotype (Li et al., 2012; van der Flier et al., 2010). However, although 
the Itga9-/- mice are born normally, the lymphatic vascular development is defective, due to abnormal 
formation of lymphatic valves (Table 1) (Bazigou et al., 2009; Huang et al., 2000). 
 
Studies in adult mice have revealed functions of various EC integrins in disease processes 
(summarized in Table 1). A recent report proposed that a5b1-integrin promotes angiogenesis in the 
context of the brain and heart ischemia (Table 1) (Lee et al., 2018; Li et al., 2012; Pang et al., 2018). 
In addition, a5b1-integrin has been found to contribute to chronic arterial inflammation (Table 1) 
(Al-Yafeai et al., 2018). VEGF has been reported to induce vascular growth via a1b1- and a2b1-
integrins, and this signaling seems to promote both VEGFR2 mediated lymphangiogenesis in healing 
wounds and tumor angiogenesis (Hong et al., 2004; Senger et al., 1997; Senger et al., 2002). avb5-
integrin in turn, has been shown to mediate VEGF-induced vascular permeability in vivo, via FAK 
recruitment by Src kinase (Table 1) (Eliceiri et al., 2002). 
 
The function of EC integrins in tumor angiogenesis has been puzzling. Itgb3 and Itgb5 deletions in 
mice resulted in enhanced angiogenesis in implanted tumors (Table 1) (Reynolds et al., 2002), 
whereas Itga1 deletion decreased tumor angiogenesis (Pozzi et al., 2000). Furthermore, it has been 
suggested that the FN binding a5b1- and avb3-integrins might play essential roles in tumor 
angiogenesis; however, contrasting results have also been published (Raab-Westphal et al., 2017). 
Despite of the many studies indicating that b1-integrin is essential in developmental angiogenesis 
(Table 1), Itga5 deletion using Tie2-Cre in mice revealed that a5b1-integrin is not essential for tumor 
angiogenesis, and neither is Itgav (Murphy et al., 2015). In general, it is now considered that some of 
the poorly understood functions of integrins can be compensated by other integrin heterodimers in 
the tumor vasculature, thus complicating attempts to inhibit integrin mediated tumor angiogenesis, 
and it further seems that the partial benefit of small molecular targeting of FN binding integrins in 
the tumor vasculature has been a result of secondary effects (Murphy et al., 2015; Raab-Westphal et 
al., 2017). 
 
Integrins have also been found to interact with growth factor receptor systems in ECs, including the 
VEGF and TIE receptor systems. While integrin – growth factor ligand or receptor interactions have 
been mostly reported to be activating, also negative regulation of the growth factor receptors by 
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integrins have been reported (Ivaska and Heino, 2011). In the blood vascular ECs, VEGFR2 has been 
reported to interact with avb3-integrin during angiogenesis, and similarly, in the lymphatic ECs, 
VEGF-A, -B and -C have been shown to bind to a9b1-integrin during lymphangiogenesis (Vlahakis 
et al., 2007; Vlahakis et al., 2005). a5b1-integrin also interacts with VEGFR3 in vitro in lymphatic 
ECs, promoting survival signals (Zhang et al., 2005).  
 
Similarly, interactions of TIE receptors with integrins have been reported. TIE2 was found to co-
immunoprecipitate with both a5b1- and avb3-integrin from ECs, and both TIE2 and TIE1 were 
found to interact with integrins using recombinant proteins (Cascone et al., 2005; Dalton et al., 2016; 
Thomas et al., 2010). ANGPTs have been also found to bind various integrins in ECs and non-ECs, 
like cardiomyocytes (Dallabrida et al., 2004), breast cancer cells (Imanishi et al., 2007) and in glioma, 
where the ANGPT2-avb1-integrin signaling promoted glioma metastasis (Hu et al., 2006). One 
report also describes endothelial interactions where ANGPT2 co-immunoprecipitated from TIE2-low 
EC tip cells with avb5- and a5b1-integrins (Felcht et al., 2012). However, the in vivo significance 
of integrin interactions is in many cases not thoroughly understood (see the discussion for further 
details on TIE-ANGPT-integrin signaling). 
 
Table 1. Genetically modified integrin mouse lines with vascular phenotypes or vascular integrin deletion. 
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 Deletion Vascular phenotype Reference 
a1 Itga1-/- Reduced tumor angiogenesis (Pozzi et al., 
2000) 
a4 Itga4flox/flox;Tie2-Cre No vascular phenotype, followed up to 1 year (Priestley et al., 
2007)  
Itga4loxp/loxp;Tie2-Cre Increased lymphangiogenesis and lymph node metastasis (Garmy-Susini 
et al., 2013) 
a5 
 
Itga5-/- Embryonic death at E9.5, defects in vasculogenesis and 
angiogenesis, reduced FN deposition 
(Francis et al., 
2002) 
Itga5flox/flox;Tie2-Cre No obvious vascular defects in vascular beds studied up to 
18 months, attenuated hypoxia-induced cerebral 
angiogenesis, no compensatory increase in avb3 levels 
(van der Flier et 
al., 2010) 
(Li et al., 2012)  
Itga5flox/flox;Pdgfrb-Cre 35% lethality before E17.5; edema, defective formation of 
lymphovenous valves 
(Turner et al., 
2014) 
Itga5+/-;Ldlr-/- Reduction of atherosclerotic lesions in atheroprone regions (Sun et al., 
2016a) 
Itga5flox/flox;Cdh5-iCre;Apoe-/-  Deletion induced in adulthood, mice on high fat diet had 
less oxidized low-density lipoprotein (oxLDL) induced 
atheromas, and matrix deposition of FN was reduced 
(Al-Yafeai et 
al., 2018) 
Itga5flox/flox;Tie2-Cre Smaller infarction zones and increased BBB integrity in a 
brain ischemia model 
(Roberts et al., 
2017) 
Aggravated progression of experimental autoimmune 
encephalomyelitis (EAE) in adult mice, elevated 
permeability of spinal cord blood vessels 
(Kant et al., 
2019) 
av/a5 Itga5flox/flox:Itgavflox/flox;Tie2-
Cre 
Most of the embryos die by E14.5, defects in the major 
vessels, minor differences according to genetic 
background 
(van der Flier et 
al., 2010) 
Itga5flox/flox:Itgavflox/flox;Cdh5-
Cre 
Normal tumor growth and tumor angiogenesis. (Murphy et al., 
2015) 
a6 
 
Itga6flox/flox;Tie1-Cre Increased tumor growth and tumor vessel angiogenesis 
mediated by elevated VEGF signaling 
(Germain et al., 
2010) 
Itga6flox/flox;Tie2-Cre 
 
Decreased ischemia-induced angiogenesis (Bouvard et al., 
2012) 
Reduced tumor growth and reduced tumor vessel number, 
reduced TIE2-expressing macrophage infiltration 
(Bouvard et al., 
2014) 
Itga6flox/flox;Pdgfrb-Cre, 
embryonic deletion 
No effect on physiological angiogenesis, retinal 
vasculature; in tumor vasculature less pericytes, reduced 
stability, increased diameter, abnormal BM 
(Reynolds et al., 
2017) 
a9 Itga9-/- P6-P12 pups smaller, respiratory distress due to 
chylothorax, edema and lymphocyte accumulation in the 
chest cavity 
(Huang et al., 
2000) 
a9 Itga9-/-;Tie2-Cre or Cdh5-Cre Deficient lymphatic valve formation and FN deposition to 
matrix 
(Bazigou et al., 
2009) 
av 
 
Itgav-/- 80% death at E9.5-11.5 but not due to angiogenic defects, 
embryos show extensive vasculogenesis and angiogenesis, 
20% die at P0 from hemorrhage 
(Bader et al., 
1998) 
Itgav flox/av null;Tie2-Cre or 
Nestin-Cre 
No phenotype in cerebral vasculature with Tie2-Cre, with 
Nestin-Cre cerebral vascular defects. 
(McCarty et al., 
2005) 
b1 
 
Itgb1-/- Embryonic lethality after implantation (Fassler and 
Meyer, 1995) 
(Stephens et al., 
1995)  
 
Itgb1flox/flox;Tie2-Cre or Tie1-Cre Embryonic lethality at E10.5-11.5 (Carlson et al., 
2008) 
Itgb1flox/flox;Tie2-Cre 
 
Embryonic lethality at E9.5-10, abnormal vascular 
patterning 
(Lei et al., 2008; 
Tanjore et al., 
2008) 
Itgb1flox/flox;Cdh5-Cre-ERT or 
Itgb1e3/e3;Cdh5-Cre  
Embryonic lethality at E13.5-17.5, disrupted vasculature, 
hemorrhage, abnormal arterial lumen formation 
(Zovein et al., 
2010) 
Itgb1flox/flox;sma22a-Cre 
Itgb1e3/e3;sma22a-Cre 
Itgb1flox/flox;Wnt1-Cre 
Itgb1e3/e3;Wnt1-Cre 
Defects in vascular wall development in the aortic arch 
and branching vessels, lethality embryonic or postnatal 
depending on deletion and Cre-line (smooth muscle cell or 
neural crest silenced) 
(Turlo et al., 
2012) 
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Itgb1lox/lox, Pdgfb-iCre or Cdh5-
iCre 
Deletion induced postnatally, deficiency in retinal vessel 
sprouting and VE-cadherin localization during vascular 
development and maturation, hyperproliferation of 
vascular front 
(Yamamoto et 
al., 2015) 
Itgb1lflox/flox;EC-SLC-Cre Deletion in adult mice, disturbed alignment of aortic ECs 
in the outer curvature 
(Xanthis et al., 
2019) 
b3/b5 Itgb3-/-;Itgb5-/- or Itgb5-/-  Enhanced tumor neoangiogenesis (Reynolds et al., 
2002) 
b3 
 
Itgb3-/- 
 
Increased VEGF stimulated permeability  (Reynolds et al., 
2004) 
Coronary capillaries fail to form in male mice (Weis and 
Cheresh, 2011) 
Enhanced vascular leakage after endotracheal LPS, 
increased mortality after LPS or CLP induced sepsis, 
increased mesenteric vascular leakage after LPS 
(Su et al., 2012) 
Itgb3mut+/+  Phosphorylation sites Tyr747 and Tyr 759 mutated to 
alanines, normal vascular development, reduced tumor 
vasculature  
(Mahabeleshwar 
et al., 2006) 
b4 Itgb4-1355T+/+  Reduced tumor vascularization, reduced retinal 
neovascularization  
(Nikolopoulos 
et al., 2004) 
b5 
 
Itgb5-/- 
 
Reduced vascular leakage in models of acute lung injury 
and (ALI) and ventilation induced lung injury (VILI) 
(Su et al., 2007) 
Reduced vascular leakage after LPS or cecal ligation and 
puncture (CLP) 
(Su et al., 2013) 
Less VEGF induced vascular leakage. No reduction in 
Itgb5+/- or Itgb3-/- mice. 
(Eliceiri et al., 
2002) 
b8 
 
Itgb8-/- 
 
65% lethality during midgestation due to improper 
vascularization of the yolk sac and the placenta. 35% 
lethality perinatally, intracerebral haemorrhage, abnormal 
capillaries in the brain, brain ECs are hyperplastic. 
(Zhu et al., 
2002) 
Itgb8flox/flox-Nestin-Cre  
 
Brain haemorrhage at P0, abnormal vascular 
morphogenesis, disorganizes glia. Mice followed to 
adulthood appeared normal due to an unknown repair 
mechanism. 
(Proctor et al., 
2005) 
Hemorrhage in the brain, abnormal vascular 
morphogenesis, leaky vasculature 
(Proctor et al., 
2005) 
Retinal hemorrhage, under-developed retinal vasculature, 
elevated branch point density and vascular coverage 
(Arnold et al., 
2012) 
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4. Regulation of endothelial barrier function in inflammation and neovascular 
disease 
 
Transient increase in vascular permeability is an essential part of a normal inflammatory response, 
when increasing plasma transport and immune cell infiltration across the vascular wall occur. Acute 
vascular leakage is induced by the release of inflammatory agents, such as histamine produced by 
mast cells, and released upon acute infection or allergy. In addition to increase in EC permeability, 
inflammation induces EC activation and changes in pericyte coverage and ECM composition, 
including the deposition of a provisional matrix, rich in plasma FN (Rahimi, 2017). The inflammatory 
ECM is considered to play a role in angiogenic destabilization of ECs via guiding EC adhesions 
(Arroyo and Iruela-Arispe, 2010). Moreover, alterations of the ECM occur during chronic 
inflammatory responses, which may further promote immune cell activation (Sorokin, 2010). In acute 
inflammation, vascular permeability affecting mostly post-capillary venules is reversible and 
decreased when inflammation resolves. However, prolonged inflammation or chronic inflammatory 
diseases that develop over time are characterized by chronic vascular permeability, which leads to 
changes in the capillary and venule structure, endothelial dysfunction and vascular remodeling, driven 
by e.g. VEGF (Claesson-Welsh, 2015; Rahimi, 2017). 
 
4.1 Vascular destabilizing factors 
 
Various growth factors, pro-inflammatory cytokines and other agents produced during inflammation 
promote EC activation and permeability. Well known mediators of the fast type I EC activation are 
thrombin, bradykinin and histamine, which can increase EC permeability in minutes via binding to 
cell surface heterotrimeric G-protein coupled receptors (GPCRs) (Beckers et al., 2010; Birukov and 
Karki, 2018). Desensitization of the GPCR signaling, which occurs within 10-20 minutes, results in 
reversible EC permeability increase. In contrast, type II EC activation is induced by inflammatory 
cytokines such as TNFa or interleukin (IL)-1b, which produce a slower response (Pober and Sessa, 
2007). During microbial infection, lipopolysaccharide (LPS), which is a cell wall constituent of 
Gram-negative bacteria, and a strong inflammatory mediator, induces EC activation and permeability 
via the Toll like receptor 4, both in vitro and in vivo, affecting both capillaries and larger vessels 
(Chatterjee et al., 2008; Gong et al., 2008). LPS is also a strong activator of the innate immune system, 
leading to immune cell secretion of numerous proinflammatory cytokines, including TNFa and IL-
1b. 
 
The intracellular signaling cascades induced by type I and type II mediators are conveyed via partially 
overlapping downstream signaling molecules. Notably, GPCRs, in contrast to type II receptor 
signaling, induce a strong Ca2+ signal via phospholipase C, resulting in prostaglandin I2 and nitric 
oxide (NO) synthesis by ECs. However, both type I and II mediators induce rearrangements in the 
actin cytoskeleton that are associated with increased contractility. Thrombin signals via protease 
activated receptor 1 to activate RhoA, which inhibits the activity of the MLCP, and via calmodulin, 
which activates MLCK, leading to MLC phosphorylation (Beckers et al., 2010; Birukov and Karki, 
2018). Thrombin also increases the expression of ANGPT2, and ANGPT2 has been found to mediate 
thrombin induced Ca2+ signaling and EC permeability (Benest et al., 2013; Huang et al., 2002) 
(Rathnakumar et al., 2016). TNFa and IL-1b stimulation of ECs also leads to actin stress fiber 
formation. TNFa suppresses cyclic adenosine monophosphate (cAMP) and Rac1 signaling, thus 
promoting stress fiber formation (Schlegel and Waschke, 2009), and IL-1b increases contractility via 
RhoA (Ganter et al., 2008). TNFa also induces expression of ANGPT2, and the effects of TNFa are 
further enhanced by ANGPT2 (Fiedler et al., 2006; Kim et al., 2000b). In vitro, LPS activates several 
tyrosine kinases, such as the Src family kinases, Protein kinase C, and Rho kinase that rearrange the 
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actin cytoskeleton into stress fibers and promote adherens junction disruption (Bannerman and 
Goldblum, 1997; Bannerman et al., 1998; Barabutis et al., 2013; Chatterjee et al., 2008; Gong et al., 
2008; Joshi et al., 2014; Zhao and Davis, 2000). In vivo, LPS induced leakage of post capillary 
venules involves decreased endothelial Rac1 activity (Schlegel and Waschke, 2009). 
 
Contractile actin stress fibers contribute to decreased EC monolayer integrity, but various 
inflammatory agents, such as histamine and bradykinin, also directly regulate VE-cadherin 
phosphorylation and internalization, leading to dismantling of EC junctions (Dejana et al., 2008; 
Orsenigo et al., 2012). TNFa also induces the phosphorylation of VE-cadherin, b- and g-catenin, 
leading to VE-cadherin internalization (Dejana et al., 2008). IL-1b decreases junctional VE-cadherin 
independently of its classical myeloid differentiation factor 88 (MyD88)-NFkB pathway, via MyD88-
ARF nucleotide binding site opener (ARNO)-ADP ribosylation factor 6 (ARF6) pathway (Zhu et al., 
2012). 
 
VEGF, which is produced by many cell types in acute inflammation, in allergy, and in hypoxia, is a 
potent inducer of vascular permeability, contributing to vascular leakage in tumors and in neovascular 
eye diseases (Ferrara et al., 2003). VEGF promotes paracellular permeability by inducing the 
phosphorylation of VE-cadherin Y658 through the adapter protein Tsad leading to Src activation, and 
VE-cadherin internalization via b-arrestin-mediated endocytosis (Dejana et al., 2008; Fukumura et 
al., 2001; Gavard and Gutkind, 2006; Sun et al., 2012). In vivo, basal VE-cadherin phosphorylation 
has been observed in veins, which is suggested to contribute to the higher permeability of veins than 
arteries. VEGF also contributes to the permeability of capillaries by inducing fenestrae formation in 
small venules and capillaries (Roberts and Palade, 1995). Thus, various permeability inducing agents 
use both distinct and overlapping signaling pathways to regulate EC permeability. 
 
4.1 Diapedesis 
 
In addition to increased fluid leakage, the paracellular route is also used by inflammatory cells during 
diapedesis, i.e. the controlled passage of white blood cells from the vasculature to tissues. Upon 
encountering an invading pathogen, macrophages and dendritic cells secrete cytokines that activate 
the ECs locally. Activated ECs express various cell adhesion proteins such as E- and P-selectin, 
ICAM1 &2 and VCAM1 that mediate sequential binding of leukocyte integrins to ECs during 
leukocyte rolling, adhesion and arrest (Vestweber, 2015). Differential integrin adaptor binding 
determines the rolling and arrest phases (Lefort et al., 2012). Transient opening of VE-cadherin 
junctions is necessary for leukocyte diapedesis. The leukocytes do not pass the EC barrier in mutated 
mice where VE-cadherin cannot dissociate from a-catenin (Schulte et al., 2011). The EC junctions 
loosen as VE-cadherin is dephosphorylated at Y731 upon contact with leukocytes, and VE-PTP 
receptor dissociates from VE-cadherin. Additionally, the platelet F11 receptor (also known as JAMA) 
either on the surface of the ECs or leukocytes, as well as CD31, may participate (Vestweber, 2015). 
EC actomyosin forms a tight actin cytoskeleton structure around the diapedesis site, ensuring that 
there is no plasma leakage to tissues (Filippi, 2016). Although inflammation normally resolves, 
persistent inflammatory infiltrates are present during pathological or chronic inflammation 
(Phillipson and Kubes, 2011; Vestweber, 2015). In summary, diapedesis does not induce fluid 
leakage, and the mechanism is therefore different from vascular permeability leading to fluid 
accumulation and tissue edema during inflammation. 
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4.3 Sepsis 
 
Sepsis is a dramatic example of increased capillary permeability that can lead to hypovolemic shock 
due fluid leakage into the tissues. Clinically, sepsis is most often caused by Gram positive- and Gram 
negative bacteria, but also by viral or fungal infections. In addition, a sterile sepsis-like syndrome 
called systemic inflammatory release syndrome (SIRS) can initiate from e.g. mechanical trauma or 
burns. Similarly, strong hypersensitivity reactions like anaphylactic shock may lead to hypovolemia 
due to SIRS. Microbial antigens, or danger-signals from damaged cells are recognized by pathogen- 
or danger associated molecular patter (PAMPs and DAMPs, respectively) receptors (PRR) on 
immune cells (Wentowski et al., 2019). 
 
In sepsis, PRR stimulation leads to an overwhelmed inflammatory response via neutrophils and 
monocytes. The innate immune complement system and the coagulation cascade are hyperactivated, 
leading to thrombin production. In some cases, the dysfunctional coagulation cascade activation leads 
to disseminated intravascular coagulation (DIC), where fibrin clots are formed in the capillaries 
causing ischemia. The complement and coagulation cascade further reinforce each other (Wentowski 
et al., 2019). The hyperinflammatory phase can lead to compensatory immunosuppression, 
highlighted by apoptosis of immune cells like dendritic cells and lymphocytes. Further, anti-
inflammatory Th2 signaling overrides proinflammatory Th1 signaling, which may lead to 
immunoparalysis; a condition where the body cannot sustain innate or adaptive immune responses 
(Rittirsch et al., 2008). 
 
The incidence of sepsis is high among infants and elderly people, and also higher among men that 
women. Specific genetic burden towards sepsis is inconsistently studied. In addition, no large-scale 
studies have been conducted to study the risk factors of sepsis (Rello et al., 2017; Wentowski et al., 
2019). The symptoms of sepsis vary according to the initial cause, affected organs, and the patient 
history (Rello et al., 2017). In the clinics, sepsis can be suspected if respiratory rates are elevated, 
systolic blood pressure has dropped, and if the patient has a mental change. The initial treatment 
involves infusion with antibiotics and controlled fluid resuscitation. Increased lactate levels predict 
capillary hypoperfusion leading to organ failure. Several other circulating factors, like procalsitonin, 
have been investigated as biomarkers of sepsis (Wentowski et al., 2019). Notably, ANGPT2 levels, 
measured upon arrival to an emergency unit, have in numerous studies been found to predict poor 
prognosis in sepsis patients (Leligdowicz et al., 2018). 
 
In the clinics, the different phases of sepsis progression are difficult to determine. Preclinically, sepsis 
can be divided into two major phases. In the SIRS phase, where proinflammatory actions are elicited 
by the body, the ECs start to respond to inflammatory stimuli in an uncontrolled manner, and become 
dysfunctional. In the compensatory anti-inflammatory response syndrome (CARS) phase organs 
suffer from hypoperfusion as the contents of the capillaries leak heavily into the tissues (Bauer et al., 
2006). 
 
For the large part, EC dysfunction and leakage are thought to drive organ failure. In sepsis, the 
endothelial hemostatic balance is compromised as the ECs turn prothrombic and antifibrinolytic. 
From preclinical models of sepsis, it is understood that leukocyte diapedesis accelerates, and the 
cytokines produced by leukocytes enhance EC inflammation. In particular, inflammatory cytokines 
like TNFa, IL-1b, and IL-6 drive EC permeability and vascular leakage (Matsumoto et al., 2018). 
Organ function is largely compromised in septic shock. Heart function decreases in septic shock due 
to insufficient myocardial function (Merx and Weber, 2007). The cardiac depression can be measured 
using echocardiography, and is caused by a combination of activated ECs and monocytes, 
inflammatory cytokines and complement activation (Merx and Weber, 2007). The glomerular and 
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peritubular capillaries of the kidney are especially challenged in sepsis and thus acute kidney failure 
is a common consequence of sepsis. The liver, recieving 25 % from all blood, suffers from 
hypoperfusion due to a collapse of the sinusoidal vascular bed, and in the lungs, permeability increase 
in the pulmonary vasculature disrupts fluid clearance in the alveoli leading to lung injury and acute 
respiratory distress syndrome (ARDS) (Ince et al., 2016). 
 
 4.3 Vascular permeability in neovascular diseases 
 
Vascular permeability is also increased in many common but difficult to cure diseases, highlighted 
by hypoxia induced neoangiogenesis or inflammation induced vascular remodeling (Baluk et al., 
2014; Fallah et al., 2019; Lyle and Taylor, 2019), including various infectious diseases, cancer, 
atherosclerosis and several ocular diseases. In the eye, pathogenesis of proliferative diabetic 
retinopathy (PDR), diabetic macular edema (DME) and neovascular age-related macular 
degeneration (nAMD), is attributed  to hypoxia-inducible angiogenic growth factors that also increase 
EC permeability (Baluk et al., 2014; Fallah et al., 2019; Lyle and Taylor, 2019). 
 
Tumor vasculature grows to support the oxygen demand of the increasing tumor mass. The main 
angiogenic stimulus in the tumor is VEGF, which is produced by multiple cell types in response to 
hypoxia-induced activation of HIF. In addition, the tumor microenvironment is rich in various other 
growth factors, such as ANGPT2, as well as inflammatory cell derived pro-inflammatory cytokines 
that together with VEGF induce a leaky tumor vasculature. The tumor endothelium is characterized 
by poorly developed EC junctions, incomplete BM and a low pericyte coverage. The leaky vessels 
are poorly perfused, leading to hypoxia and reinforcement of the angiogenesis cascade. Leakage also 
results in increased tumor interstitial pressure, which hinders delivery of chemotherapies, but 
increases metastasis (Chiang et al., 2016; Martin et al., 2019). 
 
Atherosclerosis is a chronic inflammatory disease where large and medium sized arteries accumulate 
cholesterol in regions of turbulent flow, developing atheromas. The atheromas and subsequent 
plaques consists of inflammatory monocytes producing proinflammatory cytokines, like TNFa, 
smooth muscle cells and lipids, including low-density lipoprotein (LDL) (Back et al., 2019). 
Inflammatory cytokines activate the ECs resulting in elevated reactive oxygen species (ROS) levels 
and decreased NO signaling. Increased HIF and VEGF signaling further promote endothelial 
activation, leakage, monocyte infiltration and inflammation. Furthermore, the plaque alters and 
hinders blood flow, and unstable plaques can rupture and travel to smaller sized arteries causing 
ischemia (Gimbrone and Garcia-Cardena, 2013). 
 
4.4 ANGPT–TIE pathway and vascular stability 
 
The ANGPT–TIE pathway regulates both vascular stability and leakage in homeostasis and disease, 
respectively. Various diseases associated with endothelial activation and vascular leakage, such as 
sepsis, cancer, neovascular eye diseases, atherosclerosis and diabetes, are reported to have imbalances 
in the ANGPT–TIE system. In general, ANGPT2 levels increase in activated ECs in various diseases, 
whereas ANGPT1 levels may decrease. Simultaneously, TIE receptor expression can decrease. These 
changes in the endothelium lead to decreased ANGPT1/ANGPT2 ratio, impaired vascular stability 
due to decreased TIE2 signaling, and hence facilitate plasma leakage into tissues (Saharinen et al., 
2017a). 
 
In human sepsis, elevated ANGPT2 levels have been associated with poor patient prognosis 
correlating with high mortality (Bhandari et al., 2006; Davis et al., 2010; Ebihara et al., 2009; 
Gallagher et al., 2008; Giamarellos-Bourboulis et al., 2008; Giuliano et al., 2007; Kumpers et al., 
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2010; Kumpers et al., 2008; Mankhambo et al., 2010; Orfanos et al., 2007; Page et al., 2011; Parikh 
et al., 2006; Ricciuto et al., 2011; Siner et al., 2009; Statz et al., 2018; van der Heijden et al., 2009; 
van der Heijden et al., 2008). Decrease in ANGPT1 levels has also been reported in sepsis patients 
(Ebihara et al., 2009; Giuliano et al., 2007; Mankhambo et al., 2010; Ricciuto et al., 2011). 
Interestingly, TIE2 levels have been found to correlate with the outcome of ARDS. Certain genetic 
variations in humans were associated with high TIE2 expression; such individuals had a 28% lower 
risk of developing ARDS after microbial infection. In contrast, patients harboring a more common 
variation associated with lower TIE2 levels were 31% more likely to develop ARDS (Ghosh et al., 
2016). 
 
Several lines of evidence from mouse sepsis models suggest a functional role for ANGPT2 in sepsis. 
LPS elevates ANGPT2 expression and thus attenuates ANGPT1–TIE2 EC stabilizing signaling in 
vivo (Korhonen et al., 2016; Zeng et al., 2016). In line with this, heterozygous deletion of ANGPT2, 
or in vivo ANGPT2 targeting with siRNA, protected from LPS-induced acute lung injury (ALI) 
(David et al., 2012). In the lung, ANGPT2 attenuates TIE2 signaling and induces vascular remodeling 
during Mycoplasma pulmonis infection (Tabruyn et al., 2010). Tie2 heterozygous mice, that express 
50% less TIE2, were more susceptible to both LPS and cecal ligation and puncture (CLP) -induced 
sepsis than wild type mice (Ghosh et al., 2016). TIE2 signaling was reported to inhibit tissue factor 
activation, which can lead to thrombin production hence potentially contributing to DIC (Higgins et 
al., 2018). Highlighting the counteracting role of the ANGPT1, ANGPT1 inhibits vascular leakage 
induced by histamine, thrombin and VEGF in vivo (Baffert et al., 2006; Gamble et al., 2000; Thurston 
et al., 2000). 
 
Numerous reports have found a correlation between increased circulating ANGPT2 levels and poor 
patient prognosis in cancer (Chen et al., 2018; Goede et al., 2010; Hacker et al., 2016; Helfrich et al., 
2009; Park et al., 2007). Murine tumor models have shown that ANGPT2 is upregulated in the blood 
vessels co-opted by the tumor. This induces pericyte detachment from the capillary endothelium and 
vessel regression generating hypoxic areas that further induce the expression of ANGPT2 and VEGF, 
leading to enhanced angiogenesis in the tumor (Holash et al., 1999; Scholz et al., 2016). Pericyte 
detachment and ANGPT2-mediated activation of the endothelium promote metastasis and impair 
tumor vessel integrity leading to leakiness (Falcon et al., 2009; Imanishi et al., 2007; Keskin et al., 
2015; Minami et al., 2013; Schulz et al., 2011). 
 
Antibodies blocking ANGPT2–TIE2 interaction inhibit solid tumor growth in mice (Oliner et al., 
2004), reducing metastasis (De Palma and Lewis, 2013), and improving blood vessel endothelial 
integrity at metastatic sites (Holopainen et al., 2012). Further benefit has been reported when both 
ANGPT2 and VEGF were blocked at the same time (Daly et al., 2013; Hashizume et al., 2010; 
Kienast et al., 2013; Scheuer et al., 2016). Alas, clinical trials testing ANGPT2 targeting compounds 
did not result in improvement of patient outcome in ovarian cancer. However, ANGPT2 targeting in 
combination with VEGF inhibitors is still under investigation, and currently in clinical trials in solid 
tumors (Fukumura et al., 2018). 
 
In the eye, ANGPT2 contributes to the pathological neovascularization of both retinal and choroidal 
vessels, whereas ANGPT1 suppressed pathological neovascularization and vascular leakage (Lee et 
al., 2014b). Currently, combinatorial targeting of ANGPT2 and VEGF is being tested in clinical trials 
for the treatment of DME and nAMD (Saharinen et al., 2017a). In addition to DR and DME, serum 
ANGPT2 levels are further elevated in type II diabetic patients, which correlates with diabetic 
pathologies, like diabetic angiopathy (Li et al., 2015; Rasul et al., 2011). 
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ANGPT2 is expressed in response to turbulent flow in atheroprone regions of the arteries, where it 
strengthens inflammation and promotes endothelial activation (Le Dall et al., 2010; Post et al., 2008). 
Antibodies against ANGPT2 reduced the formation of fatty streaks in hypercholesterolemic (low-
density lipoprotein receptor−/−; apolipoprotein B100/100) mice, indicating that ANGPT2 contributes 
to early development of atherosclerotic plaques (Theelen et al., 2015).  
 
Recently, an inducible endothelial specific deletion of VE-PTP was reported. Deletion of VE-PTP 
postnatally protected in Ins2Akita129/SvEv mice from diabetes. VE-PTP inhibition induced the 
activation of TIE2, leading to activation of eNOS and inhibition of FOXO1 nuclear translocation 
attenuating inflammatory signals (Carota et al., 2019). In venous malformation, the endothelial TIE2 
receptor has a gain of function -mutation that leads to TIE2 hyperactivation, causing over grown, 
distorted vessels with excessive lumens and poor smooth muscle cell coverage. Also, the matrix 
beneath the endothelium is altered. This condition is painful and highlights the fact that a balance in 
TIE2 activity is essential for proper vessel development and homeostasis (Kangas et al., 2018). 
 
The above-mentioned pathological conditions are a result of complex signaling. In vitro studies have 
revealed potential mechanisms of action for the ANGPT-TIE system, and ANGPT1–TIE2 signaling 
stabilizes the endothelium by several means. Importantly, ANGPT1 promotes VE-cadherin stability 
in the junctions and supports the cortical actin cytoskeleton, whereas ANGPT2 counteracts these 
effects especially when inflammatory stimuli are present (David et al., 2012; Gamble et al., 2000) 
(see Figure 5 for details). 
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Figure 5. ANGPT–TIE signaling in EC quiescence and destabilization. A) ANGPT1-TIE2 stabilizing signaling in 
ECs. ANGPT1 induces the phosphorylation of TIE2, and TIE1, leading to Akt activation, FOXO1 phosphorylation and 
its nuclear exclusion and degradation, attenuating ANGPT2 expression. ANGPT1–TIE2 signaling further promotes 
cortical actin cytoskeleton via Rap1-Rac1-mediated signaling, attenuating MLC phosphorylation. VE-PTP stabilizes VE-
cadherin at EC-EC junctions and further sustains EC integrity. If VE-PTP is inhibited, phosphorylated FGD5 inhibits 
stress fiber formation via Rap1 and supports cortical actin via Cdc24. ANGPT1 inhibits inflammatory gene expression 
via inhibition of NFkB signaling. B) ANGPT1–TIE signaling is attenuated in inflammation in vivo. ANGPT2 is released 
from the Weibel-Palade bodies in response to inflammatory stimuli both in vitro and in vivo. Excess of ANGPT2 inhibits 
ANGPT1-TIE2 signaling. In vivo, inflammatory signals induce the proteolytic cleavage of TIE1, supporting ANGPT2 
antagonistic function. FOXO1 gene expression, including ANGPT2, is induced, leading to a positive feedback loop, 
fortifying EC destabilization. In synergy with inflammatory agents and VEGF, ANGPT2 dismantles VE-cadherin from 
cell junctions. VEGF-VEGFR2 signaling that activates Src kinase induces VE-cadherin internalization. ICAM1, 
VCAM1, and selectins are upregulated enabling diapedesis (not illustrated). Information illustrated here is drawn from 
multiple sources (Frye et al., 2015; Saharinen et al., 2017b; Salomao et al., 2008). 
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AIM OF THE STUDY 
 
This thesis aimed to elucidate how ANGPT2 regulates EC monolayer destabilization and vascular 
permeability. Specifically, the aim was to delineate the interplay between ANGPT2, TIE receptors 
and endothelial integrins in EC destabilization. The study was undertaken to understand the 
mechanisms underlying the loss of the EC integrity in inflammation, which is expected to facilitate 
the design of vascular stabilizing therapies for diseases associated with vascular leakage. The specific 
questions were: 
 
I  How does ANGPT2 signal to destabilize the endothelium, and do endothelial integrins play a 
role in this?  
 
II  Do ANGPT2 and b1-integrin signaling promote endothelial destabilization in inflammation 
and vascular leakage in sepsis? What are the mechanisms that promote EC permeability in 
inflammation? 
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MATERIALS AND METHODS 
 
5. Cell lines and treatments (I&II) 
 
Altogether, this thesis presents similar results from three different primary human ECs derived from 
different vascular beds (Table 2). In vitro EC studies were conducted on glass coverslips or plastic 
wells, coated with FN. In vivo, however, ECs experience various ECM molecules and matrix 
stiffnesses, which were not considered in our cellular assays. Another limitation is that blood flow, 
which regulates many EC functions in vivo, was not examined.  
 
Primary human ECs (Table 2) were used between passages 1-5, except HUVECs between passages 
1-7. EC culture and experiments, unless otherwise mentioned, were performed on FN coated culture 
plates and Transwell inserts. All other cell lines (Table 2) were cultured, and used for experiments, 
without coating. 
 
Table 2. Cell lines. 
 
Cell line Source/Reference Description Growth 
medium* 
Used in: 
HMVEC (referred to 
BEC)  
Lonza Primary human Neonatal skin 
microvascular EC  
EBM2 I, II 
HMVEC  Promocell Primary human Neonatal skin 
microvascular EC 
EBM2  I, II 
HPMEC Promocell Primary human pulmonary 
microvascular EC 
EBM2 I, II 
HUVEC,  Promocell, Cell 
Applications 
Primary human umbilical vein 
EC 
EBM2 II 
b.END3 ATCC Immortalized, murine cerebral 
EC  
EBM2 II 
CHO ATCC Immortalized, Chinese hamster 
ovary cells 
DMEM I 
HeLa ATCC Immortalized, 
Epithelial cell from cervical 
cancer 
DMEM I 
LLC ATCC Immortalized, murine lung 
cancer cell line 
DMEM I 
NCI-H430-LNM-35 
(LNM-35 for short) 
ATCC Immortalized, human lung 
cancer cell line 
RPMI I 
293-GPG-VSV-G (Ory et al., 1996) Immortalized, human derived 
packaging cell line for retroviral 
production 
DMEM (4.5 
g/l glucose) 
I 
293FT (Ory et al., 1996) Immortalized, human derived 
packaging cell line for lentiviral 
production 
DMEM (4.5 
g/l glucose) 
I, II 
*) All media were from Lonza. EBM2 medium was supplemented with Lonza endothelial supplement kit; DMEM and 
RPMI with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin; DMEM 4.5 glucose/l for the 
culture of 293-GPG-VSV-G with 10% FBS, 1% glutamine, 0.2% penicillin, 0.2% streptamycin, 0.2% puromycin, 0.6% 
neomycin and 0.00008% tetracycline; and DMEM 4.5 glucose/l for 293FT with 10% FBS, 1% L-glutamine, 0.2% 
penicillin and 0.2% streptomycin. 
 
5.1 Genetic manipulation of cell lines (I&II) 
 
5.1.1 shRNA and siRNA mediated gene silencing 
 
shRNA mediated gene silencing could result in off-target effects, and activation of compensatory 
mechanism during the 48 h silencing period. To rule out off-target effects, all major results were 
verified with another shRNA target sequence (Table 3) or with siRNA for TIE2 silencing in Study I. 
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siRNA approach was not suitable to validate the effects of b1-integrin silencing in confluent 
monolayers, since siRNA transfection requires the use of subconfluent EC cultures, whereas b1-
integrin silenced cells are impaired in cell proliferation and do not grow to confluency. Further 
confirmation of the results was obtained using the inhibitory b1-integrin antibody Mab13, in addition 
to shRNA. Direct plasmid transfection can be inefficient in ECs, and was not considered an option 
for efficient gene targeting. The re-expression of silenced genes had to be ruled out in verifying the 
specificity of integrin silencing, since the efficiency of integrin overexpression was found poor in the 
ECs. Overexpression of the mouse TIE2 ectodomain in TIE2 silenced ECs was successful and TIE2 
re-expression rescued the silenced EC phenotype. 
 
Different shRNA vectors (Table 3) from the TRC1 library (Broad Institute, www.broadinstitute.org) 
were used together with packaging plasmids pCMVg and pCMVdelta8.9 to produce lentiviral 
particles in 293FT cells (Ory et al., 1996). Cells were transduced with shRNA lentivirus particles in 
the presence of 0.1% Polybrene (Sigma-Aldrich) for 48h. For siRNA silencing of TIE2, BECs were 
starved overnight in 1% FBS EBM2, without other supplements, and transduced twice for 24 h on 
subsequent days, with siRNA against TIE2 or scramble sequences (Sigma-Aldrich, SC-3667 siTIE2) 
using Oligofectamin (Invitrogen). The main results were repeated with two different shRNA 
expressing lentiviruses (Table 3). 
 
Table 3. Lentiviral shRNA target sequences  
 
Target shRNA sequence Used in 
TIE2 GCTTCTATACAAACCCGTTAA I 
TIE2 CGCTACCTACTAATGAAGAAA I 
TIE1 GACTGGAGCAACACAGTAGAA I 
TIE1 CTCTGACTTAAGCTGCCTCAA I 
ITGB1 GCCTTGCATTACTGCTGATAT I, II 
ITGB1 GCCCTCCAGATGACATAGAAA I, II 
ITGAV GTGAGGTCGAAACAGGATAAA I 
ITGB5 GCTGTGCTATGTTTCTACAAA I 
TENSIN1 CCGACTACTCACTTCAGCATT II 
TENSIN1 GCCTTTATCCACTCGAATTAT II 
ANGPT2 GATGATAGAAATAGGGACAAA I, II 
ANGPT2 CCCTAATTCTACAGAAGAGAT I, II 
ITGA5 CTCCTATATGTGACCAGAGTT II 
ITGA5 CCTCAGGAACGAGTCAGAATT II 
ITGB3 GATGCAGTGAATTGTACCTAT II 
ITGB3 CCTTAGCCTTTGTCCCAGAAT I, II 
 
5.1.2 Expression vector cloning and retroviral overexpression (I) 
 
To study weather ANGPT1 and ANGPT2 fibrinogen like domain (FLD) and N-terminal linker region 
have differential functions in integrin binding and activation, the respective domains were 
interchanged via cloning, and chimeric angiopoietins were produced in CHO cells. Angiopoietin 
chimeras ANGPT1-ANGPT2-Flag and ANGPT2-ANGPT1-Flag were constructed as follows: the 
ANGPT fibrinogen like domain (FLD) and the N-terminal linker region (amino acids R262-F498 in 
ANGPT1; K249-F496 in ANGPT2) were changed between ANGPT1 and ANGPT2 using two-step 
PCR and cloned into the pMXS vector. The constructs were tagged with a Flag-peptide coding 
sequence (DYKDDDDK), which was attached to the chimeric angiopoietin C-terminus, followed by 
a stop codon. ANGPT2 and ANGPT2-ANGPT1 contained the native ANGPT2 signal sequences, 
whereas ANGPT1 and ANGPT1-ANGPT2 were expressed under the Igk light chain signal sequence. 
 
 41 
Membrane bound murine TIE2 ectodomain (mTIE2-ECD) was cloned by PCR into the pMXs vector 
(a kind gift from Dr. Kitamura University of Tokyo, Japan) resulting in a deletion of the intracellular 
I824-A1124 amino acids in mTIE2. A membrane bound form of eGFP was created by attaching a 
myristoylation and palmitoylation sequence from the lyn kinase (MGCIKSKRKDNLNDDGVD) 
(Zacharias et al., 2002) to the eGFP N-terminus by PCR, and inserting the PCR fragment in to pMXs. 
Retroviruses were produced in 293-GPG-VSV-G cells, and transduced into cells in the presence of 
0.1% Polybrene for 48 h. 
 
5.2. Stimulation of cells in culture (I&II) 
 
HeLa cells were starved for 2 h in 2% FBS-DMEM, and stimulated in the starvation medium (I). ECs 
were starved for 1 h in starvation media consisting of overnight-conditioned medium diluted (1:5) 
with serum free medium (final FBS concentration 1%) (I&II), and stimulated with various agents as 
listed in Table 4. Experimental details are found in the original articles I&II. 
 
Table 4. Reagents used in cell stimulations. 
 
Stimulus Concentration Cell type Provider, cat. 
Nro. 
Used in: 
E. Coli LPS O111:B4 2.5 µg/ml BEC Sigma-Aldrich, 
L4391 
II 
E. Coli LPS O55:B5 10 µg/ml BEC Sigma-Aldrich, 
L2880 
II 
rhIL-1b  10 ng/ml BEC, HMVEC R&D, 201-LB II 
Thrombin 0.1, 0.2 or 1 U/ml BEC, HMVEC, 
HUVEC 
Sigma-Aldrich, 
10602400001 
II 
S-Blebbistatin 10 mol/L BEC Santa Cruz, SC-
204253  
II 
rhANGPT1 60 nM HeLa R&D, 923-AN I 
rhANGPT2 60 nM or 10 µg/ml HeLa/BEC R&D, 623-AN I, II 
Rat anti-integrin b1 mAb13 
(Table 5) 
0.1, 4 or 10 µg/ml  BEC, HUVEC BD Biosciences, 
552828 
I, II 
Hamster anti-integrin b1 
HMb1 (Table 5) 
10 µg/ml b.END3 Biolegend, 102210 II 
Cilengitide 10 µM b.END3/BEC Sigma-Aldrich II 
 
6. Immunological and RNA-based methods (I&II) 
 
Table 5. Antibodies used; antibody clone indicated for functional antibodies. 
 
PRIMARY ANTIBODIES 
Antigen Antibody (functionality, clone) Provider, cat. Nro. Used in: 
Human TIE1 Goat polyclonal R&D, AF619 I, II 
Human TIE2 Goat polyclonal R&D, AF313 I 
Mouse Tie2 Goat polyclonal R&D, AF762 I, II 
Human ANGPT2 Goat polyclonal R&D, AF623 I, II 
Human VE-cadherin Mouse monoclonal BD Biosciences, 555661 I, II 
Human VE-cadherin Rabbit monoclonal Cell Signaling, 2500 I, II 
Mouse VE-cadherin Rat monoclonal BD Biosciences, 555289 I, II 
Mouse VE-cadherin Rat monoclonal eBioscience, 14-1441 I, II 
His-tag Rabbit polyclonal Cell Signaling, 2365 I 
Flag-tag Rabbit polyclonal Sigma Aldrich, F7425 I 
Human fibronectin Rabbit polyclonal Sigma Aldrich, F3648 I 
Human b-catenin Mouse monoclonal BD Biosciences, 610153 I 
Human ZO-1 Rabbit polyclonal Invitrogen, 61-7300 I, II 
Human p-ERK1 
Thr202/Tyr204 
Rabbit polyclonal Cell Signaling, 9101 I 
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Rat ERK Rabbit polyclonal Cell Signaling, 9102 I 
Mouse p-Akt Ser473 Rabbit polyclonal Cell Signaling, 9271 I 
Mouse Akt Rabbit polyclonal Cell Signaling 9272 I 
Human b3-integrin Rabbit monoclonal Abcam, ab75872 I, II 
Human b5-integrin  Rabbit polyclonal Abcam, ab15459 I 
Mouse b1-integrin  Rat monoclonal (activating, 9EG7) BD Biosciences, 553715 I 
Human b1-integrin Mouse monoclonal (activating, 12G10) Abcam, ab30394 I, II 
Human b1-integrin Mouse monoclonal Millipore, Mab2252 I 
Human b1-integrin Mouse monoclonal (blocking, mAb13) BD Biosciences, 552828 I, II 
Mouse b1-integrin Armenian hamster monoclonal (blocking, 
HMb1) 
BioLegend, 102210 II 
Hamster a5-integrin Mouse monoclonal Hybridoma bank, PB1 I 
Mouse CD31 Armenian hamster monoclonal Millipore, Mab1398Z I, II 
Human avb3-integrin Mouse monoclonal Millipore, Mab1976 I 
Human avb5-integrin Mouse monoclonal Millipore, Mab20197 I 
Mouse a4-integrin Rat monoclonal (blocking, PS/2) BioXCell, BE0071 II 
Human a5-integrin Mouse monoclonal Novus, NBP2-50146  II 
Human a5-integrin Goat polyclonal (activating, SNAKA51) R&D, AF1864 I, II 
Human talin-1 Mouse monoclonal Sigma Aldrich, T3287 II 
Human tensin-1 Rabbit polyclonal Sigma Aldrich, SAB4200283 II 
Mouse S100A8 Goat polyclonal R&D, AF3059 II 
Mouse VCAM1 Goat polyclonal R&D, AF643 II 
Mouse desmin Rabbit monoclonal Millipore, 04-585 II 
Mouse Ly6G/C Rat monoclonal Biolegend 108402 II 
SECONDARY ANTIBODIES 
Antigen Antibody, conjugate Provider, cat. Nro. Used in: 
Rabbit IgG Goat polyclonal, biotinylated GE Healthcare, E0432 I, II 
Goat IgG Rabbit polyclonal, biotinylated GE Healthcare, E0466 I, II 
Mouse IgG Goat polyclonal, biotinylated GE Healthcare, E0433 I, II 
Rabbit IgG Swine polyclonal, HRP-conjugated GE Healthcare, P0217 I, II 
Goat IgG Rabbit polyclonal, HRP-conjugated GE Healthcare, P0493 I, II 
Mouse IgG Goat polyclonal, IRDye 800CW LI-COR, 926-32210 II 
Goat IgG Donkey polyclonal, IRDye 680RD LI-COR, 925-68074 II 
Goat IgG Donkey polyclonal, Alexa fluor488 Thermo Scientific, A11055 I, II 
Rabbit IgG Donkey polyclonal, Alexa fluor488 Thermo Scientific, A21206 I, II 
Mouse IgG Donkey polyclonal, Alexa fluor488 Thermo Scientific, A21202 I, II 
Goat IgG Donkey polyclonal, Alexa fluor594 Thermo Scientific, A11058 I, II 
Rabbit IgG Donkey polyclonal, Alexa fluor594 Thermo Scientific, A21207 I, II 
Mouse IgG Donkey polyclonal, Alexa fluor594 Thermo Scientific, A21203 I, II 
Rat IgG Donkey polyclonal, Alexa fluor488 Thermo Scientific, A21208 I, II 
Rat IgG Donkey polyclonal, Alexa fluor594 Thermo Scientific, A21209 I, II 
Goat IgG Donkey polyclonal, Alexa fluor647 Thermo Scientific, A21447 I, II 
Armenian hamster IgG Goat polyclonal, Alexa fluor568 Thermo Scientific, A21112 II 
Rat IgG Chicken polyclonal, Alexa647 Thermo Scientific, A21472  
Armenian hamster IgG Goat polyclonal, FITC conjugated Jackson Immunoresearch, 127-
095-160 
I, II 
  
6.1 Immunofluorescence staining of cultured cells on coverslips and for TIRF  
 
Cells on coverslips were fixed in 4% PFA-PBS, washed with PBS and permeabilized for 5 min with 
0.1% Triton X-100. For talin-1 or tensin-1 staining, the cells were fixed with 4% PFA containing 
0.2% Triton X-100 for 10 min and permeabilized with 0.2% Triton X-100 in PBS. Samples were 
blocked in 1% bovine serum albumin (BSA) -PBS, incubated for 30 min with primary antibodies 
(Table 5) RT in 1% BSA-PBS, washed with PBS, blocked, incubated for 30 min with secondary 
antibodies (Table 5) at RT, washed, and mounted using semisolid mounting medium with DAPI 
(Abcam). TIRF (total internal resonance fluorescence) samples were similarly stained in TIRF glass 
bottom wells (Ibidi) without BSA and post-fixed with 4% PFA. 
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6.2 Whole-mount staining (I&II) 
 
For whole mount tissue and en face aorta preparation, mice were anaesthetized and perfused with 1% 
PFA-PBS. Aortas and tracheas were further fixed for 1 h in 1% PFA-PBS, and ear skin overnight at 
4 °C in 4% PFA. Tissues were blocked with donkey immunomix (5% donkey serum, 0.2% BSA, 
0.3% TritonX-100, 0.05% sodium azide in Dulbecco’s PBS) for 1 h RT. Whole mount staining was 
performed using indicated primary antibodies for 24–48 h at 4°C, followed by extensive washing 
using 0.3%-TritonX-100-PBS RT, incubation with secondary antibodies for 16 h at RT, washing and 
post-fixing of the samples. Tissues were mounted in DAPI-Vectashield. 
 
6.3 Immunohistochemistry of frozen mouse tissue sections (II) 
 
After sacrificing the mice, lungs were fixed in 4% PFA-PBS o/n, washed in PBS and treated with 
25% sucrose o/n. Tissues were immersed in OCT compound (Tissue Tek) and frozen in dry ice. 
Frontal frozen sections of the lungs were washed with 0.3% Triton X-100-PBS, blocked with BSA 
or donkey immunomix, treated with primary antibodies o/n at +4 °C in blocking buffer, washed with 
0.3% Triton X-100-PBS, treated with secondary antibodies for 2 h RT, washed with 0.3% Triton X-
100-PBS, rinsed with PBS, and mounted in DAPI-Vectashield.  
 
6.4 Immunoprecipitation and Western blot 
 
Cell lysates were prepared in (I) MPER (ThermoFisher Scientific) or (II) PLCLB or RIPA buffers, 
and tissue lysates were prepared in RIPA buffer, containing protease and phosphatase inhibitors 
(Sigma-Aldrich). Soluble TIE1 (II) ectodomain was analyzed using Western blot from EC 
supernatants, and from mouse serum as described previously (Korhonen et al., 2016). For analysis of 
the phosphorylated TIE2, equal amounts of total protein from mouse lung lysates were used for 
immunoprecipitation with anti-mTIE2 (R&D Systems) and the protein G-Dynabeads (ThermoFisher 
Scientific) at +4 °C. The immunocomplexes or total cell lysates, supernatant and serum, were boiled 
in Laemmli sample buffer and separated on a polyacrylamide gel (Bio-Rad and ThermoFisher 
Scientific) and transferred to a methanol-activated PVDF membrane (Merck Millipore). The 
membrane was blocked in 0.05% Tween-20–TBS containing 5% BSA or BBLicor (Bio-Rad), and 
probed with primary antibodies (Table 5) at +4 °C overnight, followed by secondary antibodies 
(Table 5) 30 min RT. SuperSignal West Pico and Femto Luminol reagents (ThermoFisher Scientific) 
or (II) the Odyssey CLx near-infrared fluorescence imaging system (LI-COR) were used for 
detection. (I&II) Fluorescent Western blots were converted to grayscale images in Adobe Photoshop 
CS6. Quantifications of band intensities were performed using LI-COR software or ImageJ software. 
 
6.5 ELISA (I&II) 
 
Standard sandwich enzyme linked immunosorbent assay was used to measure human ANGPT2 from 
EC supernatants using the Quantikine kit according to the manufacturer’s instructions (R&D 
Systems) (I). Blood was collected through the heart of anaesthetized mice and serum was separated 
by centrifugation. Standard sandwich enzyme linked immunosorbent assays were used to measure 
mANGPT2, mIL-1b, mTNFa and mIL-6 serum levels with the Quantikine kits (R&D Systems) 
according to the manufacturer’s instructions (II). 
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6.6 Quantitative real time PCR 
 
For Q-RT-PCR, total RNA from cell cultures was isolated using RNA NucleoSpin II Kit (Macherey-
Nagel), or from murine tissues with Trisure reagent (Bioline) according to the manufacturer’s 
protocol. RNA was reverse transcribed to cDNA using SuperScript® VILO™ cDNA Synthesis Kit 
(Invitrogen), RT2 First Strand Kit (Qiagen), or iScript cDNA Synthesis Kit (Bio-Rad). RT-PCR was 
carried out using the DyNAmo HS SYBR Green master mix (Thermo Scientific) and run on a BIO-
RAD C1000 Thermal cycler (Bio-Rad). Primers used are listed in Table 6. Estimate of Angpt2 mRNA 
copy number was calculated based on control samples of known Angpt2 cDNA concentrations. 
Integrin expression was analyzed using the RT2 profiler PCR Array Wound Healing (Qiagen). Mouse 
samples were normalized to Gapdh and human samples to GAPDH or CD31. Fold changes were 
calculated using the comparative CT (threshold cycle) method. 
 
Table 6. Q-RT-PCR primers*. 
 
Target: Forward (5’-3’) Reverse (5’-3’) Used in: 
ANGPT1 AACATGGGCAATGTGCCTACACTT CATTCTGCTGTATCTGGGCCATCT I 
ANGPT1 ACGTGGAACCGGATTTCTCT TTTAGTACCTGGGTCTCAACATCT I 
ANGPT2 CAGATTTTGGACCAGACCAGTGA TCAATGATGGAATTTTGCTTGGA I 
ANGPT4 ATCCAGCGCCGTGAGAATG AAATGTTCGTACTGGGCATAGG I 
ANGPT4 CAGGACTGTGCAGAGATCCA TCTCCGAAGCCCTGTTTGTA I 
Angpt1 CATTCTTCGCTGCCATTCTG GCACATTGCCCATGTTGAATC II 
Angpt2 TTAGCACAAAGGATTCGGACAAT TTTTGTGGGTAGTACTGTCCATTCA II 
Tnfa CATCTTCTCAAAATTCGAGTGACAA CATTGAGGTGGAGAGCTTTC II 
Il1b GTGTGACGTTCCCATTAGAC CATTGAGGTGGAGAGCTTTC II 
Il6 AGTTGCCTTCTTGGGACTG AGGTCTGTTGGGAGTGGTATC II 
Gapdh CCACTAGGCGCTCACTGTTC CCCCATACGACTGCAAAGAC II 
ITGB1 CCGCGCGGAAAAGATGA GAATTTGTGCACCACCCACAA II 
PECAM1 CTGCTGACCCTTCTGCTCTGTTC GGCAGGCTCTTCATGTCAACACT II 
TNS1 TCTTGAAGGGAGACATCTTG TTGAAAGCATCATCAAGGTC II 
*) Primers from Sigma-Aldrich 
 
7. In vitro assays 
 
7.1 Microscopy and image analysis (I&II) 
 
This thesis entails a large body of image analyses, which is the method of choice to observe cellular 
morphology and subcellular localization of proteins, and may not be replaced by other methods. 
Majority of the in vitro analyses were focused to monitor the presence of VE-cadherin or stress fibers 
(Table 7), which were used to reveal the EC monolayer integrity. Image quantitation was carried out 
using manual thresholding (VE-cadherin and other analyses, Table 7) or visual evaluation (stress 
fibers), whereas a more automated approach would offer an investigator-blinded approach. In study 
I, VE-cadherin cell surface expression was used to complement immunofluorescence studies, but this, 
nor VE-cadherin internalization, were not investigated in study II (Orsenigo et al., 2012). 
Additionally, traction force microscopy, utilized in study II, could have been an elegant means to 
report functional effects of TIE2 and integrin silencing also in study I. In addition, imaging was used 
to observe vascular structures and inflammatory cells in tissues using whole mount preparations, 
complemented with protein and RNA analysis. 
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Table 7. Image analyses in short* 
 
Analysis Material Image type Quantification Used in: 
VE-
cadherin 
EC coverslips 40x epifluorescence/63x 
confocal 
Total area of pixels per image ** normalized to 
the total cell number *** 
I: Fig 1; II: 
Fig 1, Fig 2, 
Fig 7, Fig S3, 
Fig S4, Fig S6 
Stress fibers  EC coverslips 40x epifluorescence Presence of stress fibers extending across the 
longitudinal cell axis normalized to the total cell 
number per image *** 
I: Fig 1, Fig 3, 
Fig S1, Fig 
S2, Fig S3, 
Fig S5, Fig 
S6; II: Fig S5 
EC 
elongation 
EC coverslips 40x epifluorescence EC length/width ratio I: Fig S1 
ZO-1  EC coverslips 63x confocal Total length of ZO-1 positive junctions per image 
normalized to the total cell number ** 
II: Fig 2, Fig 
S3 
a5-integrin 
adhesions 
EC coverslips 63x confocal Total area of pixels per image ** normalized to 
the total cell number *** 
II: Fig 7 
b5-integrin 
adhesions 
HeLa 63x confocal total pixels/area ** II: Fig 4 
ANGPT2 
binding 
HeLa 63x confocal Number of cells that stain positive for ANGPT2 
normalized to total cell number *** 
II: Fig 4 
Tensin-1 TIRF wells 63x TIRF /100x TIRF  Total area of pixels per image ** normalized to 
the total cell number *** 
II: Fig 7 
TIE2 
complement
ation 
EC coverslips 40x epifluorescence Ratio of SF positive+mTIE2-ECD+ or SF 
positive+GFP+ cells normalized to the total cell 
number *** 
I: Fig 5 
EC 
spreading, 
b1-integrin 
adhesions 
EC coverslips 63x confocal Total pixels from the central 50% of cell area ** I: Fig2, Fig S4 
 
EC 
spreading, 
cell area 
EC coverslips 63x confocal Total actin pixels per area** II: Fig S1, Fig 
S7 
a5-integrin 
recycling 
EC coverslips 63x confocal Total pixels per area of a5-integrin positive 
vesicles quantified from cropped images: 1 
cell/image 
II: Fig 7 
Cancer cell 
transmigrati
on 
Transwell 
inserts 
40x epifluorescence Total count of GFP positive cancer cells in the 
insert or total GPF signal 
I: Fig 1, Fig 
S2 
Aortic EC 
junctions 
En face whole 
mount 
63x confocal maximum 
intensity projections 
including the complete 
VE-cadherin signal from 
the total thickness 
total pixels/area ** I: Fig 6 
EC 
junctions 
Fixed 80nm 
sections of 
trachea and 
lungs 
4800x TEM images Relation of electron dense area to the total length 
of EC-EC contact 
II: Fig 5 
Vascular 
leakage 
Whole mounts 
of trachea and 
ear skin 
5x epifluorescent total pixels/area of fluorescent tracer ** II: Fig 3, Fig 
6, Fig S10, 
Fig S12 
VCAM-1  Frozen O.C.T. 
sections of 
lungs 
20x epifluorescent  total pixels/area of fluorescent tracer ** II: Fig 4 
S100A8 Frozen O.C.T. 
sections of 
lungs 
Slide scanner whole tissue 
images 
total pixels/area of fluorescent tracer ** II: Fig S11 
Ly6/G  Frozen O.C.T. 
sections of 
lungs 
20x epifluorescent total pixels/area of fluorescent tracer ** II: Fig 4 
*) All image analyses were performed with ImageJ software (version 1.46, http://imagej.nih.gov/ij/), from at least three 
independent experiments, and results are expressed as the mean with standard deviation. **) Using a similar threshold 
value for each image within one experiment. ***) DAPI positive cell nuclei. 
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Images of cells on coverslips, whole mounts and frozen tissue sections were captured using an Axio 
Imager Z2 microscope (Zeiss) connected to a Hamamatsu Orca Flash 4.0 LT camera, or using a laser 
scanning confocal microscope (Zeiss LSM 780 or Zeiss LSM 880). Three-dimensional maximum 
intensity projections were digitally reconstructed from confocal z-stacks. TIRF images of EC tensin-
1 and talin-1 were acquired using a Laser-TIRF 3 Imaging System (Zeiss) with an EMCCD camera 
(Hamamatsu ImageEM C9100-13; Chip size 512x512; Hamamatsu Photonics K:K:) controlled by 
the Zen software (Zen 2012 Blue Edition Systems; Zeiss), or using the Nikon Eclipse Ti-E N-STORM 
inverted microscope, with an EMCCD camera (512x512) controlled by the NIS-Elements advanced 
research ver.4.2 (Nikon) (II). Whole tissue sections were imaged using a 3DHistech Pannoramic 250 
FLASH II digital slide scanner. Transwell inserts were imaged with Zeiss Axiovert microscope. 
 
7.2 Analysis of cell surface expressed TIE2 and VE-cadherin (I) 
 
shRNA lentivirus transduced BECs were treated with sulfo-NHS-SS-biotin (0.2mg/ml) in Dulbecco’s 
PBS (DPBS) for 30min at +4°C. The reaction was stopped using 20 mM sodium-2-mercapto-ethane-
sulphonate (MesNa) in 50mM Tris-HCl pH 8.6, 100mM NaCl in DPBS for 15min at +4°C, and 
subsequently replaced with 20 mM iodoacetamide in DPBS for 10min in +4°C. After washing with 
DPBS, the cells were lysed (25 mM Tris pH 7.4, 100 mM NaCl, 2mM MgCl2, 0,5 mM EGTA, 5% 
glycerol and 1% Triton-X100 supplemented with the protease inhibitor cocktail). The lysates were 
incubated with Streptavidin-coupled Dynabeads (Life Technologies) for 60 min and boiled in 
1xLaemmli loading buffer. Surface-expressed, biotinylated VE-cadherin and TIE2 were analyzed 
using Western blot. 
 
7.3 TIE2 complementation assay (I)  
 
BECs grown to 50% confluence were transduced for 24 h with lentiviral shRNA against TIE2 or 
scramble sequences, followed by transduction with retroviruses coding for membrane-anchored 
mouse TIE2 ectodomain (mTIE2-ECD) or membrane-anchored GFP for another 24 h. Cells were 
fixed and mTIE2-ECD transduced samples were stained using specified antibodies against mTIE2.  
 
7.4 Tumor cell-EC transmigration assay (I) 
 
The transmigration assay was used to investigate the integrity of the EC monolayer, and served as a 
functional in vitro evidence on the roles of ANGPT2 and TIE2 in the ECs. However, as other options, 
in vitro permeability conducted with fluorescent tracers, or impedance measurements (Bischoff et al., 
2016), of which the latter was carried out in study II, could offer knowledge on EC monolayer 
permeability without the apparent interactions between cancer cells and ECs. 
 
Tumor cell transmigration across an EC monolayer was performed using Transwell chambers (6.5 
mm insert diameter, 8 µm pore size, Corning Life Sciences, NY, USA). 100 000 BECs, transduced 
with TIE2 or scramble shRNA lentiviruses, were seeded on the upper compartment overnight. 100 
000 LLC-GFP cells were applied on top of the confluent EC monolayer for 9 hours, with complete 
growth media in both chambers. Inserts were fixed in 4% PFA-PBS and mounted onto glass slides. 
Alternatively, 100 000 LNM-35-GFP cells were applied on top of the confluent BEC monolayer for 
5 or 9 hours and treated with control or anti-ANGPT2 antibody.  
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7.5 Spreading assay (I&II) 
 
EC spreading assays were used to monitor the development of EC adhesions on FN. Since collagens 
represent ligands for b1-integrins, the studies could have been complemented using additionally 
collagen coated coverslips (Humphries et al., 2006). 
 
BECs or b.END3s transduced with scramble or TIE2 shRNA lentiviruses for 48 h, were detached, 
and let to recover in complete medium for 30 min. 15 000 cells were seeded on coverslips, pre-coated 
with 10 µg/ml of FN for 1 h, in the presence antibodies against human b1-integrin mAb13, mouse b1 
integrin HMb1, control IgG (Table 5), and/or cilengitide (Table 4), and let adhere for indicated times. 
Coverslips were fixed and stained. 
 
7.6 Integrin activation assay (I) 
 
The integrin activation assay provided a quantitative means to evaluate ANGPT2 and ANGPT1-
induced a5b1-integrin activation, measured by fluorescent FN binding. The assay was performed in 
CHO cells, which express a5b1-integrin, but not other FN binding integrins, enabling the assessment 
of a5b1-integrin only. This assay is complementary to ELISA, which was used to measure ANGPT2 
binding to integrin without information on integrin activation status.  
 
To determine the effect of ANGPTs on integrin activation, the binding of cells to a fluorescently 
labelled FN7-10 fragment of FN was measured using fluorescence activated cell sorting (FACS). In 
short, CHO cells, or CHO cells transduced with retroviral vector for mTIE2-ECD, were collected and 
preincubated 30 min with various concentrations of rhANGPT2, rhANGPT1 or EDTA, and 
subsequently with fluorescent FN, anti-hamster a5b1-integrin antibody (recognizing total a5b1-
integrin, PB1, Table 5), and Alexa-488 conjugated anti-mouse secondary antibody and analyzed 
using FACS. The results were expressed as the a5b1-integrin activation index, calculated as a ratio 
of mean fluorescent intensity of activated (Alexa-647-FN binding measured against background 
signal in the presence of EDTA) relative to total a5b1-integrin (PB1 staining). Alternatively, CHO 
cells transduced with plasmid constructs for ANGPT1-ANGPT2-flag, ANGPT2-Flag or ANGPT2-
ANGPT1-flag were used similarly as above to measure integrin activation. 
 
7.7 Fibronectin matrix remodeling (I) 
 
BECs were plated on vitronectin (Invitrogen) coated coverslips and transduced with scramble or 
shTIE2 lentiviruses. Cells were maintained in EBM2, supplemented with FN-depleted serum which 
was prepared by rotating the serum with gelatine sepharose (GE Healthcare, Fairfield, CT, USA) two 
times for 1 h, and spinning the sepharose containing serum with Micro Bio-Spin chromatography 
columns (Bio-Rad, Hercules, CA, USA). Depletion of FN was confirmed using Western blotting. 
Cells were stained for FN and analyzed using confocal microscopy. 
 
7.8 a5-integrin internalization assay (II) 
 
The a5-integrin internalization assay was used to follow the recycling of a5b1-integrin in the ECs, 
after inflammatory stimuli, which we found to be dependent on ANGPT2. However, this assay did 
not include an acid wash step to remove unbound antibody before internalizing the antibody at +37°C, 
but instead the cells were rinsed before the antibody was let to internalize. Thus, some of the antibody-
labeled a5-integrin could recycle from the cell surface directly into EC-ECM adhesions, and not via 
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the internalized vesicles. However, the analysis was based on the intensity of a5-integrin positive 
intracellular vesicles, and thus, the results were not affected by this possibility. 
 
Confluent BEC coverslips transfected with shScr or shANGPT2 lentiviral vectors (Table 3) were 
labeled on ice for 30 min with non-function blocking monoclonal antibody against the a5-integrin 
ectodomain or with control antibodies (goat IgG isotype, Sigma-Aldrich, both at 2 µg/ml in 
Dulbecco’s PBS containing 1% BSA) (Table 5). Cells were subsequently rinsed with ice-cold 
Dulbecco’s PBS, incubated at +37 °C for 1 h, and stimulated with LPS O111:B4, IL-1b or thrombin. 
Cells were fixed with 4% PFA-PBS, and the internalized a5-integrin antibody and control Ig were 
detected after permeabilization using anti-goat-Alexa488 secondary antibody. The internalized a5-
integrin antibody was localized and quantified in intracellular vesicles (confirmed using confocal z-
stack projections) around the nucleus. 
 
7.9 Measurement of EC barrier function (II) 
 
Impedance measurements using the XCelligence system were used to measure the integrity of the EC 
monolayer. The advantage of this method is the continuous (one-minute interval) recording of the EC 
monolayer. This method was accompanied by evaluation of the EC morphology and VE-cadherin 
quantitation at selected time points. IL-1b could not induce a detectable decrease in EC monolayer 
impedance using this system, which applies a high frequency electrical current (50 000 Hz) 
(Robilliard et al., 2018), whereas the system was sensitive enough for the robust impedance drop 
elicited by thrombin. Alternative equipment, like the ECIS system, would allow the use of a selection 
of lower frequency electrical currents, detecting more sensitive paracellular changes in the EC 
monolayer (Robilliard et al., 2018). 
 
For non-invasive electrical cell impedance measurements, ECs were grown to confluency on E-plates 
with gilded electrodes. Continuous impedance measurements were performed (XCelligence, Acea 
Biociences) before and after stimulation of cells with thrombin in the presence of function-blocking 
human b1 integrin Ab mAb13 or control antibody. Alternatively, BECs silenced for 48 h using shScr 
or shITGβ1 lentiviral vectors were used in impedance measurements. The start of the stimulation was 
set as time point zero. Results were expressed as Cell Index (normalized impedance). 
 
7.10 Traction force microscopy (II) 
 
Traction force microscopy (TFM) was performed to measure EC contractility after thrombin 
stimulation in the presence or absence of inhibitory mAb13 antibody against b1-integrin. In short, 
Hydrogels were prepared on glass coverslips to achieve a Young’s modulus of 3 kPa, as determined 
in Georgiadou et al. (Georgiadou et al., 2017). HUVECs were plated onto TFM gels O/N and imaged 
live at +37 °C with a 3i Marianas Spinning disk confocal microscope (Intelligent Imaging 
Innovations, 3i Inc.). Z stacks of the beads and a phase-contrast image of the colonies were recorded 
for 6-10 replicates per sample (each 12-16 images). Imaging was repeated after mAb13 antibody and 
thrombin addition. Reference images for every monolayer without cells (after trypsin detachment) 
were recorded in a similar manner. To extract the bead displacement fields, a MATLAB software 
package (MathWorks), utilizing a correlation algorithm was used (provided by T. Betz University of 
Münster, Münster, Germany). Traction forces were determined as described in Peuhu et al. using the 
same MATLAB software package after the Fourier transform traction force algorithm (Peuhu et al., 
2017). 
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7.11 Time-lapse microscopy (II) 
 
BECs expressing Paxillin-TagGFP2 were generated using the LentiBrite™ Paxillin-GFP Lentiviral 
Biosensor (Merck Millipore). Paxillin-TagGFP2 BECs were plated on µ-Slide 8-Well slides (Ibidi) 
and 48 h later stimulation media, supplemented with 50 mM HEPES, was added. Cells were 
stimulated with thrombin or IL-1b and imaged using a Marianas spinning disk confocal microscope 
controlled by SlideBook 6 (Intelligent Imaging Innovations, Inc.), equipped with a Yokogawa CSU-
W1 scanning unit, an inverted Zeiss Axio Observer Z1 body and a 100× (NA 1.4 oil, Plan-
Apochromat, M27) objective. Images were acquired every two minutes using an Orca Flash4 sCMOS 
camera (chip size 2,048 × 2,048; 2 x 2 camera binning enabled; Hamamatsu Photonics), at 37°C and 
in the presence of 5% CO2. Images were processed using ImageJ to remove background (rolling ball 
radius: 10 pixels), and to compensate bleaching (exponential fit method) and drifting (StackReg, 
Rigid body). 
 
8. In vivo mouse experiments (I&II) 
 
In study I, we performed in vivo experiments using ANGPT2 overexpression in the murine vascular 
endothelium. Overexpression of murine ANGPT2 did not induce any severe phenotype in otherwise 
healthy transgenic mice. Inflammatory challenge and/or a functional approach could have been taken 
to further assess harmful ANGPT2 signaling in vivo. In study II, we performed functional leakage 
assays (see below) using a murine endotoxemia model. Endotoxemia was induced using a high dose 
of LPS, resulting in the development of systemic inflammation within hours. This method is widely 
used, and thus comparison of our results with those from other laboratories is an advantage. However, 
sepsis does not always progress fast, and here another preclinical model, the CLP model, could have 
been used to complement the endotoxemia model. Intervention studies, where HMb1 b1-integrin 
functional antibody would be administered after the onset of CLP-induced sepsis, would further 
strengthen our findings. A potential limitation of our study is that the mechanism of the injected 
HMb1 antibody may involve multiple cell types. However, we observed vascular localization of 
HMb1, and confirmed our studies using a heterozygous endothelial deletion of b1-integrin, indicating 
that inhibiting endothelial b1-integrin protects from vascular leakage in endotoxemia. 
 
The mice (Table 8) were maintained in the Laboratory Animal Centre of the University of Helsinki 
according to IACUC and IRB guidelines. The National Animal Experiment Board in Finland 
approved animal experiments used in this study. Transgenic female and male mice (Table 8) at the 
age of 8–18 weeks were genotyped and used for experiments. Single transgenic or wild type 
littermates were used as controls for double transgenic mice. Wild type mice (C57Bl/6J) were housed 
shortly before experiments, and male mice were used in the experiments. 
 
8.1 Vascular leakage 
 
b1- (HMb1) or a4-integrin (PS/2) blocking antibodies (Table 6), or control (hamster IgG) (all 2.5 
mg/kg) were administered into 2–4-month-old wild type male mice using intraperitoneal (i.p.) 
injection. Endotoxemia was induced 24 h later, with intraperitoneal administration (i.p.) of LPS 
(O55:B5, 11 mg/kg) for 2 h or 16 h. Throughout this work, the mice were sacrificed after maximum 
of 16 h after LPS administration. Alternatively, mice were first given LPS 2 h followed by i.p. 
injection of HMb1 or control antibody for further 14 h. Mice were anaesthetized with i.p. injections 
of xylazine (10 mg/kg) and ketamine (80 mg/kg). 100 nm Alexa-594 labelled fluorospheres (0.6 % 
solution in 1% BSA-PBS) or 70 kD Texas red labeled Dextran (1% solution in 1% BSA-PBS) 
(Invitrogen, ThermoFisher Scientific) were injected intravenously through the tail vein, and let to 
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circulate for 4 min. The animals were perfused with PBS and 1% PFA in PBS via the left ventricle, 
followed by tissue collection, staining, imaging, and image analysis (for analysis, see Table 7). 
 
8.2 Echocardiography 
 
b1-integrin blocking antibodies (HMb1), or control (hamster IgG) (all 2.5 mg/kg) (Table 5) were 
administered into male mice using intraperitoneal (i.p.) injection for 24 h. Cardiac function was 
monitored 24 h later, and again 16 h after LPS (O55:B5, 11 mg/kg) administration under isoflurane 
anaesthesia using Vevo 2100 ultrasound system (Fujifilm, VisualSonics) with a linear array 40-MHz 
transducer. After obtaining parasternal short-axis view at the papillary muscle level, two-dimensional 
B-Mode and M-mode recordings at sweep speed of 1200 Hz were done. M-mode images were used 
to measure left ventricular end diastolic diameter (LVEDD) and left ventricular end systolic diameter 
(LVESD). Ejection fraction (EF) and fraction shortening (FS) were calculated as EF (%) = ((LVEDD 
– LVESD)2/LVEDD2) x 100 and FS (%) = ((LVEDD – LVESD)/LVEDD) x 100. 
 
8.3 Analysis of EC-EC junctions using transmission electron microscopy (TEM) 
 
b1-blocking antibodies (HMb1), or control (hamster IgG) (all 2.5 mg/kg) were administered into 
male mice using i.p. injection. 24 h later LPS (O55:B5, 11 mg/kg) was administered i.p. for 16 h. 
Tissue samples from lung and trachea were first fixed in 1% glutaraldehyde and 4% formaldehyde in 
0.1 M phosphate buffer, pH 7.4, and then post fixed in 1% osmium tetroxide, dehydrated in acetone 
and embedded in Epon LX 112 (Ladd Research Industries). Semi-thin sections were stained with 
toluidine blue to locate vascular structures for ultrastructural analysis. For TEM, 80 nm sections were 
cut with a Leica Ultracut UCT microtome and examined in Tecnai G2 Spirit transmission electron 
microscope (Fei Europe). Images were captured by Quemesa CCD camera (Olympus Soft Imaging 
Solutions GMBH). 
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Table 8. Genetic mouse lines and wild type mice (I&II) 
 
Mouse Description Injection/ 
treatment 
Experimental 
procedure 
Source/ref
erence 
Used 
in: 
C57Bl/6J Wild type mice Ab or LPS i.p. injection, 
anaesthesia i.p. 
Murine 
endotoxemia, 
vascular leakage 
Charles 
River or 
Janvier 
II 
VEC-tTA/Tet-OS-Ang2 Inducible 
mANGPT2 
overexpression 
in EC W/O 
tetracycline 
Tetracycline (Sigma) 2.0 
mg/mL in 5 % sucrose in 
drinking water (Tet off), 
anaesthesia i.p. 
Aortic en face 
preparations 
(Holopainen 
et al., 2012) 
I 
Itgb1fl/fl Floxed Itgb1 
allele 
Tamoxifen (Sigma) i.p. 
injection (30 µl of 1 
mg/ml) x3 P1-P7, LPS i.p. 
injection, anaesthesia i.p. 
Murine 
endotoxemia, 
vascular leakage 
The Jackson 
Laboratory; 
(Raghavan et 
al., 2000) 
II 
Pdgfb-iCreERT2 Tamoxifen 
inducible 
expression of 
the Cre 
recombinase 
under the 
Pdgfb 
promoter 
Tamoxifen (Sigma) i.p. 
injection (30 µl of 1 
mg/ml) x3 P1-P7, Ab or 
LPS i.p. injection, 
anaesthesia i.p. 
Murine 
endotoxemia, 
vascular leakage 
The Jackson 
Laboratory; 
(Madisen et 
al., 2010) 
II 
B6.Cg.-
Gt(ROSA)26Sortm14(CAG-
tdTomato)Hze/J 
tdTomato 
fluorescent 
protein 
expression 
upon Cre 
expression 
Tamoxifen (Sigma) oral 
gavage (2 mg/mouse/day) 
5x adult mice, anaesthesia 
i.p. 
Tracheal whole 
mounts 
The Jackson 
Laboratory; 
(Madisen et 
al., 2010) 
II 
 
Statistical analysis (I&II) 
 
For pairwise comparisons of two treatment groups, Student’s t-tests (two-tailed, unequal variance) 
were used (I&II). For comparisons of multiple groups, Dunnet’s (I) or Tukey’s (II) multiple 
comparison tests were used in conjunction with ANOVA post-hoc pairwise testing. A P-value of less 
than 0.05 was considered statistically significant. Experimental group sizes are indicated in the figure 
legends of the original publications. 
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RESULTS 
 
Collectively, our results demonstrated that ANGPT2 and b1-integrin mediated EC monolayer 
destabilization in inflammation, and when the TIE2 levels in ECs were decreased via shRNA 
silencing. Moreover, the results suggested that ANGPT2 and b1-integrin may act in the same 
signaling pathway that involves integrin recycling and integrin activation by the N-terminal domain 
of ANGPT2. Finally, the results suggested that targeting b1-integrin signaling may have translational 
relevance via inhibition of vascular leakage in inflammation and sepsis. 
 
9. ANGPT2–b1-integrin signaling pathway destabilizes the endothelium (I) 
 
In study I, we discovered that ANGPT2 destabilized EC monolayers via b1-integrin-dependent 
signaling, when the levels of the cognate ANGPT2 receptor TIE2 were decreased, and that ANGPT2 
activated b1-integrin via the ANGPT2 N-terminal domain. 
 
TIE2 silencing destabilizes endothelial monolayers 
 
In order to investigate the function of EC-secreted ANGPT2 on EC monolayer integrity, we silenced 
ANGPT2, TIE2 or TIE1 in primary human ECs. TIE2 silencing led to the loss of cortical actin 
cytoskeleton and to the formation of actin stress fibers (Figure 6 A, B), leading to elongated EC 
morphology. In contrast, ANGPT2 or TIE1 silenced ECs retained a cortical actin phenotype similar 
to scrambled control silenced ECs (I: Fig 1, Fig S1). 
 
Actin stress fibers can generate centripetal tension that weakens EC-EC contacts in adherens 
junctions. In line with this, immunofluorescence analysis showed that VE-cadherin and β-catenin, 
both located in the adherens junctions of control cells, were reduced in the cell–cell contacts of TIE2 
silenced ECs (I: Fig 1, Fig S2). Supporting these observations, cell surface VE-cadherin, but not total 
VE-cadherin, was decreased in TIE2 silenced cells. In contrast, tight junction protein ZO-1 was 
retained in the EC-EC contacts of TIE2 silenced cells (I: Fig S2). 
 
Functionally, LNM-35 cancer cell transmigration across the EC monolayer was inhibited in samples 
treated with anti-ANGPT2 antibodies (I: Fig 1, Fig S2). This result complements earlier studies where 
ANGPT2 blocking antibodies improved EC-EC junctions and inhibited lung metastasis (Holopainen 
et al., 2012). In line with the decreased integrity, TIE2 silenced monolayers were more permissive 
for tumor cell transmigration than control cells (I: Fig 1). 
 
ANGPT2 is required for destabilization of TIE2-silenced EC monolayers 
 
We considered that ANGPT2 signaling may be deregulated upon loss of its classical TIE2 receptor. 
Indeed, when ANGPT2 was co-silenced with TIE2, ECs retained their cortical actin shape, indicating 
that ANGPT2 was necessary for stress fiber formation in TIE2 silenced cells, via a TIE2-independent 
mechanism (Figure 6 C; I: Fig 1, Fig S2). 
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TIE2 silencing alters EC-ECM adhesions 
 
Integrins have been reported to function as alternative receptors for ANGPT2 both in ECs and non-
ECs (Carlson et al., 2001; Felcht et al., 2012; Scholz et al., 2011). Since β1-integrin was the most 
prominent integrin subunit expressed in BECs (I: Fig 3), we investigated whether β1-integrin activity 
was altered in the TIE2-silenced cells using activation-state-specific antibodies against β1-integrin 
(12G10 and 9EG7, Table 5). Active β1-integrin containing focal adhesions were located in the 
periphery of control ECs, whereas β1-integrin was located along the actin stress fibers extending 
across the longitudinal axis of TIE2 silenced ECs (Figure 6 A; I: Fig 2, Fig S3). In contrast to focal 
adhesions present in control cells, the β1-integrin positive adhesions in TIE2 silenced ECs resembled 
fibrillar adhesions. Moreover, FN remodeling was altered in the TIE2 silenced ECs (I: Fig 2). During 
short term spreading on FN, the TIE2 silenced ECs also harbored more centrally located b1-integrin 
positive adhesions than control ECs, indicating increased b1-integrin activity upon TIE2 silencing (I: 
Fig 2, Fig S4). Thus, TIE2 silencing altered EC-ECM adhesions and increased active β1-integrin. 
Notably, when both TIE2 and ANGPT2 were silenced, the β1-integrin-positive elongated adhesions 
were decreased, indicating that ANGPT2 was required for the increased β1-integrin activation in 
TIE2 silenced ECs (Figure 6 A; I: Fig 2). 
Co-silencing of b1-integrin protects from destabilization of TIE2-silenced EC monolayers 
To investigate whether β1-integrin was required for the alteration of the actin cytoskeleton in the ECs, 
β1-integrin was co-silenced together with TIE2. Although β1-integrin expression was significantly 
reduced in the silenced ECs, some β1-integrin remained in adhesions localizing at the cell periphery, 
and the silencing did not affect the EC cortical actin cytoskeleton. However, β1-integrin silencing 
prevented the formation of the actin stress fibers in the TIE2-co-silenced ECs (I: Fig 3). In contrast, 
Figure 6. ANGPT2 induces 
b1-integrin translocation 
and destabilizes the TIE2 
silenced monolayer. A-C: 
ECs were silenced for control 
(shScr), TIE2 (shTie2), 
ANGPT2 (shAngpt2) or both 
TIE2 and ANGPT2. A) ECs 
were stained with b1-integrin 
(12G10) and TIE2 
antibodies. Actin was 
visualized with Phalloidin 
staining. Representative 
images were obtained with 
confocal microscopy. B) 
Quantification of VE-
cadherin from microscopic 
images (Table 7). C) Actin 
stress fiber positive ECs were 
quantified from microscopic 
images. Scale bars: 20 µm. 
The figures have been 
modified from Hakanpää et 
al. 2015 (study I) with the 
permission from Macmillan 
Publishers Ltd. 
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high concentration of β1-integrin-blocking antibodies (mAb13, Table 5) disrupted both actin stress 
fibers and the cortical actin rim of TIE2 silenced and control cells, respectively (I: Fig 3, Fig S3). 
Thus, we contemplated that central β1-integrin adhesions promoted actin stress fibers, and were more 
sensitive to decreased β1-integrin levels when compare to peripheral focal adhesions that stabilized 
the cortical actin in control cells. 
 
In addition to β1-integrin, BECs expressed β3- and β5-integrins, which together with the αv-integrin, 
form RGD-binding heterodimers (I: Fig 3). However, silencing of αv-, β3- or β5-integrins did not 
rescue the cortical actin structure in the TIE2 silenced cells. avb3-integrin signal was detected at the 
junctional area in EC monolayers, and in focal adhesions. In line with previous reports, silencing αv- 
or β3-integrin in ECs resulted in disorganized cortical actin and increased stress fiber phenotype, 
implicating that αvβ3-integrin activity stabilizes the EC cortical actin cytoskeleton (I: Fig 3, Fig S3). 
Taken together, EC monolayer destabilization induced by TIE2 silencing was specifically dependent 
on β1-integrins, but not αv-integrins. 
 
To understand more about the intracellular signaling pathways that were activated in TIE2 silenced 
ECs, we utilized phospho-protein signaling blots. Akt and ERK were strongly phosphorylated in TIE2 
silenced cells, however, co-silencing of TIE2 and ANGPT2 or TIE2 and β1-integrin, decreased the 
phosphorylation of both signaling mediators to the level of control cells (I: Fig S5). Increased Rho 
kinase activity induces the formation of actin stress fibers. Functional inhibition of the PI3K or the 
Rho kinase pathways using kinase specific inhibitors, decreased stress fibers and supported the 
formation of cortical actin structures in the TIE2 silenced cells (I: Fig S5). 
Effect of ANGPT2 on EC junctions in vivo 
 
It has been previously shown that overexpression of mANGPT2 in the endothelium (VE-cadherin-
tTA (VEC-tTA)/Tet-OS-Angpt2 mice) resulted in increased lung metastasis (Holopainen et al., 2012). 
In those studies, it was found that EC integrity of pulmonary capillaries adjacent to extravasated 
tumor cells was decreased: disturbed association of ECs to the underlying BM, reduced EC-EC 
junctions and gaps between the ECs were described. However, the changes were significantly less in 
wild type tumor-bearing littermates suggesting that the increased ANGPT2 levels aggravated EC 
destabilization by tumor cells (Holopainen et al., 2012). 
 
In order to study the effects of ANGPT2 on vascular stability, we used the transgenic VEC-
tTA/Angpt2 mice that secrete ANGPT2 into the circulation (I: Fig S8). Interestingly, whole-mount 
staining of en face prepared mouse aortas for VE-cadherin, CD31, active β1-integrin, filamentous 
actin and TIE2 revealed marked differences between VEC-tTA/Angpt2 and control mice. The VEC-
tTA/Angpt2 mice showed more irregular VE-cadherin and CD31 staining in all aortic regions 
analyzed, when compared to control littermates, with an interdigitating pattern at EC–EC junctions. 
Active β1-integrin was detected in the junctional area of aortic ECs of control mice, whereas it was 
detected in central elongated adhesions in the aortic ECs in VEC-tTA/Angpt2 mice (I: Fig 6). In 
addition, in the ascending aorta, filamentous actin was resembling a stress fiber phenotype in VEC-
tTA/Angpt2 mice, but not in control mice, where actin signal was more restricted to junctional area 
of aortic ECs (I: Fig S8). Furthermore, TIE2 co-localized with VE-cadherin staining in the aortic ECs 
of control mice but less in VEC-tTA/Angpt2 mice (I: Fig 6). Altogether, the altered VE-cadherin and 
CD31 positive EC junctions in VEC-tTA/Angpt2 mice were associated with altered 
immunohistochemical localization of actin, TIE2 and β1-integrin. 
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ANGPT2 can activate b1-integrin via the ANGPT2 N-terminal domain 
 
The results suggested that ANGPT2 can signal via β1-integrin in ECs expressing low TIE2 levels. 
Thus, we investigated ANGPT2 signaling in cell systems that do not express TIE2 (I: Fig S6). First, 
we studied HeLa adenocarcinoma cells ectopically expressing ANGPT2 or HeLa stimulated with 
recombinant ANGPT2. Based on immunofluorescence stainings, recombinant or ectopically 
expressed ANGPT2 was found to be deposited in cell–matrix adhesions of Hela cells, adjacent to 
active β1-integrin staining, and ANGPT2 also stimulated the formation of central b-integrin 
containing adhesions (I: Fig 4, Fig S6). ANGPT2 deposition was significantly inhibited by the 
inhibitory β1-integrin antibody, mAb13, but not by cilengitide, which mainly inhibits αv-integrins 
(I: Fig 4, Fig S6). ANGPT1 localization was diffuse, and independent of β1-integrin after stimulation 
of HeLa cells (I: Fig S6). 
 
Secondly, we examined whether ANGPT2 is able to activate β1-integrin. Since integrin activation 
results in increased ability of integrins to bind ECM proteins, we measured the binding of a 
recombinant FN fragment (encompassing the FN domains 7–10) to the cell surface of CHO cells, 
which express α5β1-integrin, but not TIE2. Interestingly, incubation of CHO cells with ANGPT2 
enhanced the binding of FN to CHO cells dose-dependently, whereas ANGPT1 did not (I: Fig 4). 
Notably, when mTIE2 ectodomain was expressed in CHO cells, ANGPT2 mediated integrin 
activation was decreased, suggesting that mTIE2 (murine) ectodomain captured ANGPT2, inhibiting 
ANGPT2 signaling via β1-integrin. Similarly, complementing TIE2 silenced EC by the mTIE2 
ectodomain stabilized the cortical actin cytoskeleton (I: Fig 5). Further, in HeLa overexpressing full 
length human TIE2, ANGPT2 bound to TIE2 receptor, as did ANGPT1, inducing the typical receptor 
internalization, whereas overexpression of TIE1, that does not bind ANGPTs, had no effect (I: Fig 
S7). 
 
The mechanism of ANGPT2-mediated β1-integrin activation was investigated more closely using 
chimeric angiopoietin growth factors. Expression vectors were generated for angiopoietins where the 
N- and C-terminal domains of ANGPT1 and ANGPT2 were changed vice versa (I: Fig 4). In 
summary, results from both HeLa and CHO cells pointed towards a crucial function of the N-terminal, 
but not the C-terminal domain, of ANGPT2 and none of the ANGPT1 domains in b1-integrin 
signaling, whereas overexpression of TIE2 interfered with ANGPT2–b1-integrin signaling. 
 
10. ANGPT2 and b1-integrin in endothelial destabilization in inflammation (II) 
 
In this study we discovered that b1-integrin was required for inflammation-induced EC 
destabilization and permeability, and provided evidence on how ANGPT2 may regulate b1-integrin 
in inflammation. Notably, in a preclinical murine model of endotoxemia, we demonstrated that 
inhibitory b1-integrin antibody decreased vascular leakage and protected from cardiac failure. 
 
Inflammatory agents mediate EC monolayer destabilization via β1-integrin 
 
Our previous results identified that ANGPT2 can signal via b1-integrin when the levels of its cognate 
receptor, TIE2, were decreased. Inflammation is known to decrease the expression of both TIE1 and 
TIE2 (Ghosh et al., 2016; Kim et al., 2016; Korhonen et al., 2016; Kurniati et al., 2013; Li et al., 
2014). Thus, we hypothesized that ANGPT2 might signal via b1-integrin in inflammation, and asked 
whether b1-integrin is involved in inflammation induced EC monolayer destabilization that affects 
the integrity of EC-EC junctions. We utilized several inflammatory agents: thrombin, IL-1b and LPS 
that are known to cause EC monolayer destabilization. 
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To investigate the function of b1-integrin in inflammation-induced EC monolayer permeability, ECs 
were stimulated with the inflammatory agents, and β1-integrin was simultaneously inhibited. For 
inhibition of b1-integrin, we used shRNA silencing or a β1-integrin antibody (mAb13), which 
stabilizes the β1-integrin in an inactive, closed conformation, via binding to the beta-I-domain in the 
headpiece of β1-integrin (Byron et al., 2009; Mould et al., 1996). In line with its ability to inhibit β1-
integrin binding to the ECM, a high concentration of mAb13 inhibited EC spreading on FN, and 
thereby, also interfered with EC junction organization (II: Fig S1). Notably, a low mAb13 
concentration (0.1 μg/ml) did not affect EC monolayer integrity and was selected for further studies. 
 
All inflammatory agents tested induced the destabilization of the EC monolayer. IL-1b and thrombin 
induced a significant loss of VE-cadherin (II: Fig 1, Fig 2, Fig S3, Fig S5, Fig S6) although with 
varying kinetics (II: Fig S4). IL-1b, thrombin and LPS also stimulated the formation of actin stress 
fibers, quantified for LPS (II: Fig S5), in confluent EC monolayers. shRNA silencing of ANGPT2, 
b1-integrin or a5-integrin, but not b3-integrin, protected from inflammation-induced monolayer 
destabilization, i.e. the formation of stress fibers and the loss of VE-cadherin or the tight junction 
protein ZO-1 that connects catenins to actin cytoskeleton (II: Fig 1, Fig 2, Fig S3, Fig S5, Fig S6). In 
addition to inflammatory agents, stimulation with a high concentration of recombinant ANGPT2 
induced the loss of VE-cadherin in a b1-integrin dependent manner (II: Fig 7). 
 
mAb13 prevented the thrombin induced loss of VE-cadherin, whereas it had no effect on VE-cadherin 
in unstimulated control ECs (II: Fig 1). mAb13 also significantly decreased thrombin induced EC 
monolayer permeability which was analyzed using noninvasive electrical cell impedance monitoring 
(II: Fig 1). Blebbistatin, an inhibitor of nonmuscle myosin II, prevented thrombin-induced loss of 
VE-cadherin and stress fiber formation (II: Fig 1). mAb13 and blebbistatin had similar effects 
suggesting that b1-integrin was involved in tension mediated loss of EC junction integrity. This was 
verified using traction force microscopy, which demonstrated that mAb13 attenuated thrombin 
induced cellular contractility and traction force generation (II: Fig 1). 
 
Inflammation alters EC-ECM adhesions  
 
We hypothesized that β1-integrin promotes inflammation-induced EC permeability via altered EC-
ECM adhesions. Therefore, we investigated the dynamics of EC–ECM adhesions after inflammatory 
stimulation using spinning disk confocal microscopy of paxillin-GFP expressing ECs. Both control 
and thrombin-stimulated ECs contained focal adhesions localized in the cell periphery, however, 
thrombin stimulation additionally induced the formation of centrally located cell adhesions (II: 
SMovie, Fig. 7). This finding was confirmed in fixed ECs: β1- and α5-integrin were enriched at 
centrally located, elongated matrix adhesions after IL-1β, thrombin, or LPS stimulation (II: Fig 7). 
 
Using TIRF microscopy, we found that talin-1 localized in focal adhesions in ECs in non-
inflammatory conditions (II: Fig S19), whereas tensin-1 that shares a binding site with talin-1, and 
binds to β1-integrin in fibrillar adhesions, was less visible (II: Fig 7, Fig S19). However, LPS and IL-
1b stimulations significantly increased tensin-1 positive adhesions along stress fibers, in a pattern 
similar to active b1- and a5-integrins. The increase in tensin-1 was ANGPT2-dependent, since LPS 
induced significantly less tensin-1 positive adhesions in ANGPT2 silenced ECs (II: Fig 7, Fig S19). 
Supporting a functional role for tensin-1, more VE-cadherin was retained in EC junctions after IL-1b 
stimulation in tensin-1 silenced ECs compared to control cells (II: Fig 7). 
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Taken together, inflammatory agents stimulated the formation of fibrillar EC–ECM adhesions, which 
contained a5b1-integrin and tensin-1. ANGPT2-mediated increase in tensin-1 positive fibrillar 
adhesions promoted monolayer destabilization in inflammation, most likely via coupling a5β1-
integrin to actin stress fibers and contractile forces that led to decreased junctional localization of VE-
cadherin and ZO-1. 
 
ANGPT–TIE pathway in the inflamed endothelium 
 
It has been previously shown that inflammation downregulates TIE1 and TIE2 mRNA and protein 
levels, and results in the cleavage of the TIE1 ectodomain, leading to vessel destabilization in vivo 
(Figure 5) (Korhonen et al., 2016). Therefore, we studied whether b1-integrin signaling was linked 
to decreased TIE pathway activity in EC inflammation in vitro. We found that TIE1 was cleaved 
within 30 min after IL-1β or thrombin stimulation of ECs, and this was not affected by mAb13 
treatment (II: Fig S13). Thus, mAb13 did not improve EC monolayer integrity via enhanced 
expression of the TIE receptors. Instead the inflammatory agents induced the downregulation of TIE1 
also in an in vitro EC model system, similarly to in vivo. 
 
Since a5-integrin was localized in fibrillar adhesions following LPS, IL-1b, and thrombin 
stimulations, we studied whether a5b1-integrin trafficking was dependent of ANGPT2. a5-integrin 
was followed, using an antibody recognizing the a5-integrin ectodomain, from the cell membrane 
(labeled on ice) to internalized perinuclear vesicles. All inflammatory agents stimulated the recycling 
of a5-integrin from internalized vesicles to inflammatory EC-ECM adhesions, and interestingly, the 
recycling from the vesicles was inhibited by ANGPT2 silencing (II: Fig 7, Fig S20). In summary, 
inflammatory agents induced ANGPT2-dependent recycling of a5-integrin, and the cleavage of 
TIE1, which was not affected by mAb13 (Figure 8). 
 
Inhibition of b1-integrin decreases vascular leakage in endotoxemia inflammation-
independently 
 
From the in vitro experiments it was evident that inhibition of b1-integrin supported EC integrity in 
inflammation. Therefore, we decided to test the concept in vivo, in inflammation-induced vascular 
leakage. Murine endotoxemia is manifested by systemic inflammation, vascular leakage, and organ 
failure, thus mimicking human sepsis. Whereas the function of b1-integrin had not been investigated 
in endotoxemia, several studies had demonstrated that ANGPT2 aggravated whereas ANGPT1 and 
TIE2 protected from endotoxemia (Leligdowicz et al., 2018). Moreover, previous work has shown 
that mouse ANGPT1, TIE1 and TIE2 were downregulated, whereas ANGPT2 was upregulated in 
endotoxemia (II: Fig 4, Fig S9) (Korhonen et al., 2016). 
 
We administered sub-lethal doses of LPS, or PBS as a control, in C57Bl/6J mice and measured 
vascular leakage after two and 16 hours. In addition, mice received injections of control or b1-integrin 
inhibitory (HMb1) antibodies 24 hours before LPS (preventive treatment), or 2 hours after LPS 
(intervention). 
 
Vascular leakage was visualized with fluorescent tracers injected via the tail vein. Two different 
tracers were used: fluorospheres of a diameter of 100 nm that correlate to the size of a 1000 kD 
protein, and 70 kD dextran. 100 nm spheres do not leak out in homeostatic conditions, aside from 
sinusoidal vascular beds, which were not analyzed in this work, whereas 70 kD dextran, which is 
approximately the size of albumin, may leak out from capillaries. The tracers were analyzed 4 min 
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ear and in the trachea of PBS-administered control mice showed no leakage, whereas leakage was 
induced in LPS-administered mice (Figure 7; II: Fig 3, Fig. 4, Fig S10, Fig S12). However, vascular 
leakage was significantly decreased in mice that received the HMb1 antibody, but not the control 
antibody, prior to LPS administration (Figure 7; II: Fig 3, Fig S12). HMb1 did not increase vascular 
leakage in PBS-treated control mice (Figure 7; II: Fig 3, Fig S12). Importantly, administration of 
HMb1 two hours after LPS, when systemic inflammation and vascular leakage were increased, 
decreased the leakage in an intervention setting (II: Fig. 4, Fig S10). 
 
Inflammatory response after LPS administration, i.e. levels of serum proinflammatory cytokines, 
VCAM-1 expression, and neutrophil infiltration in the lungs, were similar in mice that received the 
HMb1 or control antibodies (II: Fig 4, Fig S9), indicating that attenuated inflammation did not explain 
for the observed decrease in vascular leakage in HMb1 administered mice. In addition, a4-integrin 
function blocking antibody, which binds the leukocyte a4b1-integrin, had no effect on LPS-induced 
vascular leakage, suggesting that leukocyte integrin was not involved (II: Fig S12). Moreover, using 
the conditionally targeted Itgb1flox/flox;Pdgfb-iCRE mice, we found that heterozygous inducible 
Itgb1 deletion in the endothelium of adult mice protected from LPS-induced vascular leakage, 
indicating an EC autonomous function for b1-integrin in regulation of vascular leakage (II: Fig. 6). 
 
Inhibitory antibody against b1-integrin protects from cardiac failure in murine endotoxemia 
 
In addition to reduced vascular leakage, HMb1 protected from LPS-induced cardiac failure. Heart 
function was monitored using echocardiography 24 hours after HMb1 antibody, and again 16 hours 
after LPS administration. LPS reduced the cardiac output measured by ejection fraction and fractional 
shortening. Prophylactive treatment with the HMb1, but not the control antibody, significantly 
increased cardiac output after LPS administration (II: Fig 3). 
 
Inhibitory antibody against b1-integrin does not affect ANGPT–TIE signaling 
 
Over time, we observed an increase in Angpt2 mRNA and ANGPT2 serum protein levels, and a 
decrease in Angpt1 mRNA levels in LPS-administered mice, as reported also by Korhonen et al. 
(Korhonen et al., 2016). The levels were similar in mice that received either HMb1 or control 
antibodies (II: Fig 4, Fig S9). Similarly, the HMb1 antibody had no effect on LPS-induced decrease 
in TIE2 and TIE1 protein levels in the lung lysates, or soluble TIE1 in serum samples (II: Fig. 4, Fig 
S13). Consequently, the LPS-induced decrease of TIE2 phosphorylation was unaltered by the HMb1 
treatment (II: Fig 4). 
 
Inhibitory antibody against b1-integrin improves EC junctions in endotoxemia 
 
We asked, if HMb1 could directly improve the integrity of the blood vessels in endotoxemia. 
Interestingly, 48 hours after i.p. injection in mice, HMb1 was detected in the tracheal vasculature (II: 
Fig S15), overlapping with staining for CD31. We utilized transmission electron microscopy to 
visualize the ultrastructure of EC junctions in HMb1 or control antibody treated mice after LPS or 
PBS administration. In mice that received LPS, the cell junction length was significantly shorter than 
in PBS treated control mice (II: Fig 5, Fig S14). However, the junction length was preserved in HMb1 
administered LPS-treated mice, when compared to control antibody treated mice. Improvement in 
the EC-EC integrity was seen both in the pulmonary microvasculature and in capillaries, postcapillary 
venules, and collecting veins in the tracheal vasculature (II: Fig 5). 
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Overall, targeting b1-integrin either using HMb1 or genetic deletion decreased vascular leakage in 
murine endotoxemia. HMb1 protected from cardiac failure and improved EC-EC junctions, but did 
not affect LPS-induced inflammatory response or TIE signaling. 
 
 
 
Figure 7. b1-integrin targeting antibody decreases vascular leakage in murine endotoxemia. A, C) Adult wild type 
mice we administered with HMb1 or control antibodies for 24 h, followed by 16 h of LPS, and injection of either 100 nm 
fluorospheres or 70 kD dextran to the circulation for 4 min. B) Quantification of leaked tracer. Scale bars: 100 µm. The 
figures have been modified from Hakanpää et al. 2018 (study II) with the permission from The National Academy of 
Sciences. 
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DISCUSSION 
 
The results of this thesis provided new insight into the functions of ANGPT2 and b1-integrin in EC 
monolayer destabilization in inflammation and vascular leakage in endotoxemia. The main results 
are discussed below. 
 
11. ANGPT2–b1-integrin interactions in EC destabilization (I) 
 
We found that TIE2 silencing in ECs led to monolayer destabilization, in line with a previous 
publication (Parikh et al., 2006), and that unexpectedly, the monolayer destabilization could be 
prevented by co-silencing of ANGPT2. This was surprising, since ANGPT2 is known to act as a weak 
context-dependent agonist/antagonist of TIE2. To identify the mechanism by which ANGPT2 could 
signal in the absence of TIE2, we considered integrins, which have been implicated in ANGPT2 
signaling, although with little mechanistic insight. We discovered that expression of b1-, but not 
avb3- or avb5-integrins, was necessary for EC monolayer destabilization in TIE2 silenced ECs. 
 
In subsequent studies we aimed to more thoroughly characterize ANGPT2 signaling via b1-integrin, 
and hypothesized that ANGPT2 and b1-integrin could interact directly. Our results showed that 
ANGPT2 bound to b1-integrin ectodomain, but the b1-integrin domain mediating the binding was 
not identified. Using an integrin activation assay we found that ANGPT2 activated a5b1-integrin via 
the ANGPT2 N-terminus. In these studies, the N- and C-terminal domains of ANGPT1 and ANGPT2 
were changed vice versa. This approach was possible, since ANGPT1 did not activate integrin. The 
ANGPT N-terminal domain consists of the coiled-coil and superclustering domains that participate 
in dimerization/trimerization and further multimerization of the ANGPTs (Davis et al., 2003; Kim et 
al., 2005; Leppanen et al., 2017). However, previously, the N-terminal domains of ANGPT1 or 
ANGPT2 have not been linked to any signaling function. Thus, besides the differential TIE2 agonist 
activity of ANGPT1 and ANGPT2, the ability to activate a5b1-integrin is a major difference between 
the signaling mechanisms of the homologous ANGPT1 and ANGPT2. More work is required to 
understand the potential function of the ANGPT2 N-terminus. 
 
Figure 8. Summary of the findings: ANGPT2–b1-integrin pathway induces EC destabilization and leakage in 
inflammation. A) In endothelial homeostasis, EC s are stabilized by VE-cadherin and TIE2 receptor signaling, and talin-
1 positive focal adhesions. ANGPT2 expression is low, whereas TIE2 expression is high. B) In systemic inflammation in 
vivo, the TIE1, TIE2 and ANGPT1 levels are decreased. TIE1 is cleaved and ANGPT2 acts as an antagonistic TIE2 
ligand, decreasing the stabilizing phospho-TIE2 and downstream signaling. TIE1 is also cleaved in cultured ECs 
stimulated with IL-1b or thrombin. Inflammation, or TIE2 silencing, decreases junctional VE-cadherin. Inflammatory 
agents also decrease ZO-1. Inflammation also induces a5b1-integrin activation and translocation to tensin-1 positive 
fibrillar adhesions via an ANGPT2-dependent mechanism that may involve integrin recycling. The inflammatory 
adhesions promote stress fiber formation leading to increase in EC permeability and intracellular tension. TIE2 silencing 
increases ERK phosphorylation and stress fibers via the PI3K and ROCK pathways. Silencing of ANGPT2, a5- or b1-
integrin, but not b3- or b5-integrins in ECs stabilizes the EC monolayer, retains cortical actin and junctional VE-cadherin 
of TIE2 silenced and inflammatory agent stimulated ECs. Inhibitory b1-integin antibody stabilizes the EC monolayer in 
vitro in inflammation, and decreases vascular leakage protecting from sepsis-induced cardiac failure in an in vivo model 
of murine endotoxemia. The information in this figure is derived from publications of this thesis. 
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Previous work has suggested various mechanisms by which ANGPT2 can signal via integrins. It was 
reported that ANGPT2 induced the sprouting of TIE2 low ECs, in an integrin-dependent manner, in 
an in vitro sprouting assay. Although the specific integrins were not identified, sprouting was 
inhibited by antibodies against a5b1-, avb3-, and avb5-integrin (Felcht et al., 2012). It was 
additionally found that ANGPT2 co-immunoprecipitated with avb5- and a5b1-integrin from TIE2 
low ECs, and in a cell-free system also with avb3-integrin. All three integrins also bound to ANGPT2 
in an ELISA assay, in an acidic environment, resembling angiogenic microenvironment, whereas 
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ANGPT2 binding to TIE2 was observed in both acidic and physiological pH. However, ANGPT2 
was not found to promote the activation of b1-integrin, as measured using conformation specific 
antibodies (Felcht et al., 2012).  
 
In another study, ANGPT2 was found to bind to CHO cells in a flow cytometric assay more strongly 
via a5b1-integrin than via avb3-integrin (Lee et al., 2014a). siRNA targeting of either a5- or b1-
integrin abolished ANGPT2 binding in this assay. The ANGPT2–a5b1-integrin interaction was 
mapped to a C-terminal glutamine 362 of ANGPT2, and to the CALF-domains of a5-integrin 
ectodomain. Mutation of Glut-362 disrupted ANGPT2 binding to a5-integrin, but not to TIE2 (Lee 
et al., 2014a). Both of the above-mentioned studies concluded that ANGPT2 does not compete with 
FN in binding to RGD-recognizing integrins. Lee et al. further suggested that the a5-integrin tailpiece 
is essential for ANGPT2–a5b1-integrin interaction, since ANGPT2 did not bind a chimera where 
a5-integrin tailpiece was substituted with that of an av-integrin, but did bind to an a5b1-b3-integrin 
chimera, where the tail piece of b3-integrin was cloned to that of b1-integrin (Lee et al., 2014a). In 
summary, both N- and C-termini of angiopoietins have been implicated in interacting with (a5)b1-
integrin, and our work suggested that the ANGPT2 N-terminus activates a5b1-integrin. Further work 
is needed to elucidate this question. 
 
Recently, ANGPT2 was reported to destabilize endothelial integrity in a heart ischemia model, by 
antagonism of ANGPT1–TIE2 signaling, but it also polarized proinflammatory macrophages through 
a5b1-integrin signaling (Lee et al., 2018). In HUVECs, a5b1-integrin silencing decreased ANGPT2-
induced FAK phosphorylation, indicating that ANGPT2 induced FAK via a5b1-integrin (Lee et al., 
2018). 
 
Adding to the complexity, several lines of evidence suggest that ANGPT1 can also signal via b1-
integrin. Originally, a5b1-integrin was found to sensitize TIE2 to low levels of ANGPT1 in cells 
growing on FN (Cascone et al., 2005). These results were more recently supported by another study, 
which showed that a5b1-integrin was necessary for ANGPT1-mediated TIE2 signaling in cultured 
ECs, and for TIE1-TIE2 interaction in EC-EC junctions (Korhonen et al., 2016). Thus, matrix 
composition and the abundance of TIE receptors appear to play a role in ANGPT1–TIE2 signaling. 
In another study, FN was found to promote a5b1-integrin–TIE2 interaction assessed using co-
immunoprecipitation in a cell-free system, whereas interaction of a5b1-integrin with TIE1 did not 
require FN. In the same study, investigators found using co-immunoprecipitation that the ANGPT1 
FLD, but not ANGPT2 FLD, bound to a5b1- and avb3 integrins in the absence of TIE receptors 
(Dalton et al., 2016).  
 
The studies by Cascone et al. and Korhonen et al. have been subsequently supported by studies using 
brain ECs. It was shown that TIE2 is activated in an a5-integrin dependent manner in an in vitro 
model of oxygen-glucose deprivation/restoration of brain ECs. Upon a5-integrin silencing, TIE2, 
FAK and Akt phosphorylation were attenuated. Similarly, ANGPT1-induced TIE2 phosphorylation 
was decreased after oxygen deprivation when a5-integrin was silenced. In an in vivo model of mouse 
brain ischemia, phosphorylated TIE2 colocalized with a5-integrin, as detected using confocal 
microscopy (Pang et al., 2018). In contrast, another study found that the BBB integrity was increased 
upon a5-integrin silencing in mouse brain ischemia models in vivo (Table 1) (Roberts et al., 2017). 
Recently, in experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple 
sclerosis, EC deletion of a5-integrin in mice enhanced the symptoms and vascular leakage of EAE 
at early stages of the disease, but not at the late stages (Table 1) (Kant et al., 2019; Wang et al., 
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2019a). Here, the authors did not, however, report whether this signaling is dependent or independent 
of TIE2 signaling. 
 
Collectively, our studies together with those from other laboratories suggest that ANGPT2–integrin 
signaling could occur via multiple mechanisms, in a context-dependent manner. Based on our results 
it is tempting to speculate that ANGPT2 signals via b1-integrin when TIE2 signaling is suppressed 
(Figure 8), such as in the inflammatory endothelium, and that some of the vascular destabilizing 
functions of ANGPT2 might be mediated via its poorly characterized N-terminal domain. It remains 
to be investigated how ANGPT1 and ANGPT2 differentially signal via a5b1-integrin. One 
explanation that can be envisioned is that ANGPTs can interact with integrins via multiple mechanism 
and some of these mechanisms are shared between ANGPT1 and ANGPT2, whereas some 
interactions occur in a unique ANGPT2-dependent manner, such as the N-terminus dependent b1-
integrin activation. Further, ANGPT–integrin signaling could be modified by the presence or absence 
of the TIE2 receptor, as well as by the ECM composition, but these theories remain to be confirmed. 
 
Thus, our results add to the existing body of evidence that ANGPT2 signals via integrins. The novel 
aspects of our study include: 1) identification of a specific function for b1-integrin, but not other 
integrins, in ANGPT2 mediated EC destabilization, and 2) discovery that ANGPT2 can activate 
a5b1-integrin, whereas previous work mostly measured ANGPT2 binding to integrins. 3) We 
demonstrated specificity between ANGPT2 and ANGPT1 in their N-terminal domains in a5b1-
integrin activation, whereas in many studies comparisons between ANGPT1 and ANGPT2 were not 
performed. Knowledge on 1) the effects of ANGPT-integrin signaling on ECs and 2) the effects of 
ANGPT-integrin signaling on vascular functions including vessel integrity, should facilitate attempts 
to target ANGPT2 in disease. 
 
12.1 Signaling in TIE2 silenced ECs (I) 
 
Using a phosphoprotein screen, we discovered that TIE2 silencing in ECs increased Akt and ERK 
phosphorylation in an ANGPT2- and b1-integrin-dependent manner. PI3K inhibition decreased stress 
fiber formation in TIE2 silenced BECs and supported actin rearrangement into a cortical actin rim, 
indicating that the increase in Akt phosphorylation was functionally relevant (Figure 8). The 
increased Akt activity in TIE2 silenced cells was surprising, since Akt is a key downstream signaling 
mediator of the ANGPT1–TIE2 pathway (Figure 8). However, the PI3K–Akt pathway is activated 
downstream of multiple cell surface receptors, including integrins (Moreno-Layseca and Streuli, 
2014). Although not well understood, it has been suggested that Akt can be differentially activated 
by various cell surface receptors, leading to distinct cellular outcomes. A recent report suggested that 
Akt could be activated in a specific subcellular location via ectopic expression of a constitutively 
active R-Ras, but not after VEGF stimulation, explaining barrier promoting properties of R-Ras, but 
not VEGF (Li et al., 2017). 
 
In addition, ERK is known to be activated downstream of the integrin-FAK pathway, leading to RhoA 
activation (Burridge and Wittchen, 2013). Indeed, ERK can be activated in response to stress fiber 
formation, and ERK phosphorylation decreases upon inhibition of stress fiber formation in ECs (Hsu 
et al., 2010). In fibroblasts, ERK phosphorylation correlates with increased tension and Myosin II 
activity (Hirata et al., 2015). As expected, an inhibitor of ROCK abolished already formed stress 
fibers and b1-integrin positive central adhesions, leading to formation of peripheral b1-integrin 
positive focal adhesions that overlapped with cortical actin (Figure 8).  
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12.  ANGPT2 and b1-integrin signaling in inflammation (II) 
 
We extended our studies in TIE2 silenced ECs to inflammation, since upregulation of ANGPT2 and 
downregulation of TIE1 and TIE2 are hallmarks of inflamed endothelium. Inflammatory agents 
induce barrier loss and stress fibers in EC cultures, and thus we expected a role for b1-integrin in 
these processes. 
 
Our novel finding was that β1-integrin was required in ECs for IL-1β-, thrombin-, and LPS-induced 
EC destabilization, permeability and contractility, and that b1-integrin silencing similarly protected 
from inflammation-induced EC barrier loss (Figure 8). Based on our results, it is plausible that β1-
integrin functions downstream of multiple inflammatory agents, providing a common downstream 
target in EC permeability signaling. Indeed, the inflammatory agents IL-1β, thrombin, and LPS signal 
via different cell surface receptors and induce EC destabilization with different kinetics. However, 
here all inflammatory agents induced the loss of VE-cadherin in EC junctions, as well as the formation 
of actin stress fibers (Figure 8). Thus, β1-integrin likely functions upstream of mechanisms that 
regulate VE-cadherin and actin cytoskeleton in inflammation induced EC permeability pathways. 
Previously, ANGPT2 has been found to prime ECs for inflammation by e.g. sensitizing ECs for 
TNFa , in line with our results (Fiedler et al., 2006; Benest et al., 2013; Rathnakumar et al., 2016). 
 
mAb13 is a b1-integrin blocking antibody that binds to the headpiece of b1-integrin (beta-I domain) 
and prevents b1-integrin heterodimers from binding FN (Mould et al., 1996). mAb13 did not 
significantly alter VE-cadherin or actin cytoskeleton when used at a low concentration. Instead, 
mAb13 pretreatment inhibited the IL-1b or thrombin induced loss of VE-cadherin, translocation of 
b1-integrin into fibrillar adhesions, and stress fiber formation (Figure 8). Mould et al. have reported 
that mAb13 preferentially binds to ligand-free b1-integrin heterodimers, inhibiting ligand (FN) 
binding (Mould et al., 1996). Thus, it is likely that in ECs mAb13 binds to a pool of inactive b1-
integrin heterodimers and prevents their binding to ECM proteins. This likely explains how mAb13 
prevents fibrillar adhesion formation, which is associated with adhesion maturation in fibroblasts. 
Moreover, whereas mAb13 inhibited inflammatory agent-induced incorporation of b1-integrin into 
fibrillar adhesions, the small pool of b1-integrin already engaged at focal adhesions would be largely 
unaffected. This concept is in line with our finding that very high concentrations of mAb13 were 
required to impair EC stability. 
 
One possibility how mAb13 can affect EC barrier maintenance in inflammation is via FAK, which 
has been reported to maintain endothelial stability but also act downstream of e.g. VEGF to increase 
permeability. Conditional deletion of FAK in the vascular endothelium in mice led to increased basal 
vascular permeability (Schmidt et al., 2013). On the other hand, VEGF-induced permeability was 
decreased in mice lacking endothelial FAK (Chen et al., 2012). Thus, similarly to b1-integrin, FAK 
is known to play a dual role in regulation of both vascular stability and stimuli-induced permeability. 
Since FAK signals downstream of multiple integrins, it remains to be found out if FAK is involved 
in the regulation of the EC barrier function via b1-integrin. In line with our studies and supporting a 
role for FAK, a recent publication showed that silencing of a5- or b1-integrin in ECs abolished 
rhANGPT2 induced increase in FAK phosphorylation (Lee et al., 2018). 
 
Alternatively, mAb13 may affect Src kinase-mediated EC permeability, which is reported to regulate 
VEGF, bradykinin and TNFa induced EC permeability (Adam et al., 2016; Kim et al., 2009) in part 
via increased stress fiber formation (Burridge and Wittchen, 2013). Recently, Src has been linked to 
FAK activation on stiff matrices, and subsequent VE-cadherin phosphorylation and EC barrier 
disruption (Wang et al., 2019b). Another recent study showed dynamic Src-mediated regulation of 
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the EC barrier, via expression of activated Src. Initially, active Src induced the phosphorylation of 
VE-cadherin on Tyr731, which enhanced barrier function. Subsequently, Src induced the 
phosphorylation of VE-cadherin on Tyr685, promoting disruption of EC barrier function (Klomp et 
al., 2019). Previously, it has been reported that even though Src promotes initial thrombin mediated 
BBB break down in vivo, it is involved in the long-term improvement of the barrier (Liu et al., 2010). 
Thus, FAK and Src are capable of both stabilizing and destabilizing the EC barrier in a dynamic, 
context-dependent manner. The potential contribution of FAK or Src to β1-integrin-mediated EC 
barrier regulation remains to be found out. 
 
Conclusively, the results by us and others indicate a dual function for β1-integrin in 1) supporting EC 
monolayer stability, and in 2) actively promoting EC monolayer destabilization following 
inflammatory stimuli.  
 
13. ECM adhesions in EC destabilization and inflammation (II) 
 
In order to understand the function of β1-integrin, EC adhesion to FN was investigated. A novel 
finding was that inflammation induced the formation of fibrillar adhesions that contained the a5b1-
integrin and the adapter protein tensin-1 that were both required for inflammation-induced loss of 
junctional VE-cadherin, and further b1-integrin was required for thrombin induced increase of 
cellular tension. Talin-1 is a well-established mediator of mechanosensitive coupling of active 
integrins to actin, via an integrin–talin–vinculin complex, whereas tensin-1, a marker of fibrillar 
adhesions, has been less studied (Bachmann et al., 2019). However, tensin-1 can bridge several 
integrin heterodimers to actin cytoskeleton, and its coupling to a5b1-integrin in fibroblasts promotes 
FN fibrillogenesis. Moreover, α5β1-integrin, but not avb3-integrin, translocated to fibrillar 
adhesions during fibroblast adhesion maturation and an inhibitor of tensin-1 prevented fibrillar 
adhesion formation, but did not affect focal adhesions (Pankov et al., 2000). Supporting our findings, 
a recent report using fibroblasts demonstrated that tensin-1 and tensin-3 maintain the active state of 
β1-integrin in fibrillar adhesions, suggesting that the integrin–tensin complex has mechanosensitive 
properties similar to the integrin–talin complex (Georgiadou and Ivaska, 2017). Although our work 
did not elucidate the mechanisms leading to increased tensin-1 in inflammation, it is tempting to 
speculate that this would involve e.g. the activity of Src, which has been found to phosphorylate the 
cytoplasmic NPxY motif of b1-integrin supporting tensin-1 binding, while inhibiting talin-1 binding 
(McCleverty et al., 2007). 
 
We further discovered that inflammatory agents enhanced the recycling of a5b1-integrin from 
internalized vesicles into fibrillar adhesions, in an ANGPT2-dependent manner (Figure 8). Integrin 
recycling provides a mechanism of dynamic regulation of integrin activation, and active and inactive 
b1-integrins are known to undergo differential recycling. Active integrins are recycled faster than 
inactive dimers, and the recycling pathways are different, resulting in distinct pools of active and 
inactive integrins (Moreno-Layseca et al., 2019). In this respect, it is interesting to note that 
segregation of b1-integrin into spatially distinct nanoclusters of active and inactive integrins, was 
recently reported to regulate integrin overall activity (Spiess et al., 2018). 
 
Both talin-1 and tensin-1 have been found to play a role in vascular formation and stability, although 
their endothelial specific functions are not fully understood. Tensin-1 knock-out mice show decreased 
angiogenic capacity in a Matrigel plug assay, and isolated ECs from these mice also have defective 
tube forming capacity in vitro (Shih et al., 2015). Interestingly, tensin-1 knock-out mice suffer from 
renal failure, but other tissues seemed unaffected (Lo et al., 1997). An EC specific deletion of talin-
1 led to the death of gene targeted embryos due to early vascular defects by E3 (Monkley et al., 2011). 
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A recent study investigated the role of talin-1 in the endothelial barrier function in the mature 
vasculature of adult mice, using the inducible Cdh5-Cre (Tln1-1flox/flox;Cdh-5-CreERT). After 16 days 
of tamoxifen injection, Tln1-1flox/flox;Cdh-5-CreERT mice (Talin1-ECKO) started to die due to severe 
bleeding in the microvasculature of the intestine (Pulous et al., 2019) whereas other organs were not 
affected. However, in addition to intestinal capillaries, also the junctions of retinal vessels were 
disorganized with more internalized VE-cadherin in the Talin1-ECKO mice (Pulous et al., 2019). It 
was suggested that the phenotype was mediated via b1-integrin, although in vivo evidence was 
lacking. Indeed, since talin-1 is a universal adaptor of several integrins, it is plausible that talin-1 
deletion affected the function of several integrins. However, the high tissue specificity of talin-1 and 
tensin-1 knock-outs is remarkable, suggesting that perhaps other integrin activators can compensate 
for these adaptors in other tissues. Overall, the functions and tissue specificities of integrin adaptors 
in ECs needs to be more thoroughly investigated.  
 
14.1 b1-integrin inhibitory antibody in vascular leakage in vivo (II) 
 
We found that a b1-integrin functional antibody, HMb1, that has been reported to inhibit capillary 
formation during mouse embryogenesis (Carlson et al., 2008), prevented LPS-induced vascular 
leakage in mice, both as a pretreatment and as an intervention therapy, administered after the onset 
of systemic inflammation. Although high levels of HMb1 disrupted EC adhesion in vitro, the HMb1 
dose of 2.5 mg/kg, which was used in our studies in vivo, did not affect the CD31 positive junctions 
in the tracheal vasculature, during the 40 hour-experiment. This suggests that ECs in vivo are not 
highly sensitive to b1-integrin loss, possibly due to vascular maturation including BM and pericyte 
support, or due to compensation by other integrin heterodimers. It is also possible that the dose of 
HMb1 did not reach a sufficiently high concentration in vivo, to cause loss of EC integrity and that 
longer treatments would be needed to fully inhibit b1-integrin. Supporting these possibilities, a high 
molar concentration of ATN-161, a peptide inhibitor of a5b1-integrin, induced EC apoptosis during 
retinal neovascularization, and JSM6427, a small molecule inhibitor of a5b1-integrin, inhibited 
neovascularization in rodent, rabbit, and non-human primate models without any adverse effects (Sui 
et al., 2018; Zahn et al., 2009). Our results using HMb1 suggest that short-term b1-integrin inhibition 
does not lead to aberrant changes in a mature vasculature, suggestive of a potential therapeutic 
window. Similarly, Zovein et al. have reported that adult retinal vasculature was mostly unaffected 
by b1-integrin blocking antibodies (Zovein et al., 2010). 
 
14. Destabilizing function of endothelial b1-integrin in the vasculature 
 
EC specific b1-integrin has previously been found important for vascular formation and maintenance 
of EC polarity in arteries, as summarized in Table 1. In addition, Yamamoto et al. showed that b1-
integrin was necessary in the growing vasculature to inhibit EC proliferation, to maintain vascular 
stability, and VE-cadherin and FN deposition (Yamamoto et al., 2015). We found that heterozygous 
deletion of b1-integrin in the endothelium of adult mice protected from LPS-induced vascular 
leakage, but did not lead to any obvious vascular defects, including vascular leakage or capillary loss. 
The effect of homozygous EC specific deletion of b1-integrin in adult mice has not been published 
so far, and was also not studied in this work. 
 
Our results highlighting a vascular destabilizing role for b1-integrin in the mature vasculature are 
supported by previous studies using integrin knock-out mice and an a5b1-integrin targeting peptide 
that demonstrated a proinflammatory function for a5b1-integrin. Specifically, a5b1-integrin was 
found to promote atherosclerosis, since the ATN-161 peptide that inhibits a5b1-integrin, reduced 
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atherosclerosis and endothelial inflammation in ApoE-/- mice that develop atherosclerosis on a high 
fat diet (Yurdagul et al., 2014). In addition, EC specific deletion of a5-integrin protected from 
atherosclerosis in the ApoE-/- mice (Table 1) (Al-Yafeai et al., 2018). Further, knock-in mice, where 
the a5-integrin intracellular domain was replaced by that of the a2-integrin, did not develop 
atherosclerosis in ApoE-/- background, suggesting that the cytoplasmic domain of a5-integrin was 
needed for the formation of atherosclerotic plaques (Budatha et al., 2018). Mechanistically, the a5b1-
integrin-mediated progression of arterial inflammation and atherosclerosis has been found to depend 
on the mechanotransduction signaling via actin cytoskeleton and membrane lipid rafts (Albarran-
Juarez et al., 2018; Sun et al., 2016a), FN deposition into the ECM (Budatha et al., 2018; Feaver et 
al., 2010), and downregulation of anti-inflammatory cAMP signaling (Yun et al., 2019). Increased 
ANGPT2 levels have been reported in atherosclerosis (Le Dall et al., 2010; Post et al., 2008). Theelan 
et al. found that a neutralizing ANGPT2 antibody reduced serum triglyceride levels and the formation 
of fatty streaks in arteries of hypercholesterolemic LDL-/-;ApoB100/100 mice (Theelen et al., 2015). 
Our studies support the concept that elevated ANGPT2 signaling in the aortic ECs decreases 
junctional TIE2, promoting inflammatory signaling and predisposing the vasculature to ANGPT2–
b1-integrin signaling and EC destabilization. 
 
In addition to atherosclerosis, a5b1-integrin has been also implicated in neovascular diseases of the 
eye. ATN-161 was found to inhibit neovascularization and vascular leakage in a preclinical model of 
laser-induced choroidal neovascularization (CNV), resembling choroidal neovascular formation in 
nAMD (Maier et al., 2007; Umeda et al., 2006; Wang et al., 2011). More recently, another integrin 
binding peptide, AXT107, was reported to potentiate EC junction integrity in vitro by disrupting the 
a5b1-integrin heterodimer. Interestingly, AXT107 also improved EC barrier function in vivo in a 
CNV model, as efficiently as the VEGF trap that is used to treat wAMD in patients (Mirando et al., 
2019). 
 
Thus, work from other laboratories has shown that a5b1-integrin promotes chronic inflammation in 
atherosclerosis and hypoxia-associated neoangiogenesis and leakage in the eye. Our work, on the 
other hand, discovered that b1-integrin promotes vascular leakage in acute EC responses such as 
endotoxemia-induce vascular leakage. We demonstrated that 1) short-term blocking or heterozygous 
deletion of b1-integrin protected from vascular leakage, and 2) administering the b1-integrin 
functional antibody decreased vascular leakage, improved EC junctions, and protected from cardiac 
failure in murine endotoxemia. 
 
Subsequent work should identify, 1) which a-integrins are essential in regulation of vascular leakage 
and 2) which ab-integrin heterodimers are essential in homeostasis. Based on our results we suggest 
that b1-integrin plays a dual role, being required for both homeostatic vascular stability and 
specifically for inflammation-induced vascular leakage. 
 
15.1 Integrins in regulation of EC stability and vascular permeability (I&II) 
 
Mechanistic insight into the function of b1-integrin signaling has been obtained using cultured ECs. 
All alpha subunits capable of binding to b1-integrin, namely integrins a1, a2, a3, a5, a6 and av, 
were expressed in cultured ECs (I), although a5-integrin was expressed at least four times higher 
than the other alpha subunits. However, the high expression levels of a5-integrin did not correlate 
with an EC stabilizing function, since silencing of av- but not a5-integrin destabilized EC 
monolayers. Our results are in line with previous findings that avb3-integrin stabilizes EC cortical 
actin (Su et al., 2012), and in addition, we demonstrate that avb3-integrin stabilizes EC junctions. 
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Our results also concur with previous work showing that ANGPT2 can stimulate avb3-integrin 
internalization, which would add to the mechanisms by which ANGPT2 can promote EC 
destabilization (Thomas et al., 2010). 
 
Instead, our results demonstrated that a5-integrin silencing, similarly to b1-integrin silencing, 
protected from EC destabilization in TIE2 silenced or inflammatory stimulated ECs (I-II). a5b1-
integrin was also activated upon ANGPT2 stimulation in an integrin activation assay (I), and 
inflammatory agents induced a5-integrin recycling that was ANGPT2-dependent (II). Finally, 
inflammation stimulated the formation of a5b1-integrin positive fibrillar adhesions (II) (Figure 7). 
Previously, it has been shown that a5b1-integrin translocates to central fibrillar adhesions creating 
tension that is essential for FN fibrillogenesis and assembly into the ECM in fibroblasts (Faurobert et 
al., 2013; Pankov et al., 2000). Thus, the adhesion maturation observed in fibroblasts shows similarity 
to inflammation-induced adhesion formation in ECs. 
 
The avb3-integrin has been found necessary for maintenance of cortical actin in EC monolayers, via 
sphingosine 1 phosphate (S1P) (Su et al., 2012). S1P is known to promote cortical actin through Rac1 
activity, and it is also involved in the formation of adherens junctions (Belvitch and Dudek, 2012). 
On the contrary, it has been shown that blocking antibody against avb5-integrin decreases LPS-, 
VEGF-, transforming growth factor b (TGFb)- and thrombin-elicited drop in EC permeability, and 
further prevents RhoA-mediated stress fiber formation (Su et al., 2013; Su et al., 2007). Based on 
these reports, it would seem that avb5- and avb3-integrins have opposing effects on the endothelial 
barrier, via RhoA or Rac1, respectively. 
 
Yamamoto et al. proposed that b1-integrin is needed for VE-cadherin maintenance in vitro in 
HUVEC junctions and in vivo in the postnatal retina (Table 1) (Yamamoto et al., 2015). In line with 
Yamamoto et al., we conclude that b1-integrin is required for maintenance of EC monolayers, since 
high levels of b1-integrin antibody disrupted EC adhesion and thereby EC junctions (II). In our 
studies, silencing of b1-integrin did not however, disrupt the EC monolayer. This can be possibly 
explained by the incomplete loss of b1-integrin from the focal adhesions during the 72 hour-silencing, 
although 96% of the b1-integrin mRNA and the majority of the b1-integrin protein was depleted. 
Moreover, since our silencing experiments were based on lentiviral vectors, all experiments were 
performed using confluent EC monolayers to avoid any potential effects of b1-integrin loss on EC 
division and subsequent adhesion (Malan et al., 2010), whereas Yamamoto et al. utilized siRNAs to 
silence b1-integrin. 
 
avb3-integrin was originally proposed an angiogenic role, and the expression of avb3-integrin is 
increased in the activated endothelium (Weis and Cheresh, 2011). However, studies of av- or b3-
integrin knockout mice have revealed that avb3-integrin may not be uniquely required for 
angiogenesis (Bader et al., 1998; Hodivala-Dilke et al., 1999), rendering the role of avb3-integrin in 
angiogenesis controversial. Furthermore, VEGF stimulation enhances angiogenesis in Itgb3-/- mice 
(Table 1) (Reynolds et al., 2004), suggesting compensatory mechanism via other integrins, like a5b1-
integrin. Further studies using b3-integrin deleted mice showed increased vascular leakage in a 
murine model of ALI, and mortality in murine sepsis (Table 1). In this study, the b3-integrin was 
deleted ubiquitously, but effects through macrophage or platelet b3-integrins were ruled out by bone 
marrow transplantation (Su et al., 2012). In a cerebral injury model, avb3-integrin inhibitory peptide 
alone, and together with recombinant ANGPT1, improved the cerebral vasculature (Han et al., 2010). 
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In the tumor vasculature, simultaneous silencing of a5- and av-integrins had no effect on tumor 
angiogenesis (Table 1) (Murphy et al., 2015). The authors thus propose that the effects of blocking 
the function of these integrins with antibodies or small molecular inhibitors relies on dominant 
negative functions, but offer no conclusive evidence to support this theory (Murphy et al., 2015). In 
addition, since many of the integrin heterodimers are ubiquitously expressed, the use of blocking 
reagents in vivo is likely to target various cell types simultaneously. In our studies, we confirmed the 
results using both inhibitory antibodies and endothelial heterozygous gene deletion of b1-integrin. 
 
15. Preclinical approaches of vascular stabilization in sepsis (II) 
 
Decreased endothelial barrier function and increased EC permeability are associated with numerous 
diseases, including atherosclerosis, ocular neovascular diseases, cancer and sepsis (Jeong et al., 
2019). Systemic inflammation results from the aberrant activation of the innate immune system, 
leading to the production of numerous inflammatory mediators including TNF-a, IL-1b, IL-6, and 
thrombin, which can act on ECs to cause vascular leakage. Additionally, EC apoptosis may contribute 
to loss of vascular integrity in sepsis (Saharinen et al., 2017a; Wentowski et al., 2019). 
 
The fundamental problem remains that there are no treatments for pathological vascular leakage in 
sepsis. Several clinical trials testing various therapeutic approaches have failed to improve patient 
survival, such as targeting of the IL-1 receptor or activated protein C (Marshall, 2014). Therapies 
aiming to attenuate inflammation may show complex outcomes, since the inflammatory response also 
serves the vital purposes of eradication of the invading pathogen, and tissue regeneration and repair 
(Cooke, 2019). Various preclinical approaches, some of which are discussed below, have targeted the 
vasculature aiming to improve the hemodynamics, vascular perfusion and integrity.  
 
Repurposing of existing drugs for alternative use is an attractive approach to provide a faster route to 
novel therapies. Imatinib, a kinase inhibitor of the Abl and Arg kinases, has shown efficacy in 
decreasing vascular leakage in murine sepsis models (Waller, 2010). Imatinib was reported to 
decrease VEGF-induced vascular leakage in the skin and to attenuate acute pulmonary edema and 
vascular leakage in the kidney in a CLP model (Aman et al., 2012). Another study concluded that 
LPS-induced lung catalase activity, a marker of oxidative EC injury and DNA damage, was decreased 
using a prophylactive imatinib dosing in mice. Further, LPS-elicited increase in lung caspase3/7 
activity, circulating TNFa and IL-6 as well as pulmonary edema were diminished, whereas survival 
after LPS administration was improved in imatinib-treated mice compared to control group (Stephens 
et al., 2015). Similarly, in ALI, prophylactic imatinib improved lung morphology and decreased LPS-
induced increase of total protein levels and inflammatory cell counts in bronchoalveolar lavage. 
However, contradicting results have also been reported. Specifically, prophylactic imatinib enhanced 
the symptoms of ventilation induced lung injury (VILI) (Letsiou et al., 2015). 
 
VEGF inhibitors are in therapeutic use in several cancers. However, VEGF inhibition using e.g. 
bevacizumab has yielded controversial reports in preclinical models of sepsis. In one preclinical 
study, bevacizumab decreased vascular leakage in the lung, spleen and kidney, and increased the 
overall survival (Jeong et al., 2013). However, another study-conducted after the clinical trial for 
bevacizumab in the treatment of sepsis was canceled-reported no significant benefit on overall 
survival in a CLP model of murine sepsis (Besnier et al., 2017). It is likely that VEGF plays a less 
prominent role in vascular permeability in sepsis, compared to hypoxia-driven neovascular diseases. 
 
Preclinically, a promising way of alleviating sepsis and sepsis-like syndromes, has been the 
manipulation of the ANGPT–TIE2 signaling pathway (David et al., 2011; Kumpers et al., 2011; 
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Witzenbichler et al., 2005). In murine LPS-induced endotoxemia, adenoviral overexpression of 
ANGPT1 improved the survival of septic mice, and ameliorated lung injury, in part via restoring 
eNOS function (Witzenbichler et al., 2005). In a murine VILI model, human ANGPT1 recombinant 
protein therapy decreased inflammation and VEGF and ANGPT2 expression, but not vascular 
leakage (Hegeman et al., 2010). A powerful way of promoting TIE2 signaling has been achieved via 
inhibition of VE-PTP that dephosphorylates TIE2. In mice, administration of a VE-PTP blocking 
antibody, or genetic deletion of VE-PTP, decreased VEGF and histamine-induced vascular leakage 
(Frye et al., 2015). VE-PTP antibodies did, however, increase vascular leakage in TIE2 negative mice, 
potentially via disturbing the VE-PTP–VE-cadherin association. Interestingly, it was recently 
reported that VE-PTP inhibition can stabilize EC junctions independently of VE-cadherin, and even 
independently of its phosphatase activity (Frye et al., 2015; Juettner et al., 2019). However, potential 
adverse effects due to long-term VE-PTP inhibition, namely downregulation of TIE2 in 
inflammation, and a tendency for aggregation of ANGPT1, may limit the use of these approaches. 
 
Although ANGPT2 enforces inflammation promoting vascular leakage in sepsis, a synthetic antibody 
ABTAA that clusters ANGPT2 fortified TIE2 signaling, resulting in decreased leakage and prolonged 
survival in a murine CLP model (Han et al., 2016). Mechanistically, ABTAA was found to diminish 
inflammation, via decreased expression of ICAM-1, VCAM-1 and E-selectin, neutrophil infiltration 
to lungs as well as expression of proinflammatory cytokines (Han et al., 2016). The beneficial effects 
of ABTAA were not limited to sepsis, but instead, ABTAA was found to normalize the leaky tumor 
vasculature, and decrease neovascularization and leakage in a murine laser-induced choroidal 
neovascularization model (Kim et al., 2019; Park et al., 2016). ABTAA appeared more efficacious 
than ANGPT2-TIE2 blocking antibodies that have shown some efficacy in various models (Lomas-
Neira et al., 2016; Ziegler et al., 2013).  
 
In contrast to ABTAA, VE-PTP or ANGPT1, which are associated with decreased inflammation, the 
inhibitory b1-integrin antibody in our studies did not attenuate inflammation or enhance TIE2 
activation, suggesting a novel mechanism of action for the b1-integrin antibody, potentially involving 
direct effects on the EC barrier. Thus, one interesting possibility would be to combine ANGPT2 
antibodies, like ABTAA, with an inhibitor or an antibody targeting b1-integrin. Vascular integrins 
have also been considered as targets for sepsis before.  b5-integrin knock-out mice have been reported 
to survive better in LPS-induced endotoxemia, manifested by decreased albumin leakage to small 
bowel and colon (Table 1) (Su et al., 2013). Weather avb5-integrin has similar endothelial functions 
as b1-integrin, is yet to be investigated. Since a5b1-integrin targeting has showed promise in other 
preclinical disease models, it would be of interest to determine the a-integrin subunit that is involved 
in vascular leakage in systemic inflammation. In summary, our results demonstrated that the 
inhibitory b1-integrin antibody decreased vascular leakage by enhancing vascular stability in murine 
endotoxemia as a prophylactic and as an intervention therapy. 
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CONCLUSIONS AND FUTURE PROSPECTS 
 
This thesis investigated the mechanisms that promote vascular permeability in inflammation, and 
more specifically, the roles of ANGPT2 and b1-integrin in endothelial destabilization. High 
ANGPT2/ANGPT1 ratio has been associated with various human diseases characterized by increased 
capillary leakage, including sepsis, and functional studies in mice have demonstrated a key role for 
ANGPT2 in many of the diseases. However, b1-integrin has not been previously reported to increased 
endothelial permeability and pathological leakage.  
 
We discovered 1) a novel signaling pathway of ANGPT2 signaling via b1-integrin that leads to EC 
destabilization in inflammation and in TIE2 low ECs, 2) that inflammation regulates EC-ECM 
adhesion dynamics via formation of tensin-1 and a5b1-integrin positive fibrillar adhesions that create 
tension leading to weakening of the EC barrier function, and 3) inhibiting b1-integrin function in in 
vivo preclinical model of sepsis decreased vascular leakage and protected from endotoxemia-induced 
cardiac failure. 
 
The results established a novel concept, whereby ANGPT2–b1-integrin signaling plays a role in 
vascular destabilization in inflammation, especially when the levels of TIE2 are decreased. Our 
results showing that heterozygous deletion of EC b1-integrin in endotoxemia decreases vascular 
leakage, strongly supports the concept. However, based on our results, it is not possible to formally 
prove the existence of the ANGPT2–b1-integrin signaling in vivo. The results showing that inhibition 
of b1-integrin not only improved vascular integrity, but also improved cardiac function in 
endotoxemia, are intriguing from a translational point of view, since these effects were obtained in 
the presence of EC and humoral inflammation. Thus, the mechanism of action of b1-integrin 
inhibition did not involve decreased inflammation, which might be beneficial in diseases where 
eradication of microbial pathogens is necessary. The results of this thesis encourage further studies 
to determine whether b1-integrin inhibition, in one way or another, might be utilized in future therapy 
development to inhibit vascular leakage in e.g. sepsis, or in numerous other diseases involving 
endothelial permeability. 
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